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GENERAL ABSTRACT 
Bifidobacteria are Gram-positive, anaerobic bacteria belonging to the 
Actinobacteria phylum, and are commensals of the mammalian, avian and 
occasionally insect gastrointestinal tracts. In humans, bifidobacteria are 
typically highly abundant in the intestinal microbiota of healthy breastfed 
infants, in particular a small number of infant-associated species, including 
Bifidobacterium breve, Bifidobacterium longum subsp. infantis, 
Bifidobacterium bifidum and Bifidobacterium kashiwanohense. A key 
adaptation, facilitating the establishment and dominance of these species in 
the breastfed infant gut microbiota, is the ability to consume and metabolise 
specific glycans only found in breastmilk, and indigestible for the infant, 
known as Human Milk Oligosaccharides (HMOs). Fascinatingly, the 
adaptation to utilise HMO as a substrate by bifidobacteria is almost 
exclusively reserved for infant-associated species, and even more 
fascinatingly, these species have developed strikingly varying strategies for 
the consumption of different HMO components. Strategies for the 
metabolism of various individual HMO glycans in different species of 
bifidobacteria shall be discussed in this thesis, with particular focus on B. 
breve UCC2003 and the novel isolate B. kashiwanohense APCKJ1. 
Chapter II of this thesis is comprised of work elucidating the mechanisms and 
components of LNT, LNnT and LNB utilisation pathways in Bifidobacterium 
breve UCC2003. Using a combination of experimental approaches, the 
enzymatic machinery involved in the metabolism of LNT, LNnT and LNB is 
identified and characterised. Furthermore, the distribution across the genus, 
of homologs for the key genes involved in the utilisation of these substrates, 
is analysed.  
Chapter III focuses on identifying the regulatory network responsible for the 
transcriptional control of the genes involved in LN(n)T and LNB metabolism, 
as described in Chapter II. Three transcriptional regulators and corresponding 
operator and associated (inducible) promoter sequences are characterised, the 
latter governing transcription of the genetic elements involved in 
LN(n)T/LNB metabolism. Furthermore, identification of the transcriptional 
xviii 
 
effectors reveals the presence of a series of positive-feedback loops, inducing 
expression in the presence of breakdown products of key HMO-derived 
metabolites. 
In Chapter IV, Bifidobacterium isolates are obtained by screening a number 
of faecal samples from breastfed infants, using HMO components 
fucosyllactose and sialyllactose as selective carbohydrates, and compared 
with isolates obtained using lactose or GOS. A range of bifidobacterial 
species were obtained, varying between the selective carbohydrate used, and 
supporting the notion of selective HMO consumption. Analysis of the 
glycosyl hydrolase profiles of representative strains of the species obtained 
reveals interesting correlations with their preferential carbohydrate-based 
selection.  
In Chapter V, a novel B. kashiwanohense isolate, APCKJ1, which was 
isolated in the work of Chapter IV, is demonstrated to consume 
fucosyllactose, and the mechanisms of its utilisation of both fucosyllactose 
and L-fucose is examined. Using a combination of approaches, the main 
cellular machinery involved in the uptake and degradation of fucosyllactose 
is characterised, and heterologous expression of these genes in a B. breve 
UCC2003 host reveals not only the mechanisms of the utilisation of 
fucosyllactose, but a potentially functional pathway for the catabolism of 
fucose, in both strains.  
The work presented in this thesis represents novel information on the 
metabolism of HMO glycans in bifidobacteria, particularly in the species B. 
breve and B. kashiwanohense, as well as key insights into the strategies of 
HMO utilisation by infant-associated bifidobacteria in general, as an 
adaptation to the GIT of breastfed infants.  
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Chapter I 
General Introduction 
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1.1 Summary 
Consumption of breastmilk is considered to be an important factor that 
determines the development and composition of the mammalian infant gut 
microbiota. A specific subset of glycans secreted in human mothers’ milk, 
known as human milk oligosaccharides (HMOs), are believed to be 
particularly instrumental in the compositional development of the neonatal 
gut microbiota in humans. Among other functions, HMOs act as growth 
factors for specific (beneficial, see below) bacteria, and are thus considered 
to be prebiotics, thereby supporting the establishment of a (healthy) infant-
type microbiota. Of the bacterial components of the neonatal (human) gut 
microbiota, members the genus Bifidobacterium are dominant, in particular a 
small number of species, which are believed to bestow a range of health 
benefits to the infant host. It is thus hardly surprising that these infant-
associated bifidobacterial species possess the ability to directly or indirectly 
consume HMOs as their sole carbohydrate source. A number of different 
strategies for HMO utilisation have been observed in these species, targeting 
various HMO components of this highly heterogeneous glycan mixture. In 
this review, we discuss the structures and biological functions of HMOs, and 
the role of bifidobacteria in the gut microbiota of the breastfed infant, as well 
as describing the various approaches employed by infant-associated 
Bifidobacterium species for the utilisation of HMOs in order to establish 
stable populations in this highly specific niche. 
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1.2 Introduction 
1.2.1 General features of the infant gut microbiota. Among the many 
ecological niches within and on the human body, the most densely populated 
with microbial species is the intestine. Composed of trillions of microbes, this 
complex community is known as the gut microbiota [1, 2]. This anaerobic 
ecosystem is rich in nutrients, and populated by microbial members of the 
three domains of life, Eukarya, Bacteria and Archaea, as well as viruses, all 
of which may be present as autochthonous or transient inhabitants of this 
niche [3]. The composition of this community is affected by a range of 
environmental conditions within the host, which means that the microbiota 
will not only vary between hosts, but also within a single host during its life 
span [4]. These microorganisms are believed to influence each other through 
countless, yet mostly unexplored interactions, while they also affect and are 
affected by the host via a range of interactions, both symbiotic and parasitic 
[5]. Such microbe-microbe and microbe-host interactions, and thus the 
composition of this community, are increasingly being implicated in host 
health, acting as a critical factor in the development or prevention of 
numerous health conditions [6, 7]. Food breakdown and nutrient liberation, 
direct pathogen inhibition or exclusion, immune system priming and 
modulation, and promotion of host cell differentiation are just some of the 
functions attributed to (elements of) the gut microbiota. The concept of the 
overall ecosystem of the human body as a so-called holobiont means that the 
various associated communities are dynamic, and change with and in 
response to the host, in an attempt to achieve the most harmonious symbioses 
possible [2, 8]; however, it is also the changeable nature of these communities 
that allow disease states to develop [6]. 
The composition and interactions of this community are known to change 
over the lifetime of a (mammalian) host [9-11], with a very clear development 
from an infant-type to an adult-type microbiota as the infant progresses in age 
and changes dietary habits [12-15]. It is thought that members of the early gut 
microbiota significantly impact on the health of the infant host [16]. Until 
recently, the limitations of culture-based techniques meant that only a small 
proportion of all members of the human gut microbiota had been cultured, let 
4 
 
alone studied in pure culture [17]. This led to the rapid development and use 
of culture-independent approaches for the determination of microbiota 
composition [2, 18]. Recent developments in culturomics, however, are 
aimed at closing the gap between cultivation-dependent and cultivation-
independent knowledge of the microbiota by enabling in vitro cultivation and 
characterisation of an ever increasing number of microbes [19, 20].  
The infant gut microbiota is typically viewed as that of subjects aged <1 year, 
is considered to have a low diversity, yet being highly dynamic and unstable 
as compared to the adult-type microbiota (often described as present in 
individuals aged >1 year, although this can vary depending on the individual) 
[13, 21]. Despite this, it has been observed that across individuals, the 
dominant genera of the infant gut microbiota are Bifidobacterium, 
Veillonella, Streptococcus, Citrobacter, Escherichia, Bacteroides and 
Clostridium [13, 22], with in particular bifidobacteria being dominant in 
breastfed infants [21, 23-26].  
 
1.2.2 Factors affecting the development of the infant gut microbiota. A 
range of factors, both environmental and host-specific, play a role in the 
development and composition of the gut microbiota in the neonatal gut, which 
is essentially a blank canvas for the establishment of a complex microbial 
community [14]. Accordingly, these factors have a major bearing on the 
overall health status of the infant host, and their development as they progress 
in age [21]. 
Recent studies have suggested that establishment of the infant gut microbiota 
begins as early as during pregnancy [27-29] through microbial exposure in 
utero, although these claims are still controversial. The three biggest 
determinants of neonatal microbiota composition as we currently know them 
are delivery mode, gestational age and feeding mode. In full term infants, 
delivery mode is the first major determinant of neonatal gut microbiota 
composition [30]. Contact with the maternal faecal and vaginal microbiotas 
during vaginal delivery results in the colonisation of the neonatal gut with 
vaginal commensals such as Lactobacillus and Prevotella [31-33], whereas 
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caesarean-section (C-section)-delivered neonates are more frequently 
colonised with microbes associated with the maternal epidermal microbiota 
and nosocomial microbes [12, 14, 32, 34], such as Proteobacteria, Firmicutes 
(including Staphylococcus and Clostridium) and Propionibacterium [33, 35-
37]. As well as a reduced diversity, the microbiotas of C-section-delivered 
infants (compared to vaginally-delivered infants) have also been shown to 
display reduced relative abundance of Bifidobacterium and Bacteroides, and 
increased relative abundance of some groups of Clostridium [13, 31, 32, 35]. 
The differences between the compositions of naturally-delivered and C-
section-delivered infants do, however, tend to vanish over time, particularly 
after 12 months [38, 39].  
Gestational age also plays a major role in the composition of the neonatal 
microbiota. Preterm infants are classed as neonates born before 37 weeks 
gestation [40, 41], and because of developmental immaturity, are often 
subject to extended stays in hospital following birth, which may include 
artificial feeding, antibiotic administration and other drug treatment regimes, 
all of which are known to affect the composition of the gut microbiota. 
Greater abundances of bacteria of the Enterobacteriaceae family and species 
of the Enterococcus, Lactobacillus and Staphylococcus genera have been 
observed in the microbiota of pre-term than full-term neonates, as well as 
reduced abundances of Bacteroides and Bifidobacterium species [13, 42-49] 
initially following birth, with the absence of bifidobacteria noted as far as 7 
days post-birth in pre-term neonates [50].  
Last of the three major factors to affect the microbiota of the neonatal gut is 
the manner of feeding. Numerous studies have identified significant 
differences in the gut microbiota composition of breastfed and formula-fed 
infants [13, 51, 52], which is believed to be caused by the presence of unique 
compounds present in breastmilk, including specific carbohydrates known as 
human milk oligosaccharides (HMOs; see below). Breastfed infants have 
been demonstrated to possess a gut microbiota with increased abundances of 
bifidobacteria and lactobacilli [24, 53-56], whereas that of formula-fed 
infants displays a greater diversity, including species of Escherichia, 
Clostridium, Bacteroides, Prevotella and Enterococcus [38, 49, 52-54, 56, 
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57]. It has furthermore been observed that formula-fed infants adopt an adult-
type microbiota sooner in life as compared to their breastfed counterparts 
[34]. In breastfed infants, the weaning stage from exclusive breastfeeding to 
solid foods encourages the development of the gut microbiota from the 
dynamic infant-type composition to the more stable, yet much more complex 
adult-type microbiota [22, 58, 59], which functions more specifically in the 
metabolism of nutrients derived from an omnivorous diet, including plant-
derived carbohydrates [25]. 
Use of the once-popular term ‘dysbiosis’ has recently become unfashionable 
for some [60], as the concept of a universal template for a healthy, ‘normal’ 
microbiota is undefinable due to natural inter- and intra-personal variations 
in microbiota composition. However, it has been well-documented that 
certain changes in the gut microbiota composition predispose to the 
development of disease states in the host, whether pathogenic or 
immunogenic [6]. In the infant gut microbiota, factors such as pre-term birth 
and its associated (disturbed) microbiota have been implicated in the 
development of infectious diseases, including necrotising enterocolitis (NEC) 
[61] and neonatal sepsis [62, 63]. Immune disorders such as asthma [64], 
allergy [65] and type 1 diabetes [66], as well as increased risk of obesity in 
later life [67] have all been correlated with a variety of factors, such as C-
section birthing, that are potentially disruptive to the development of the 
healthy infant microbiota.   
 
1.2.3 Pre- and pro-biotics, and their role in infant microbiota 
development. As our knowledge of the presence and roles of various member 
of the infant gut microbiota increases, so too increases the potential for their 
use in and/or modulation by intervention treatments. The realisation of this 
potential has come to fruition through the development of the concepts of 
probiotics and prebiotics.  
Probiotics are defined as “live microorganisms that, when administered in 
adequate amounts, confer a health benefit on the host” [68]. The use of 
probiotics as clinical interventions in infants is progressively becoming a 
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more tangible possibility, for example in the treatment of conditions such as 
neonatal sepsis [69] or NEC [70]. Such interventions rely on direct 
interactions between the probiotic strains and the pathogens themselves, or 
the modulation of the immune system for the prevention of disease.  
The definition of the term ‘prebiotic’ has undergone a number of iterations 
since its original description [71-74], but the most recent consensus on the 
term defines it as “a substrate that is selectively utilized by host 
microorganisms conferring a health benefit” [75]. To be considered a 
prebiotic, an ingredient must: (I) resist gastric activity, hydrolysis by 
mammalian enzymes and gastrointestinal absorption; (II) be fermented by 
(particular elements of) the intestinal microbiota; and (III) stimulate growth 
and/or activity of intestinal bacteria associated with health and well-being 
[71]. By the rules of its strictest definition, only two commercially-used food 
ingredients currently meet the criteria to be classed as prebiotics, namely 
(trans-)galactooligosaccharides (TOS/GOS) and fructooligosaccharides 
(FOS), including inulin [76]. Inclusion of a mixture TOS and inulin in infant 
formula has been shown to increase the abundance of faecal bifidobacteria in 
both preterm and term infants [77, 78]. Furthermore, the potential of 
synbiotics, which are defined as “mixtures of probiotics and prebiotics that 
beneficially affect the host by improving the survival and implantation of live 
microbial dietary supplements in the gastrointestinal tract, by selectively 
stimulating the growth and/or by activating the metabolism of one or a limited 
number of health-promoting bacteria, thus improving host welfare” [79], is 
showing promise for the treatment of infant conditions such as NEC [80] and 
neonatal sepsis [81].  
While the idea of pre- and pro-biotics as clinical or commercially-available 
interventions may be considered a relatively recent invention, both of these 
phenomena have naturally evolved in mammals, including humans. The 
process of vaginal birthing encourages the vertical transfer of microbes from 
mother to infant, and recent work has also shown the potential transfer of 
indigenous breastmilk bacteria from mother to infant [82, 83]. Breastmilk 
functions as a prebiotic through the presence of HMOs, which encourage the 
establishment of specific microbes by selective utilisation of these sugars [74, 
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84, 85] (see below). Breastmilk itself can therefore be viewed as the 
archetypal synbiotic, conveying both vital microbes and prebiotic substrates 
to the neonatal host.  
1.3 Human Milk Oligosaccharides (HMOs) 
1.3.1 General features. HMOs constitute a heterogeneous mix of structurally 
diverse unconjugated glycans that are highly abundant in and rather unique 
to human milk [74, 86-88]. Over 200 different structures have been identified 
[89], with oligosaccharide concentration and compositions varying between 
individual women and over the course of lactation [87, 90]. In fact, a recent 
study found that HMO concentration and composition profiles vary 
substantially across populations from different geographical regions [91]. 
While colostrum, the thick secretion produced by the mammary glands in the 
days leading up to and following birth, has been found to contain as much as 
20-25 g HMOs per litre [92, 93], the concentration of HMOs in human 
breastmilk is typically 5-20 g/L [87, 92-97]. This, however, still exceeds the 
total amount of protein in breastmilk, and in fact is 100 to 1000 times greater 
than the total oligosaccharide concentration of bovine milk [88]. 
 
1.3.2 Structure and composition. HMO glycans are structures composed of 
5 monosaccharides: glucose (Glc), galactose (Gal), N-acetylglucosamine 
(GlcNAc), fucose (Fuc) and Sialic/N-acetylneuramic acid (Sia/Neu5Ac) [74, 
87]. Lactose (Galβ1-4Glc) is the base glycan forming the reducing end of all 
HMO structures, and can be elongated through a β1-3 or β1-6 linkage with 
lacto-N-biose, (LNB; Galβ1-3GlcNAc) or its isomer N-acetyllactosamine 
(LacNAc; Galβ1-4GlcNAc) [87]. This results in the generation of the 
tetrasaccharides lacto-N-tetraose (LNT; Galβ1-3GlcNAcβ1-3Galβ1-4Glc) or 
lacto-N-neotetraose (LNnT; Galβ1-4GlcNAcβ1-3Galβ1-4Glc), respectively, 
the latter of which can be further elongated by the addition of further LNB or 
LacNAc moieties [74, 88]. HMO structures with LNB linked to the terminal 
lactose (at the non-reducing end) are classed as Type 1 structures, while those 
with LacNAc at this position are classed as Type 2 HMOs. Type 1 HMOs 
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have been found to predominate over Type 2 HMOs in human breastmilk 
[98]. Interestingly, this is in contrast to other lactating mammals (which 
produce similar milk oligosaccharides), where Type 2 structures dominate 
over (or are present in the absence of) Type 1 structures [99-101]. β1-6 
linkages between disaccharide units allows chain branching of chains [74]. 
Lactose or larger chains can be fucosylated via an α1-2, α1-3 or α1-4 linkage, 
or sialylated via an α2-3 or α2-6 linkage, with many HMO structures 
occurring in several isomeric forms [74, 87]. The mechanisms of HMO 
synthesis are as yet poorly understood [74]. A schematic of a selection of 
HMO structures and their components is shown in Figure 1.1. 
On average, fucosylated structures are thought to comprise 50-80 % of all 
HMOs in mature human milk, with sialylated HMOs comprising 10-20 % 
[89, 90, 92-97, 102, 103]. These values, however, are a composite of data 
obtained from a range of individual studies in various geographical locations, 
and don’t reflect the extent of inter-individual variations in fucosylation and 
sialylation. The level of fucosylation of HMOs corresponds to the mother’s 
Lewis blood group status [95, 104-107]. Women expressing the enzyme 
fucosyltransferase 2 (FUT2), which catalyses the addition of Fuc via an α1-2 
linkage to Lewis blood group epitopes and HMOs, are known as Secretors, 
and produce high levels of α1-2-fucosylated HMOs in their breastmilk [104]. 
Likewise, women expressing the enzyme fucosyltransferase 3 (FUT3) are 
known as Lewis-positive, and produce high levels of α1-3/4-fucosylated 
HMOs [105, 108]. The milk of non-Secretors and/or Lewis-negative mothers 
contains little to no α1-2-fucosylated and/or α1-3/4-fucosylated HMOs, 
respectively [104, 105], and accordingly, HMO composition of Secretor +/- 
Lewis +/- women varies greatly [95, 106, 107]. Typically, α1-2-fucosylated 
HMOs is considerably more prevalent than α1-3/4-fucosylated HMOs [91]. 
Subtle variation in sialylation does also occur, though it has been suggested 
that this is not correlated to genotype, yet is due to inter-individual variation 
in expression patterns of the metabolic machinery required for sialylation 
[88]. The various concentrations of individual HMO structures thus does vary 
between individuals, although recent work has demonstrated patterns of 
different HMO profiles more common to specific geographical regions and 
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ethnicities [91]. For example, roughly 70 % of Caucasian women are 
Secretors [88]. 
Once ingested, HMOs resist degradation in the upper gastrointestinal tract by 
gastric acid and pancreatic enzymes en route to the distal small intestine and 
colon [109, 110]. As they do not serve any direct nutritional function to 
humans (since they are not metabolised by the infant), it is in the gut that 
HMOs perform their beneficial activities for the neonate, as outlined in the 
two sections below. The vast majority of HMOs are either metabolised by 
infant gut microbes, or excreted intact in the faeces and urine [111-114]. 
 
1.3.3 HMOs as the archetypal prebiotic. The best-studied beneficial HMO 
function is its role as a prebiotic. HMOs meet all criteria necessary for their 
definition as a prebiotic [71, 76], encouraging the growth of particular, 
beneficial microbes in the infant gut. Only a specific set of bacteria are 
capable of successfully metabolising HMOs, and using them as a substrate 
for growth, and HMOs are therefore believed to select a specific infant-type 
microbiota through the provision of a significant metabolic competitive 
advantage [84, 87, 115, 116]. HMOs, when provided as the sole carbohydrate 
source, have been demonstrated to encourage the growth of a number of 
species of Bacteroides [117] and Bifidobacterium [118-120]. It is this 
‘bifidogenic’ effect, in particular, that is thought to serve as the main driver 
for the dominance of bifidobacteria in the breastfed neonatal gut microbiota 
[24]. The mechanisms and implications of this bifidogenic effect will be 
discussed later. Interestingly, a recent study demonstrated the powerful 
microbiota-determining effect of HMOs, where it was found that different 
HMO compositions were in fact correlated with distinct microbiota 
populations in breastfed infants [121]. 
 
1.3.4 Other beneficial properties of HMOs. One of the other important 
functions of HMOs in shaping the neonatal gut microbiota and benefiting the 
health of the infant host is that they can prevent or reduce the chance of 
infection caused by pathogens. As well as competitively excluding 
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pathogenic microbes through the encouragement of non-pathogenic 
commensals, HMOs may also prevent infection through direct interaction 
with pathogens [122]. HMOs are known to prevent adhesion of pathogenic 
bacteria, protozoans and viruses to the mucosal surfaces, by acting as decoy 
receptors for pathogen binding, thus preventing colonisation [123, 124]. This 
anti-adhesive mechanism has been demonstrated to prevent mucosal adhesion 
by bacterial pathogens such as Campylobacter jejuni [125, 126], protozoan 
pathogens such as Entamoeba histolytica [127] and possibly viral pathogens 
such as human immunodeficiency virus (HIV) [128]. In fact, another study 
showed the ability of some strains of the common mastitis-causing bacterium 
Streptococcus to bind the HMO 2’-fucosyllactose (2-FL) [129], indicating the 
potential for HMO to act as a natural anti-mastitis agent in lactating mothers. 
HMOs have also been demonstrated to function as antimicrobials, preventing 
the proliferation of pathogens, such as Group B Streptococcus [130] and 
Candida albicans [131].  
Apart from their prebiotic function, another indirect method of prevention of 
infection possessed by HMOs is their ability to modulate host cellular 
responses, such as intestinal epithelial cell apoptosis, proliferation and 
differentiation [132]. Furthermore, HMOs have been shown to induce 
changes in the host intestinal epithelial glycocalyx [133], which may prevent 
adhesion of pathogens to this surface. Immune cells have also been shown to 
be affected by HMOs [134, 135], thus suggesting immunomodulatory effects 
that may benefit the infant. Finally, the HMO component sialic acid has been 
implicated in brain development and cognition in infants [136]. 
 
1.3.5 Potential for HMOs as nutritional supplements and clinical 
therapeutics for infants. Given the benefits that HMOs provide to the infant 
gut microbiota and, directly or indirectly, the infant itself, the use of these 
glycans for therapeutic and/or commercial seems to have a lot of potential. 
As prebiotics, HMOs shape the overall infant gut microbiota and its 
associated interactions, and thus may present a more effective intervention 
compared to single-strain or multi-strain probiotics. As a therapeutic, HMO 
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components are currently enjoying interest as a possible treatment for NEC 
in infants. Breastfed infants are 6-10 time less likely to develop NEC than 
their formula-fed counterparts [137-139], and more recent work has shown 
promise for the prevention of NEC by individual HMO components such as 
2-FL and disialyllacto-N-tetraose in both rat and murine models [140-143].  
The use of HMOs as (part of) commercially available supplements also 
presents an attractive prospect. The inclusion of non-human oligosaccharides, 
such as GOS, fructo-oligosaccharides (FOS) and inulin, in supplements and 
formula milk for infants, for the modulation of infant gut microbiota is a wide-
spread practice [144, 145]. However, the evident structure-specific effects of 
HMOs mean that the benefits conferred by these structurally distinct glycans 
cannot fully mimic the beneficial effects of HMO on the infant. For this 
reason, the inclusion of actual HMO structures in supplements or formula 
milk may at some point become feasible. Recent work has demonstrated the 
safety of the inclusion of specific HMOs in infant formula [146], and even 
observed lower inflammatory cytokines in infants that had been receiving 
formula milk supplemented with 2-FL, as compared to that of formula-fed 
controls, and similar to that of breastfed infants [147]. The main prohibitive 
factor in the advancement of this technology, however, is the present inability 
to artificially (chemically or biotechnologically) synthesise a wide range of 
HMO glycans in sufficient quantities, although this is becoming a more 
tangible possibility, with a number of companies moving into this area. 
Furthermore, we currently do not know if the administration of high quantities 
of individual HMO glycans in (infant) humans, as opposed to the 
heterogeneous mix of glycans naturally found in breastmilk, is associated 
with any health risks [2]. 
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1.4 Infant-Associated Bifidobacteria 
1.4.1 General features of bifidobacteria. As mentioned above, the infant 
gut microbiota is heavily enriched in species of Bifidobacterium [13, 22], 
particularly in healthy, full-term, breastfed infants [21, 23-26]. First isolated 
from the faeces of a breastfed infant by Tissier in 1899, bifidobacteria are 
Gram-positive, saccharolytic, typically Y-shaped anaerobes, whose 
chromosomes have a high G-C content. Belonging to the Bifidobacteriaceae 
family and the Actinobacteria phylum [148-151], the genus Bifidobacterium 
at present includes 59 different taxa [2, 45, 151]. These species fall within 7 
phylogenetic clusters; namely (I) the B. asteroides group, (II) the B. 
pseudolongum group, (III) the B. longum group, (IV) the B. bifidum group, 
(V) the B. adolescentis group, (VI) the B. pullorum group and (VII) the B. 
boum group [150]. Species of bifidobacteria can also be clustered into seven 
ecological niches of origin, namely the human GIT, human blood, human oral 
cavity, non-human mammals, birds, social insects and wastewater [152]. As 
of December 2017, there are 56 complete bifidobacterial genome sequences 
in the database of the National Centre for Biotechnology Information (located 
at the following website: 
https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi), 
representing 40 species. Bifidobacterial genomes typically possess a G-C 
content that varies between 58 and 61 %, ranging in size from 1.73 to 3.16 
Mb, the largest being that of B. scardovii JCM 12489 [153-155].  
A recent study of the distribution of bifidobacterial species in a wide range of 
hosts across the mammalian branch of the tree of life revealed a high 
prevalence (>85 %) of 4 Bifidobacterium species across the 67 mammalian 
taxa studied [156]. These four highly ubiquitous species, namely B. longum, 
B. adolescentis, B. bifidum and B. pseudolongum, are also commonly 
associated with the gut microbiota of humans. Despite the presence of 
bifidobacteria in both infant and adult microbiota, there is considerable 
variation between the typical species make-up of either [157, 158]. Following 
the depletion of oxygen in the infant gut by facultative anaerobes, 
bifidobacteria become dominant in the associated gut microbiota [159]. Their 
relative abundance decreases as the infant develops and the microbiota 
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progresses from an infant-type to an adult-type [158, 160]. The abundance of 
bifidobacteria in the adult gut microbiota remains stable at a relative 
abundance of between 2 % and 15 % [158]. A number of studies have 
observed that the most prevalent species of Bifidobacterium in the adult gut 
microbiota is B. longum subsp. longum [161, 162]. While a study by Matsuki 
et al. also detected the high prevalence of this species in the microbiota of 
healthy adults, they observed a greater abundance of the species B. 
adolescentis and B. catenulatum [162]. Levels of B. breve and B. bifidum, 
which are among the most abundant species in the infant gut microbiota (see 
below), were observed to markedly decrease as hosts progressed in age, and 
their microbiota developed into an adult-type [163]. The bifidobacterial 
component of the gut microbiota generally remains stable throughout 
adulthood [158, 160], but a general decrease in the relative abundance of 
Bifidobacterium species has been observed in elderly individuals [164-167]. 
A multitude of purported benefits are correlated to the presence of 
bifidobacteria in the adult host, ranging from management of inflammatory 
gut conditions, to improved neurocognition, to potential antitumor effects 
[168-170], and as such, a number of adult-targeted probiotic supplements 
containing bifidobacteria are now commercially available.  
 
1.4.2 Bifidobacteria in the infant gut. The infant gut microbiota typically 
possesses a significantly higher relative abundance of bifidobacteria than that 
of the adult [24, 161]. As with the entire infant gut microbiota, the 
colonisation and establishment of bifidobacteria in this niche is dependent on 
several extrinsic factors. Vertical transmission from the mother is believed to 
be an important contributor to the bifidobacterial component of the neonatal 
gut microbiota, with a number of maternal sources implicated in this process, 
including the vagina, faeces, breast milk, amniotic fluid and placenta [171-
173]. Significantly higher (relative abundance) levels of bifidobacteria have 
been detected in vaginally-born infants as compared to their C-section-born 
counterparts [31]. As mentioned above, considerably lower levels of 
Bifidobacterium species have been observed in pre-term as compared to full-
term infants [13, 42-49, 174].  
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Perhaps the most significant factor in the establishment and persistence of 
high levels of bifidobacteria in the infant gut microbiota is breastfeeding. In 
general, the most abundant species of Bifidobacterium in the neonatal gut 
microbiota are B. longum, B. breve and B. bifidum [24, 159, 161], and to a 
lesser extent B. pseudocatenulatum and B. adolescentis [24, 54, 175-177]. B. 
kashiwanohense is also considered an infant-associated species, but appears 
to be much less frequently detected, with only two strains classified at present 
[178, 179]. Evidence exists for the correlation of breastfeeding and formula-
feeding with the abundance of particular bifidobacterial species in the infant 
[26]. This is likely due to the ‘bifidogenic’ effect of breastmilk, in particular 
HMOs, which only specific infant-associated species of Bifidobacterium are 
capable of metabolising. B. breve, B. bifidum, B. longum subsp. infantis and 
B. longum subsp. longum have been detected in both breastfed and formula-
fed infants [180, 181], Interestingly, one study found that B. longum subsp. 
infantis was more abundant in breastfed infants, whereas B. longum subsp. 
longum was found to be more abundant in formula-fed neonates [54]. 
Additionally, B. adolescentis, a typical adult-associated species, has been 
identified in the faecal microbiota of formula-fed infants, but appears to be 
rarely found in that of their breastfed counterparts [181], an observation 
consistent with the notion that an adult-type microbiota develops earlier in 
formula-fed infants as compared to age-matched breastfed infants [34]. 
Interestingly however, a very recent study, on inheritance of maternal 
bifidobacteria in infants by vertical transmission, observed the abundance of 
typically adult-associated Bifidobacterium species B. adolescentis and B. 
catenulatum in infant faecal samples [177]. This puts into question the 
currently-accepted notion of typical infant-associated and adult-associated 
species, though it would be interesting to assess the feeding status of the 
infants in question, which may have a bearing on these results.  
 
1.4.3 Health benefits of bifidobacteria in the infant host. As the healthy 
infant gut microbiota is heavily enriched for bifidobacteria, it is hardly 
surprising that this bacterial group is thought to provide various benefits to 
the infant host. From a metabolic perspective, the microbiota, and thus 
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bifidobacteria as a dominant component in the case of infants, may act as a 
virtual organ, degrading otherwise non-digestible carbohydrates, thereby 
releasing metabolites such as short-chain fatty acids (SCFAs) [182, 183], 
which can be absorbed by and benefit the host [184-186]. Bifidobacteria have 
also been demonstrated to exhibit antimicrobial activity against pathogens 
such as Salmonella typhimurium and Listeria monocytogenes [187, 188], and 
have been shown to inhibit growth of Enterobacteriaceae within colicky 
infant microbiota cultures [189]. Through interactions with host cells, 
bifidobacteria are also thought to benefit the infant host with anti-
inflammatory activity; growth B. longum subsp. infantis and B. bifidum in the 
presence of HMOs has been shown to promote the expression of anti-
inflammatory cytokines in eukaryotic cells [190], while B. longum subsp. 
infantis alone has been demonstrated to reduce intestinal permeability [191]. 
Studies using murine models have demonstrated the potential for the use of 
bifidobacterial strains as probiotics with reported effects on coeliac disease 
[192], obesity [193] and infection-induced psychology [194]. Human studies 
involving treatment with bifidobacteria have also reported benefits in infants 
[195], with effects ranging from reduced allergic responses [196], the 
prevention of NEC and infant colic [197-199], to the prevention of diarrhoea 
[197] and improved enteral feeding in low birth-weight neonates [200, 201], 
all supporting the potential of bifidobacteria as a bio-therapeutic that can be 
used for a variety of disorders/diseases/conditions. 
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1.5 Metabolism of Human Milk Oligosaccharides by Infant-Associated 
Bifidobacteria 
1.5.1 Carbohydrate metabolism in bifidobacteria. Perhaps the most useful 
tool at the disposal of bifidobacteria in order to successfully colonize and 
persist in the human gut is their ability to metabolize a wide array of both 
plant- and host-derived glycans [202]. The carbohydrate-containing portion 
of the human diet can be divided into two general categories in the context of 
digestibility in the GIT: (i) simple sugars, absorbed in the host intestine 
directly or following hydrolysis by host-coded enzymes; and (ii) complex 
carbohydrates of plant (e.g cellulose, arabinoxylan) or human/animal (e.g. 
HMO, glycogen, mucins) origin that are resistant to degradation by host-
encoded enzymes and absorption [74, 88, 203-205]. Thus, whether of host-, 
carer-, or diet-derived origin [206], a plethora of carbohydrates reach the 
small and large intestine and will then be metabolized by elements of the 
microbiota. It is believed that this abundance of carbohydrate substrates 
allows bifidobacteria to thrive, owing to their dynamic and highly specialised 
saccharolytic metabolism.  
Bifidobacterial carbohydrate metabolism depends on systems to internalize 
the carbohydrates, while hydrolytic abilities are also required, being present 
as intra- and/or extracellular enzymes. A recent study of predicted proteins in 
different bifidobacterial species found that 13.7 % of identified cluster of 
orthologous groups (COGs) were associated with carbohydrate metabolism, 
across the 47 (sub)species assessed, whereas carbohydrate metabolism-
associated COGs were only found to comprise 8.0 % of the COGs for the 
entire gut microbiome [202]. Interestingly, in this same study, the core 
carbohydrate metabolism-associated COGs were found to represent just 5.5 
% of all identified bifidobacterial COGs, suggesting strong selective pressure 
for the acquisition of accessory genes necessary for the utilisation of specific 
carbohydrates, allowing a species of Bifidobacterium to thrive within a 
particular niche.  
While most gut bacteria rely on the glycolytic pathway for energy generation 
when metabolising carbohydrates [207], bifidobacteria utilise the fructo-6-
phosphate phosphoketolase pathway (also known as the Bifid Shunt) as their 
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central catabolic pathway [208, 209]. Fructose-6-phosphoketolase (F6PPK) 
is the key enzyme in this pathway, and its presence can be used as a signature 
property for members of the Bifidobacterium genus [210]. This pathway 
yields 2.5 ATP molecules for every mole of glucose, making it more efficient 
in energy production than carbohydrate fermentation pathways of other gut 
commensals, including lactic acid bacteria [211]. Fermentation of 1 mole of 
hexose sugar via the Bifid Shunt theoretically yields 1.5 moles of acetate and 
1 mole of lactate, while the fermentation of pentose sugars typically yields 
one mole each of acetate and lactate, although factors such as carbon source, 
cell growth phase and external pH can affect these ratios [207, 211]. This 
doesn’t, however, account for the energy cost of the internalisation of 
carbohydrate substrates. The end products of other monosaccharide 
catabolism pathways in Bifidobacteria, such as the Leloir pathway (glucose-
6-phosphate) and the amino-sugar metabolism pathway (fructose-6-
phosphate), are subsequently shuttled through the central catabolic pathway 
of the Bifid shunt [208].  
In nearly all bifidobacteria, carbohydrate transport is predominantly mediated 
using ATP-requiring ATP-binding cassette (ABC) transporters, proton 
symporters and proton-motive force-driven permeases, with energy cost-
neutral phosphoenolpyruvate-phosphotransferase systems (PEP-PTS) being 
much less common than other transport systems [212-215], as exemplified in 
B. longum subsp. longum NCC2705 [216]. This may be due to the metabolic 
preferences of bifidobacteria for the more abundantly available complex 
carbohydrates in the intestinal niche, as ABC transporters have been 
demonstrated to transport a variety of oligosaccharides [217], whereas PEP-
PTS systems are normally only associated with the transport of mono- and 
certain di-saccharides [218, 219]. Interestingly, this notion is supported by 
the finding that B. bifidum PRL2010 atypically (for bifidobacteria) possesses 
more PEP-PTSs than ABC transporters, however, since B. bifidum 
extracellularly hydrolyses complex HMO structures, members of this species 
internalize the released mono- and di-saccharide constituents (see for further 
details and references below).  
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As the majority of the carbohydrates available to bifidobacteria in the 
intestine arrive in the form of di-, tri- or more complex oligo-saccharides, a 
crucial family of proteins are those which degrade these carbohydrates into 
their constituent monosaccharides, known as glycosyl hydrolases (GHs). 
Found in all three kingdoms (Archaebacteria, Eubacteria and Eukaryota), 
GHs hydrolyse the glycosidic bond between monosaccharides [220, 221], of 
which there are 148 families, listed in the CAZy database (available at 
http://www.cazy.org/Glycoside-Hydrolases.html) [221, 222]. A recent study 
of the carbohydrate-active enzymes encoded by the Bifidobacterium 
pangenome revealed the presence of proteins belonging to 57 GH families 
encoded among 47 species [202]. B. scardovii, B. biavatii, B. saeculare and 
B. dentium were each found to possess a GH index (the number of GHs 
predicted in each genome normalized by genome size) that is higher than the 
bifidobacterial average. It has previously been suggested that the large GH 
arsenal encoded by B. dentium Bd1 is due to the availability of a wider array 
of complex carbohydrate sources in its niche, the oral cavity [214]. While 
predicted GHs required for the hydrolysis of both plant-derived and 
human/host-derived glycans were detected across the pangenome, those 
associated with the degradation of human-derived glycans were found to be 
particularly prevalent in B. longum subsp. infantis and B. bifidum [202]. 
These include GH33 exo-sialidases, GH29 and GH95 fucosidases, GH20 
hexosaminidases and lacto-N-biosidases, GH20 lacto-N-biosidases, GH38 
and GH125 α-mannosidases, and GH101 and GH129 α-N-
acetylgalactosaminidases. This is not surprising, as both of these species are 
commonly infant-associated, and it would follow that they preferentially 
target the human-derived carbohydrates present in breastmilk for metabolism 
(see below). 
 
1.5.2 Transcriptional regulation of carbohydrate metabolism in 
bifidobacteria. As with other bacteria, bifidobacteria appear to employ the 
regulatory process known as carbon catabolite repression (CCR) to, when 
presented with multiple carbon sources, preferentially utilise the substrate 
yielding the greatest amount of energy, while inhibiting the expression or 
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activity of proteins involved in the uptake and catabolism of other substrates 
[223, 224]. This typically occurs either via the inhibition of expression of 
genes involved in the uptake or utilisation of secondary substrates [225], or 
via the inhibition of proteins involved in the uptake of secondary substrates 
[223, 226].  
The phenomenon of CCR is of vital importance to (bifido)bacterial 
metabolism, particularly those found in niches such as the intestine, where 
multiple carbohydrate sources are likely to be available, and utilisation of the 
most energy-efficient substrates is key to remain competitive, and establish 
and maintain a stable population. So far in bifidobacteria, CCR appears to 
predominantly occur by the inhibition of expression of genes involved in 
secondary substrate uptake and catabolism. Down-regulation of expression of 
genes involved in fructose metabolism was observed in B. breve UCC2003 
grown in the presence of ribose and/or glucose [227]. Likewise, B. longum 
subsp. longum NCC2705 was shown to preferentially consume lactose over 
glucose, with the downregulation in expression of a glucose-specific 
permease [228], and B. longum subsp. infantis ATCC15697 was 
demonstrated to downregulate transcription of two fucosidase-encoding 
genes (and the concurrent upregulation of another) when grown on a complex 
mixture of HMOs as opposed to lactose [229]. 
These transcriptional regulatory processes are presumed to be mediated by 
the activity of transcription factors (TFs), which can act as transcriptional 
activators and/or repressors. Bacterial TFs are typically DNA binding 
proteins which bind to an operator sequence in the region around a regulated 
promoter, which impedes (or promotes) the binding of RNA polymerase, and 
thus the initiation of transcription. This is best characterised for the LacI 
regulator protein, which represses transcription of the lac (lactose uptake and 
utilisation) operon in E. coli [230, 231]. Binding of an effector molecule to 
the repressor protein induces a conformational change in the repressor, which 
prevents its binding to the operator sequence, and thus allowing transcription 
to proceed. In the case of the lac operon from E. coli, the inducer molecule is 
allolactose, a product of the β-galactosidase activity on lactose [231]. This 
ensures the expression of the lac operon only when the breakdown product of 
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lactose, and thus lactose itself is present [232]. Multiple LacI-type regulators 
are found in E. coli, functioning in the same manner, but with distinct specific 
operator sequences, target promoters and effectors [233-235].  
LacI-type TFs are highly common in bifidobacteria, and in fact are more 
prevalent in Bifidobacterium species than any other genus in the 
Actinobacteria phylum [236]. This abundance of encoded LacI-type 
repressors in bifidobacterial genomes is believed to enable rapid adaptation 
of these species to changes in available carbohydrate sources [215]. However, 
a number of TFs type for other regulator types, including ROK-type, RpiR-
type, DeoR/SorC-type, BglG-type, TetR-type, AraC-type and GntR-type 
regulators, have been identified in bifidobacteria (although their involvement 
in the control of carbohydrate-related metabolic pathways has not been 
established yet for all) [237].  
In bifidobacteria, transcriptional repression is best studied in B. breve 
UCC2003. To date, seven predicted LacI-type regulators have been 
characterised in UCC2003: LacIfos, regulating transcription of the fos operon 
[238]; GalR, regulating transcription of the galactan utilisation operon [239]; 
CldR, regulating cellodextrin utilisation [240]; RbsR, regulating transcription 
of the ribose utilisation cluster [227]; MelR1 and MelR2, regulating 
transcription of the melezitose utilisation cluster [241]; and AtsR1, regulating 
utilisation of N-acetylglucosamine-6-sulfate (GlcNAc-6-S) [242]. A review 
of bifidobacterial LacI regulators found that 69 % of the LacI-type TFs 
studied regulate one or two operons, with 90 % of the investigated LacI-type 
TFs representing local regulators, controlling a single metabolic pathway, 
usually associated with the metabolism of one carbohydrate (where it 
involves more carbohydrates, these are then related in terms of 
monosaccharide identity and glycosodic linkage) [236]. It was also found that 
20 % of the operons regulated by LacI-type TFs contain multiple operator 
sites, and 75 % of the LacI-type TF binding motifs are located between 30 
and 140 bp upstream of the closest regulated gene. These findings agree with 
the experimentally characterised LacI-type repressor systems from B. breve 
UCC2003 (see above). The DNA binding motifs for the LacI operator 
sequences were found to share the central CG pair in the centre of the binding 
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sites for other LacI-type TFs [236, 243], with the only exception being the 
predicted binding site of LacIfos [238].  
However, LacI-type regulators are not the only repressors found in B. breve 
UCC2003. NanR, a GntR-type repressor, was identified as regulating 
utilisation of sialic acid [244], while AtsR2, a ROK-type repressor, was also 
implicated in the regulation of GlcNAc-6-S utilisation [242]. Furthermore, a 
LacI-type repressor, ROK-type repressor and an N-acetylglucosamine 
(NagC)-type repressor have all been implicated in the regulation of HMO 
utilisation in UCC2003 (see Chapter III of this thesis) [245]. In fact, a recent 
study analysing transcriptional regulons in 10 Bifidobacterium genomes 
revealed 268 predicted TFs belonging to the LacI, ROK, DeoR, AraC, GntR 
and TetR regulator families, forming 64 orthologous groups of regulators 
[237]. Transcription factors for LacI-type and ROK-type regulators were 
found to be the most common, however. Interestingly, this study predicted a 
LacI-type regulator, AraQ, as a global regulator for genes involved in central 
carbohydrate metabolism in bifidobacteria.  
Despite the abundance of repressors studied in B. breve UCC2003, as of yet 
only one carbohydrate utilisation-associated transcriptional regulator acting 
as an activator has been characterised in bifidobacteria: a ROK (repressor 
open reading frame kinase)-type regulator RafR, which was found to activate 
transcription of the raffinose-related sugar utilisation cluster [241].  
 
1.5.3 HMO metabolism by infant-associated bifidobacteria as an 
adaptation to the infant gut. It is hardly surprising that the wide-ranging 
carbohydrate-utilising capabilities of bifidobcateria extend to the utilisation 
of milk-derived glycans, as they are among the most abundant species of the 
infant gut, particularly in breastfed neonates [24]. As already mentioned, the 
repertoire of carbohydrates metabolised by bifidobacteria includes glycans of 
both plant and human origin [202], the latter including HMOs. Thus, it would 
follow that the bifidobacterial species most commonly found in the gut 
microbiota of breastfed infants possess metabolic capabilities for the 
degradation and utilisation of HMO structures. A number of studies have 
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assessed the ability of a range of Bifidobacterium species to consume various 
individual and combined HMO glycans as a growth substrate, and found that 
the only species demonstrating significant growth on these sugars were those 
commonly associated with the infant gut microbiota, namely B. bifidum, B. 
breve, B. longum subsp. infantis and, on occasion, B. longum subsp. longum 
[118-120, 246-248]. More studies have also demonstrated the ability of B. 
kashiwanohense isolates to utilise fucosyllactose as a growth substrate [249, 
250], and recently species occasionally found in the infant gut microbiota, 
such as B. pseudocatenulatum and B. longum subsp. suis, have been shown 
to utilise certain HMO substrates to a limited degree [177, 249]. These studies 
present strong evidence for the utilisation of HMOs by infant-associated 
bifidobacteria as a highly specialised adaptation to the environment of the 
breastfed infant gut [86, 251]. A recent study in fact correlated the presence 
of specific sets of GHs and transporters encoded in the genomes of infant-
associated bifidobacteria with each strain’s ability to consume various HMO 
substrates [177], further supporting the notion of HMO utilisation as a highly 
specific adaptation by infant-associated species of Bifidobacterium.  
In particular, the utilisation of the HMO component lacto-N-biose (LNB) is 
viewed as a strong indicator of overall HMO consumption by bifidobacteria 
[252]. The pathway for the utilisation of galacto-N-biose (GNB) and LNB has 
only been identified in infant-associated bifidobacteria, including B. breve, B. 
bifidum, B. longum subsp. infantis and B. longum subsp. longum [252-256]. 
This pathway, whose central enzyme is a GH112 GNB/LNB phosphorylase 
(GLNBP), functions in the degradation of LNB into glucose-1-phosphate and 
N-acetylglucosamine, which then enter the energy-generating Bifid Shunt 
and amino-sugar metabolising pathways, respectively [257]. Despite the 
relatively low abundance of free LNB in HMO [91], LNB can be found as a 
component of many larger HMO structures, especially due to the 
aforementioned predominance of Type 1 over Type 2 HMOs [98]. Thus, the 
presence of the GNB/LNB pathway in bifidobacterial species can be viewed 
as a proxy for HMO utilisation in some form, and perhaps an indicator of an 
infant-associated species, as has been previously suggested in the ‘LNB 
hypothesis’ [255]. This, however, may be something of an oversimplification, 
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as different species of infant-associated bifidobacteria utilise considerably 
varying strategies for HMO utilisation, targeting distinct HMO glycans and 
their components, as will be discussed below. 
  
1.5.4 Strategies for HMO utilisation by infant-associated bifidobacteria 
vary. The selective consumption of various HMO components by different 
species of infant-associated bifidobacteria explains the abundance and 
prevalence of a number of different species in the same niche [258]. While 
all of the species share the same central metabolic pathway, differences in 
their catabolic capabilities of higher substrate structures creates a form of 
metabolic partitioning, enabling them to target different HMO components. 
Excluding the work presented in this thesis, the species best characterised for 
their strategies of HMO utilisation are B. bifidum and B. longum subsp. 
infantis, as well as some limited knowledge of HMO metabolism in B. longum 
subsp. longum [257, 258]. Within the context of this thesis, the metabolism 
of HMO components LNT, LNnT and LNB in B. breve UCC2003 is 
described in detail (Chapter II, Chapter III) [259], as well as the elucidation 
of HMO metabolism pathways in B. kashiwanohense. In the following 
section, the current knowledge of HMO metabolism in these infant-associated 
species is discussed. A simplified schematic representing the (currently) 
known metabolic strategies for HMO utilisation by B. bifidum, B. breve, B. 
longum subsp. infantis and B. kashiwanohense is shown in Figure 1.2. 
 
1.5.5 HMO metabolism by Bifidobacterium bifidum. B. bifidum typically 
targets complex HMO structures, carrying out the extracellular hydrolysis of 
these HMOs, including LN(n)T and fucosylated and sialylated structures, 
prior to the import and metabolism of (most of) the resultant mono- and di-
saccharides [258]. This extracellular hydrolysis is enabled by the expression 
of an array of secreted GHs, including α-sialidases, α-fucosidases, β-
galactosidases, lacto-N-biosidases and N-acetylhexosaminidases [257, 260, 
261]. B. bifidum extracellularly releases fucose and sialic acid residues from 
complex fucosylated and/or sialylated HMOs through the activity of secreted 
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fucosidases and sialidases, respectively. B. bifidum strains have been shown 
to express 2 extracellular α-fucosidases; one a GH95 enzyme targeting alpha-
1,2-linked HMOs (e.g. 2- -1,3/4-
fucosylated HMOs (e.g. 3-FL), respectively, liberating fucose [262-264]. 
Likewise, a GH33 α-sialidase expressed by B. bifidum has been shown to 
liberate sialic acid residues from sialylated HMOs (e.g. 3/6-sialyllactose) 
[265, 266]. Interestingly, B. bifidum was shown not to utilise fucose or sialic 
acid residues [118, 119, 267], which can instead be consumed by other 
members of the microbiota. A recent study has indeed demonstrated the 
ability of B. breve UCC2003 to cross-feed on the sialic acid released by the 
degradation of sialyllactose by B. bifidum PRL2010 [268].  
Whether free, or released by the hydrolysis of fucosylated/sialylated HMOs, 
the tetrasaccharides lacto-N-tetraose (LNT) and lacto-N-neotetraose (LNnT) 
are also extracellularly hydrolysed by B. bifidum. LNT is hydrolysed at its 
central β-1,3-link by an extracellular GH20 lacto-N-biosidase into lactose and 
LNB, the latter being transported into the cell and then degraded by two 
distinct LNB phosphorylases (LNBP), releasing galactose 1-phosphate and 
GlcNAc, which enter the Leloir and amino-sugar metabolising pathways, 
respectively [269] (and then routed through the Bifid Shunt). An extracellular 
GH42 β-galactosidase cleaves LNnT at its Galβ-1,4 residue, liberating 
galactose and lacto-N-triose [270]. The lacto-N-triose is then further 
hydrolysed by an extracellular GH20 N-acetylhexosaminidase, releasing 
GlcNAc and lactose. Even longer HMO structures are similarly hydrolysed 
by β-galactosidases in a sequential fashion, releasing constituent mono- and 
di-saccharides which B. bifidum can successfully consume [271]. Whether 
released by the hydrolysis of fucosyllactose, sialyllactose or more complex 
structures such as LN(n)T, liberated lactose is either degraded by extracellular 
β-galactosidases (of GH42 or GH2 family) and the resulting glucose and 
galactose internalised, or the lactose is internalised intact and hydrolysed by 
intracellular β-galactosidases (of the GH2 family) [271]. The resulting 
galactose and glucose then enter the Leloir and Bifid Shunt Pathways, 
respectively.  
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1.5.6 HMO metabolism by B. longum subsp. infantis. B. longum subsp. 
infantis internalises particular, intact small-mass HMOs, and degrades these 
then into monosaccharides for further metabolic processing [120, 258]. 
Studies on bifidobacterial consumption of various HMOs have shown the 
ability of B. longum subsp. infantis to consume small-chain HMOs structures, 
typically DP≤8 (i.e. composed of ≤8 monosaccharide units) with a molecular 
mass <1400 Da [120], such as sialyllactose, fucosyllactose and LN(n)T (as 
well as their fucosylated/sialylated versions) for growth [118-120, 177]. 
These structures are internalised by B. longum subsp. infantis [272], and then 
degraded into their constituent monosaccharides by various GHs [257]. 
Fucosylated HMOs are hydrolysed at their fucosyl linkages by a number of 
both GH29 and GH95 α-fucosidases, liberating L-fucose [229]. Sialic acid 
residues are liberated from sialylated HMOs by the hydrolytic activity of two 
GH33 α-sialidases [248]. Liberated sialic acid and L-fucose are both further 
metabolised by B. longum subsp. infantis for energy generation [250, 273].  
Free LN(n)T is internalised by the cell, or may be released by the intracellular 
hydrolysis of other complex, yet internalized HMOs, as described above. 
LN(n)T is then degraded sequentially from its non-reducing end in a similar 
fate to LNnT in B. bifidum metabolism [257]. A GH42 β-galactosidase 
hydrolyses the Galβ1-3GlcNAc residue at the non-reducing end of LNT, 
releasing galactose and lacto-N-triose [274]. Likewise, both the 
aforementioned GH42 β-galactosidase and a GH2 β-galactosidase hydrolyse 
the Galβ1-4GlcNAc residue at the non-reducing end of LNnT, releasing the 
same products [274]. Galactose enters the Leloir pathway, while lacto-N-
triose is hydrolysed by a GH20 N-acetylhexosaminidase into N-
acetylglucosamine (which enters the amino-sugar metabolic pathway) and 
lactose [275]. Lactose is then hydrolysed by β-galactosidases into glucose and 
galactose, destined for the Bifid Shunt and Leloir pathways, respectively 
[274]. Free LNB, if present in the environment, is taken up by B. longum 
subsp. infantis, and is phosphorolysed by a GH112 LNBP enzyme, releasing 
galactose and N-acetylglucosamine [252]. These versatile HMO utilisation 
capabilities of B. longum subsp. infantis are enabled by the presence of a large 
43-kb gene cluster within its genome [272, 273]. This ‘HMO-utilisation 
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island’ encodes the two fucosidases, one of the sialidases, the LN(n)T-
specific β-galactosidases and N-acetylhexosaminidase mentioned above. 
While no intact equivalent to this locus has been identified in other 
Bifidobacterium species [276], segments encoding the genes for 
fucosyllactose and/or fucose utilisation have been identified in B. breve, B. 
longum subsp. suis, B. longum subsp. longum and B. kashiwanohense [249, 
250, 277].  
 
1.5.7 HMO utilisation by Bifidobacterium breve. B. breve internalises intact 
neutral HMO moieties such as LNT, LNnT and LNB, and sequentially 
hydrolyses these oligosaccharides for the subsequent metabolism of their 
monosaccharide constituents [259] (Chapter II of this thesis). Previously, it 
was thought that B. breve simply behaved as a scavenger, ‘mopping up’ 
HMO-derived monosaccharides released by the extracellular hydrolysis of 
larger HMO structures by other members of the infant gut microbiota [86]. 
This data was supported by the finding that many strains of B. breve studied 
do not grow on fucosylated or small-mass sialylated HMOs, including 
fucosyllactose and sialyllactose [118-120], and that B. breve is capable of 
cross-feeding on sialic acid and fucose released from the extracellular 
hydrolysis of sialylated and fucosylated structures by B. bifidum [268, 278]. 
In a recent study, however, we demonstrated not only that B. breve UCC2003 
is capable of internalising and metabolising small-mass neutral HMOs such 
as free LNT, LNnT and LNB for growth, but that the pathways for the 
utilisation of these three glycans in B. breve are in fact identical to those in B. 
longum subsp. infantis [259]. The mechanistics of this pathway will be 
described in detail in Chapter II [259], and the transcriptional regulation of 
the associated genetic loci will be described in Chapter III (manuscript 
submitted for review). As for its scavenging abilities, B. breve does indeed 
possess pathways for the uptake and utilisation of both free L-fucose [250] 
and free sialic acid [268].  
Interestingly, recent work has also identified the ability of a small number of 
B. breve strains to utilise fucosylated HMO and longer-chain sialylated 
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HMOs for growth [247, 279]. In the strains tested, this growth seemed linked 
with the activities of a GH29 α-fucosidase and a GH33 α-sialidase, 
respectively. As homologs of both of these genes are in fact encoded in the 
genomes of most B. breve strains [177, 202, 247, 279], the inability of many 
B. breve strains to utilise fucosylated and/or sialylated HMOs may be due to 
the absence of other essential components for their metabolism, such as 
transporter proteins. Nonetheless, the adaptations of such B. breve strains for 
the consumption these glycans demonstrates the metabolic versatility of this 
species as a bona fide HMO-utiliser. 
 
1.5.8 HMO metabolism in other Bifidobacterium species. While B. longum 
subsp. infantis, B. bifidum and B. breve are the most commonly found species 
of bifidobacteria found in the gut of the breastfed infant, there are, as 
mentioned above, other species which are associated with this niche, such as 
B. longum subsp. longum and B. kashiwanohense. The hypothesis of the 
bifidogenic effect of HMO strongly suggests the ability of such species to 
also utilise at least some HMOs for growth. The known HMO-metabolising 
capabilities of these species are outlined below.  
Strains of B. longum subsp. longum generally grow poorly on HMO 
substrates [118-120, 247]. However, B. longum subsp. longum strain 
JCM1254 was shown to utilise LNB in the same fashion as B. bifidum, 
employing the activity of an extracellular GH136 lacto-N-biosidase [269, 
280]. Additionally, B. longum subsp. longum strain SC596 was recently 
shown to utilise fucosylated HMOs, such as fucosyllactose, due to a gene 
cluster [277], which encodes the components necessary for the import of 
fucosylated structures, two α-fucosidases (GH29 and GH95) and the enzymes 
necessary for L-fucose metabolism. Both the observed utilisation of 
fucosylated HMOs in this strain and the cluster of genes responsible for this 
ability are highly similar to that employed by strains of B. longum subsp. 
infantis. These two distinct and apparently atypical adaptations in two 
different strains of B. longum subsp. longum highlight the versatility of 
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Bifidobacterium species in their carbohydrate metabolising capabilities to 
colonise and persist in a given niche.  
Only recently have the capabilities of HMO metabolism in B. 
kashiwanohense begun to be explored and understood. Two studies in the last 
number of years have identified the ability of B. kashiwanohense to grow 
using fucosyllactose as a substrate, yet also observed the inability of the 
strains tested to utilise the liberated L-fucose [249, 250]. The authors 
suggested that only the lactose was internally degraded and consumed, and 
that the L-fucose was not utilised due to the absence of genes encoding key 
components of the L-fucose utilisation pathway. However, in Chapter IV 
(manuscript in preparation), we describe the ability of a novel B. 
kashiwanohense strain, isolated from the faeces of a breastfed infant, to utilise 
fucosyllactose for growth, but do not observe the accumulation of L-fucose 
in the media following growth. We characterise the internalisation of 
fucosyllactose by B. kashiwanohense, as well as its hydrolysis by two α-
fucosidases (GH29 and GH95), and furthermore identify a putative pathway 
for the utilisation of L-fucose (Chapter IV), similar to that previously 
observed in B. longum subsp. infantis and B. breve [249, 250].  
Little investigation has taken place of HMO metabolism by B. 
pseudocatenulatum. A recent study observed the ability of one strain to 
consume and grow on LNT [177]. Another study has indicated that the GH 
content of this species is rather high as compared with that of other 
Bifidobacterium species [202], which may indicate the ability to degrade a 
range of carbohydrates, possibly including certain HMOs. Further research 
on this species is therefore required.  
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1.6 Conclusion 
The range of carbohydrate-metabolising capabilities of bifidobacteria is one 
of the key factors supporting the ability of these species to thrive in the 
various niches in which they are found. Whether this entails the metabolism 
of intact carbohydrate sources in the oral cavity by B. dentium, the 
degradation and consumption of indigestible plant-derived dietary 
polysaccharides and oligosaccharides in the adult gut by adult-type species, 
or the utilisation of HMOs in the gut of the breastfed neonate by infant-
associated species, the repertoire of GHs and other carbohydrate utilisation 
pathways expressed by bifidobacteria is very specifically tailored to the niche 
they inhabit. In no group is this better exemplified than in the infant-
associated species of Bifidobacterium. Not only do strains of B. breve, B. 
longum subsp. infantis, B. bifidum and B. kashiwanohense possess the 
capability to utilise (particular) HMOs, but they each employ specific 
strategies for the utilisation of different HMO components. Not only does this 
metabolic partitioning underpin the adaptability of these species to their 
niche, perhaps allowing them to co-exist in the same host, but it also displays 
their ability to take part in metabolic resource-sharing, as observed with B. 
bifidum and species such as B. breve. The overall metabolic adaptations of 
these species to the availability of HMO in the gut of breastfed infants, as 
well as the highly ‘bifidogenic’ effect of these glycans, provides strong 
evidence for the co-evolution of bifidobacteria and humans, and only serves 
to highlight their importance to the infant gut microbiota, and overall infant 
health and development. 
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1.7 Thesis outline 
Chapter II of this thesis is comprised of work elucidating the mechanisms and 
components of LNT, LNnT and LNB utilisation pathways in Bifidobacterium 
breve UCC2003. Chapter III focuses on identifying the network responsible 
for the transcriptional regulation of LN(n)T and LNB metabolism, as 
described in Chapter II. In Chapter IV, Bifidobacterium isolates are obtained 
by screening of the faeces of breastfed infants, using HMO components 
fucosyllactose and sialyllactose as selective carbohydrates, and compared 
with isolates obtained using lactose or GOS. In Chapter V, a novel B. 
kashiwanohense isolate obtained during Chapter IV is demonstrated to 
consume fucosyllactose, and the mechanisms of its utilisation of both 
fucosyllactose and L-fucose is examined.  
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1.8 Figures 
 
Figure 1.1. Schematic diagram of selected HMO structures. The addition of fucose (in a α1-2 or α1-3 linkage) or sialic acid (in a α2-3 or α2-6) 
linkage to lactose results in fucosyllactose or sialyllactose, respectively. Alternatively, lactose can be elongated with LNB (Type 1 structures) or 
N-acetyllactosamine (Type 2 structures). Further additions in a β1-3 linkage extends the chain (para HMO) or a β1-6 linkage introduces chain 
branching (iso HMO). Further fucose and/or sialic acid subunits may also be added to larger structures. Monosaccharide key is shown at the bottom 
of the figure.  
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Figure 1.2. Schematic representation of the differing HMO utilisation strategies in B. bifidum, B. breve, B. longum subsp. infantis and B. 
kashiwanohense, as described in the text in section 1.5. B. bifidum releases extracellular glycosyl hydrolases, and internalises small-mass neutral 
liberated components, such as lactose and LNB.  B. breve consumes and internally degrades intact neutral such as LN(n)T, as well as 
monosaccharides liberated by extracellular degradation of HMO. B. longum subsp. infantis internalises intact HMO structures (both acidic and 
neutral), and internally degrades them using an arsenal of glycosyl hydrolases. B. kashiwanohense internalises fucosyllactose, and degrades these 
structures using intracellular glycosyl hydrolases. 
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Chapter II 
Bifidobacterium breve UCC2003 metabolises the human milk 
oligosaccharides lacto-N-tetraose and lacto-N-neo-tetraose through 
overlapping, yet distinct pathways. 
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2.1 Abstract 
In this study, we demonstrate that the B. breve strain UCC2003 possesses 
specific metabolic pathways for the utilisation of lacto-N-tetraose (LNT) and 
lacto-N-neotetraose (LNnT), which represent the backbone moieties of Type 
I and Type II human milk oligosaccharides (HMOs), respectively. Using a 
combination of experimental approaches, the enzymatic machinery involved 
in the metabolism of LNT and LNnT was identified and characterised. 
Homologs of the key genetic loci involved in the utilisation of these HMO 
substrates were identified in B. breve, B. bifidum, B. longum subsp. infantis 
and B. longum subsp. longum using bioinformatic analyses, and were shown 
to be variably present among other members of the Bifidobacterium genus, 
with a distinct pattern of conservation among human-associated 
bifidobacterial species.  
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2.2 Introduction 
Consumption of maternal breast milk, or the lack thereof, influences the gut 
microbiota composition of the neonate [1-3]. Incorrect development or 
disruption of this microbial community contributes to disorders such as 
Necrotising Enterocolitis, infantile diarrhoea and Group B streptococcal 
neonatal infection [4-8]. Strikingly, the faecal microbiota of healthy breastfed 
infants is enriched for certain species of the Bifidobacterium genus [9], which 
are high-G+C Gram-positive anaerobes and members of the Actinobacteria 
phylum. Naturally found as symbionts of the mammalian, avian or insect 
digestive tract, bifidobacteria enjoy substantial scientific attention due to their 
purported beneficial properties [2, 10-16].  
While lactose (Galβ1-4Glc) comprises the main carbohydrate component of 
human breast milk and colostrum (~90 %), human milk oligosaccharides 
(HMOs) constitute the next most significant carbohydrate fraction, ahead of 
glycolipids [2, 17], and are typically found at a concentration of ≥4 g/L (and 
as high as 15 g/L) [2, 18-20]. HMOs represent a heterogeneous glycan mix, 
of which > 200 distinct structures have been identified [18]. The majority of 
these HMO structures are classified into 2 types. The abundant Type I HMOs 
contain lacto-N-tetraose (LNT; Fig. 2.1) (Galβ1-3GlcNAcβ1-3Galβ1-4Glc), 
which is composed of a lactose coupled to lacto-N-biose (LNB) (Galβ1-
3GlcNAc). Type II HMOs contain the LNT isomer lacto-N-neotetraose 
(LNnT; Fig. 2.1) (Galβ1-4GlcNAcβ1-3Galβ1-4Glc), which is composed of 
lactose linked to N-acetyllactosamine (LacNAc) (Galβ1-4GlcNAc), an 
isomer of LNB. Larger Type I and II HMOs may contain further LNB or 
LacNAc subunits, and can be fucosylated or sialylated [2, 18, 21]. 
Despite the abundance of HMOs in breast milk, these glycans cannot be 
metabolised by the infant, and it is currently believed that they facilitate the 
establishment of an infant-specific gut microbiota, with bifidobacteria being 
particularly abundant [16, 22]. Common among the latter are Bifidobacterium 
bifidum, Bifidobacterium longum subsp. infantis and subsp. longum, 
Bifidobacterium breve, Bifidobacterium pseudocatenulatum and 
Bifidobacterium kashiwanohense[9, 23-27]. Unsurprisingly, it has been 
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shown that certain bifidobacterial species can metabolize (particular) HMOs 
[18, 28-34]. Previous studies have elucidated some of the metabolic pathways 
for HMO utilisation by B. bifidum and B. longum subsp. infantis, with 
particular focus on LNT and LNnT [28]. B. longum subsp. infantis 
internalises particular, intact small-mass HMOs, including (precursors of) 
LN(n)T [18, 28, 35], which are in turn hydrolysed into lacto-N-triose and 
galactose, by two HMO type-specific β-galactosidases (i.e. one enzyme 
acting on LNT, the other on LNnT) [29]. Lacto-N-triose is further hydrolysed 
by an N-acetylhexosaminidase into N-acetylglucosamine (GlcNAc) and 
lactose, the latter of which is then hydrolysed by a β-galactosidase [30] into 
galactose and glucose, to enter the Leloir and fructose-6-phosphate (F6P) 
phosphoketolase pathways and amino-sugar metabolising pathway (for 
GlcNAc) [28, 31], all of which feed into the overall Bifidobacteriaceae-
specific metabolic pathway known as the Bifid Shunt. 
B. bifidum possesses two distinct, and apparently unique pathways for the 
metabolism of LN(n)T. Large type I and II HMOs are degraded by 
extracellular fucosidases, sialidases and glycosyl hydrolases to release LNT 
and LNnT [28]. LNT is hydrolysed at its central β-1,3-link by an extracellular 
glycosyl hydrolase into lactose and LNB, the latter being transported into the 
cell and then degraded by two distinct LNB phosphorylases (LNBP), 
releasing galactose 1-phosphate and GlcNAc [32, 33]. The released lactose is 
either hydrolysed by an extracellular β-galactosidase into galactose and 
glucose (which are both internalized by the cell), or transported into the cell, 
where it is similarly hydrolysed by intracellular β-galactosidases [28, 32, 36]. 
These monosaccharides are then further metabolised by the same pathways 
as those described for B. longum subsp. infantis. This type I HMO metabolism 
has also been observed in some species of B. longum subsp. longum [32, 37]. 
In addition, B. bifidum possesses a separate pathway to degrade and utilise 
LNnT. An extracellular β-galactosidase cleaves LNnT at its Galβ-1,4 residue, 
liberating galactose and lacto-N-triose [34]. The lacto-N-triose is then further 
hydrolysed by an extracellular N-acetylhexosaminidase, releasing GlcNAc 
and lactose, with the latter further hydrolysed by the aforementioned 
extracellular β-galactosidases into glucose and galactose (which are 
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transported into the cell) [36], or internalised and then degraded as described. 
Once within the cell, these monosaccharides are metabolised as mentioned 
above [34].  
It should be noted that a specific pathway exists for LNB metabolism, known 
as the GNB/LNB pathway. In B. bifidum, as mentioned above, LNB is 
phosphorolysed into monosaccharides by either of two different LNBP 
enzymes, while in B. infantis, LNB is phosphorolysed by a single LNBP 
enzyme, whose gene shares homology with both B. bifidum LNBP genes [28, 
31]. This GNB/LNB pathway appears to be present in bifidobacterial species 
commonly found in infant faeces [28]. The apparent absence of this 
GNB/LNB pathway and, specifically, the LNBP-encoding gene in adult-
associated bifidobacteria (such as B. adolescentis) is manifested through their 
inability to utilise LNB or other HMOs as a carbon source for growth, and 
may therefore explain, at least in part, their absence or low abundance in the 
microbiota of breast-fed infants[18]. 
Little information exists regarding HMO utilisation by B. breve, although it 
has been suggested that B. breve acts as a ‘scavenger’ through cross-feeding 
on HMO-derived monosaccharides that are released due to the extracellular 
hydrolytic activities produced by other infant gut microbiota members [18]. 
However, more recent studies have suggested that B. breve is able to utilise 
particular HMOs, such as fucosyllactose, LNT and sialyl-LNT, or derived 
structures such as LNB and sialic acid [17, 38-40]. 
In this study, we show that B. breve possesses the metabolic machinery for 
the degradation and utilisation of LNT and LNnT. Furthermore, we assess the 
presence and distribution of key gene loci involved in LNT and LNnT 
utilisation across members of the Bifidobacterium genus. 
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2.3 Materials and Methods 
Bacterial strains, plasmids, and culture conditions. Bacterial strains and 
plasmids used in this study are listed in Supplemental Table S2.2. B. breve 
UCC2003 was routinely cultured in either de Man Rogosa and Sharpe 
medium (MRS medium; Difco, BD, Le Pont de Claix, France) supplemented 
with 0.05 % cysteine-HCl or reinforced clostridial medium (RCM; Oxoid 
Ltd., Basingstoke, England). Carbohydrate utilization by bifidobacterial 
strains was examined in modified de Man Rogosa and Sharpe (mMRS) 
medium prepared from first principles[41], and excluding a carbohydrate 
source. Prior to inoculation, the mMRS medium was supplemented with 
cysteine-HCl (0.05 %, wt/vol) and a particular carbohydrate source (1 %, 
wt/vol). It has previously been shown that mMRS does not support growth of 
B. breve UCC2003 in the absence of an added carbohydrate [42]. 
Carbohydrates used were lactose (Sigma Aldrich, Steinheim, Germany), LNB 
(Elicityl Oligotech, Crolles, France), lactosamine-hydrochloride 
(lactosamine-HCl) (Glycom, Lyngby, Denmark), LNT (Glycom, Lyngby, 
Denmark; Elicityl Oligotech, Crolles, France) and LNnT (Glycom, Lyngby, 
Denmark). A 1 % wt/vol concentration of carbohydrate was considered 
sufficient to analyse the growth capabilities of a strain on a particular carbon 
source. The addition of these carbohydrates did not significantly alter the pH 
of the medium, and therefore subsequent pH adjustment was not required. 
B. breve cultures were incubated under anaerobic conditions in a modular 
atmosphere-controlled system (Davidson and Hardy, Belfast, Ireland) at 
37°C. Lactococcus lactis strains were cultivated in M17 broth (Oxoid Ltd., 
Basingstoke, England) containing 0.5 % glucose[43] at 30°C. Escherichia 
coli strains were cultured in Luria-Bertani (LB) broth[44] at 37°C with 
agitation. Where appropriate, growth media contained tetracycline (Tet; 10μg 
ml-1), chloramphenicol (Cm; 5 μg ml-1 for L. lactis and E. coli, 2.5 μg ml-1 for 
B. breve), erythromycin (Em; 100 μg ml-1) or kanamycin (Kan; 50 μg ml-1). 
Recombinant E. coli cells containing (derivatives of) pORI19 were selected 
on LB agar containing Em and Kan, and supplemented with X-gal (5-bromo-
4-chloro-3-indolyl-β-D-galactopyranoside) (40 μg ml-1) and 1 mM IPTG 
(isopropyl-β-D-galactopyranoside). In order to determine bacterial growth 
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profiles and final optical densities, 5 ml of freshly prepared mMRS medium, 
including a particular carbohydrate (see above), was inoculated with 50 μl (1 
%) of a stationary phase culture of B. breve UCC2003. Uninoculated mMRS 
medium was used as a negative control. Cultures were incubated 
anaerobically at 37°C for 24h, and the optical density at 600 nm (OD600) was 
determined manually, or  using a PowerWave microplate spectrophotometer 
(BioTek Instruments, Inc., USA) in conjunction with Gen5 microplate 
software for Windows, at the end of this period, as described previously[42, 
45]. 
 
Bifidobacterium breve Growth Assays. Growth profiles of sixteen distinct 
Bifidobacterium breve strains from the UCC collection (listed in 
Supplemental Table S2.2) on LNT or LNnT, as the sole carbohydrate source, 
using lactose as a positive control, were determined in mMRS, using the 
microplate spectrophotometer, as described above. LNB and lactosamine-
HCl were not included in these assays, as sufficient (and affordable) 
quantities of these carbohydrate substrates could not be obtained.  
Growth profiles of insertion mutant, Tn5 transposon mutant, and 
complementation strains of B. breve UCC2003 generated in this and other 
studies, were determined, manually, as described above, adopting LNT, 
LNnT or LNB as carbohydrate source and in each case using lactose as a 
positive control.  
 
Nucleotide sequence analysis. Sequence data were obtained from the 
Artemis-mediated[46] genome annotations of B. breve UCC2003[47]. 
Database searches were performed using non-redundant sequences accessible 
at the National Centre for Biotechnology Information (NCBI) 
(http://www.ncbi.nlm.nih.gov) using the basic local alignment search tool 
(BLAST)[48, 49]. Sequences were verified and analysed using the SeqMan 
and SeqBuilder programs of the DNAStar software package (version 10.1.2; 
DNAStar, Madison, WI, USA). Gene product (protein) localisation and signal 
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peptide predictions were made using the TMHMM, v. 2.0 and SignalP, v. 
4.1[50] servers, respectively, available at http://www.cbs.dtu.dk/. 
 
DNA Manipulations. Chromosomal DNA was isolated from B. breve 
UCC2003 as previously described[51]. Plasmid DNA was isolated from E. 
coli, L. lactis and B. breve using the Roche High Pure Plasmid Isolation kit 
(Roche Diagnostics, Basel, Switzerland). An initial lysis step was performed 
using 30 mg ml-1 of lysozyme for 30 minutes at 37°C prior to plasmid 
isolation from L. lactis or B. breve. DNA manipulations were essentially 
performed as described previously[44]. All restriction enzymes and T4 DNA 
ligase were used according to the supplier’s instructions (Roche Diagnostics, 
Basel, Switzerland). Synthetic single stranded oligonucleotide primers used 
in this study (Supplemental Table S2.1) were synthesized by Eurofins 
(Ebersberg, Germany). Standard PCRs were performed using Taq PCRmaster 
mix (Qiagen) or Extensor Hi-Fidelity PCR Master Mix (Thermo Scientific, 
Waltham, United States) in a Life Technologies Proflex PCR System 
(Thermo Scientific, Waltham, United States). PCR products were visualized 
by ethidium bromide (EtBr) staining following agarose gel electrophoresis (1 
% agarose). B. breve colony PCR reactions were performed as described 
previously [52]. PCR fragments were purified using the Roche high Pure PCR 
purification kit (Roche Diagnostics, Basel, Switzerland). Plasmid DNA was 
isolated using the Roche High Pure Plasmid Isolation kit (Roche Diagnostics, 
Basel, Switzerland). Plasmid DNA was introduced into E. coli by 
electroporation as described previously[44]. B. breve UCC2003[53] and L. 
lactis[54] were transformed by electroporation according to published 
protocols. The correct orientation and integrity of all plasmid constructs (see 
also below) were verified by DNA sequencing, performed at Eurofins 
(Ebersberg, Germany). 
 
Analysis of global gene expression using B. breve DNA microarrays. 
Global gene expression was determined during log-phase growth of B. breve 
UCC2003 in mMRS supplemented with either LNT, LNnT, LNB, 
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lactosamine-HCl or lactose. The obtained transcriptome was compared to that 
determined for log-phase B. breve UCC2003 cells when grown in mMRS 
supplemented with ribose. DNA microarrays containing oligonucleotide 
primers representing each of the 1864 identified open reading frames on the 
genome of B. breve UCC2003 were designed and obtained from Agilent 
Technologies (Palo Alto, Ca., USA). Methods for cell disruption, RNA 
isolation, RNA quality control, complementary DNA synthesis and labelling 
were performed as described previously [55]. Labelled cDNA was hybridized 
using the Agilent Gene Expression hybridization kit (part number 5188-5242) 
as described in the Agilent Two-Colour Microarray-Based Gene Expression 
Analysis v4.0 manual (publication number G4140-90050). Following 
hybridization, microarrays were washed in accordance with Agilent’s 
standard procedures and scanned using an Agilent DNA microarray scanner 
(model G2565A). Generated scans were converted to data files with Agilent's 
Feature Extraction software (Version 9.5). DNA-microarray data were 
processed as previously described [56-58]. Differential expression tests were 
performed with the Cyber-T implementation of a variant of the t-test[59].  
 
Construction of B. breve UCC2003 insertion mutants. An internal 
fragment of Bbr_0530 (designated here as lntS) (465 bp, representing codon 
numbers 61 through to 216 of the 420 codons of this gene), Bbr_1554 
(designated here as nahS) (488 bp, representing codon numbers 92 through to 
255 of the 442 codons of this gene), and Bbr_1556 (designated here as nahA) 
(443 bp, representing codon numbers 70 through to 218 of the 660 codons of 
this gene) were amplified by PCR using B. breve UCC2003 chromosomal 
DNA as a template and primer pairs IM530F and IM530R, IM1554F and 
IM1554R, or IM1556F and IM1556R, respectively (Supplemental Table 
S2.1). The insertion mutants were constructed using a previously described 
approach [52]. Site-specific recombination of potential tet-resistant mutant 
isolates was confirmed by colony PCR using primer combinations tetWFw 
and tetWRv to verify tetW gene integration, and primers 530confirm1 or 
530confirm2, 1554Confirm1 or 1554Confirm2, and 1556confirm1 or 
1556confirm2 (positioned upstream of the selected internal fragments of 
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Bbr_0530, Bbr_1554 and Bbr_1556, respectively) in combination with 
primer tetWFw to confirm integration at the correct chromosomal location 
(Supplemental Table S2.1).  
 
Complementation of B. breve insertion mutants. DNA fragments 
encompassing Bbr_0529 (designated here as lntA), Bbr_1554 (nahS) and 
Bbr_1556 (nahA) were generated by PCR amplification from B. breve 
UCC2003 chromosomal DNA using Q5 High-Fidelity Polymerase (New 
England BioLabs, Herefordshire, United Kingdom) and primer pairs: 
529pNZ44F and 529pNZ44R, 1554PCB1.2F and 1554PBC1.2R, and 
1556PBC1.2F and 1556PBC1.2R, respectively (Supplemental Table S2.1).  
The resulting lntA-encompassing fragment was digested with PstI and XbaI, 
and ligated to the similarly digested pNZ44 [60]. The ligation mixture was 
introduced into L. lactis NZ9000 by electrotransformation and transformants 
were then selected based on chloramphenicol resistance. The plasmid content 
of a number of Cm-resistant transformants was screened by restriction 
analysis. The integrity of the cloned insert of one of the recombinant 
plasmids, designated pNZ44-lntA, was confirmed by sequencing. The lntA-
coding sequence, together with the constitutive p44 lactococcal promoter, 
specified by pNZ44, was amplified by PCR from pNZ44-lntA using Q5 High-
Fidelity DNA polymerase and primer combination P44 Forward and 
529pNZ44R (Supplemental Table S2.1). The resulting DNA fragment was 
digested with EcoRV and XbaI, and ligated to the similarly digested 
pBC1.2[61], generating pBC1.2-lntA.  
PCR-generated DNA fragments encompassing nahS and nahA, including the 
p44 promoter upstream of each, were digested with BamHI and XbaI, and 
ligated to the similarly digested pBC1.2 to generate pBC1.2-nahS or pBC1.2-
nahA, respectively. The ligation mixtures were introduced into E. coli XL1-
blue by electrotransformation and transformants selected based on 
tetracycline and chloramphenicol resistance. Transformants were checked for 
plasmid content using colony PCR, restriction analysis of plasmid DNA, and 
verified by sequencing. Plasmids pBC1.2-lntA, pBC1.2-nahS or pBC1.2-
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nahA were introduced into the insertion mutant B. breve UCC2003-lntA, B. 
breve UCC2003-nahS and B. breve UCC2003-nahA [62], respectively, by 
electrotransformation and transformants were selected based on tetracycline 
and chloramphenicol resistance. 
 
Construction of overexpression vectors, protein overproduction and 
purification. For the construction of the plasmid pNZ-nahA, a DNA 
fragment encompassing the predicted N-acetylhexosaminidase-encoding 
gene nahA was generated by PCR amplification from chromosomal DNA of 
B. breve UCC2003 using Q5 High-Fidelity DNA polymerase and the primer 
combination 1556F and 1556R (Supplemental Table S2.1). An in-frame N-
terminal His10-encoding sequence was incorporated into the forward primer 
1556F to facilitate downstream protein purification. The generated amplicons 
were digested with PvuII and XbaI, and ligated into the ScaI and XbaI-
digested, nisin-inducible translational fusion plasmid pNZ8150[63]. The 
ligation mixtures were introduced into L. lactis NZ9000 by 
electrotransformation and transformants were then selected based on 
chloramphenicol resistance. The plasmid content of a number of Cm-resistant 
transformants was screened by restriction analysis and the integrity of 
positively identified clones was verified by sequencing. 
Nisin-inducible gene expression and protein overproduction was performed 
as described previously [64-66]. In brief, 400 ml of M17 broth supplemented 
with 0.5 % (wt/vol) glucose was inoculated with a 2 % inoculum of a 
particular L. lactis strain, followed by incubation at 30°C until an OD600 of 
0.5 was reached, at which point protein expression was induced by addition 
of cell-free supernatant of a nisin-producing strain[67], followed by continued 
incubation for a further 2 hours. Cells were harvested by centrifugation and 
protein purification achieved as described previously[64]. Protein 
concentrations were determined using the Bradford method[68]. 
 
Assay of individual and combined β-Galactosidase activities. The 
individual or sequential hydrolytic activities specified by lntA (corresponding 
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to Bbr_0529), nahA (corresponding to Bbr_1556), lacZ2 (corresponding to 
Bbr_0010) and lacZ6 (corrsponding to Bbr_1552) were determined 
essentially as described previously [66], using LNT, LNnT or lactose as a 
substrate. Briefly, a 50-μl volume of each purified protein (protein 
concentration of 0.5 mg/ml) was added to 20 mM morpholinepropanesulfonic 
acid (MOPS) (pH 7.0) buffer and 1 mg ml-1 (wt/vol) of one of the above-
mentioned sugars in a final volume of 1 ml, followed by incubation for 24 
hours at 37°C. When sequential activities were assessed, a sample was heated 
to 85°C for 15 minutes following 12 hour incubation with the first enzyme 
and a given substrate, before the addition of the addition of a second enzyme, 
which was then followed by a further 12-hour incubation at 37°C. All samples 
were subject to a final enzyme denaturation step at 85°C for 15 minutes, 
before storage at -20°C. 
 
HPAEC-PAD analysis. For HPAEC-PAD analysis, a Dionex (Sunnyvale, 
CA) ICS-3000 system was used. Carbohydrate fractions from the above-
mentioned hydrolysis assays (25 μl aliquots) were separated on a CarboPac 
PA1 analytical-exchange column (dimensions, 250 mm by 4 mm) with a 
CarboPac PA1 guard column (dimensions, 50 mm by 4 mm) and a pulsed 
electrochemical detector (ED40) in PAD mode (Dionex). Elution was 
performed at a constant flow-rate of 1.0 ml/min at 30°C using the following 
eluents for the analysis: eluent A, 200 mM NaOH; eluent B, 100 mM NaOH 
plus 550 mM Na acetate; eluent C, Milli-Q water. The following linear 
gradient of sodium acetate was used with 100 mM NaOH: from 0 to 50 min, 
0 mM; from 50 to 51 min, 16 mM; from 51 to 56 min, 100 mM; from 56 to 
61 min, 0 mM. Chromatographic profiles of standard carbohydrates were 
used for comparison of the results of their breakdown by LntA, LacZ2, LacZ6 
and NahA proteins. Chromeleon software (version 6.70; Dionex Corporation) 
was used for the integration and evaluation of the chromatograms obtained. 
A 1 mg/ml stock solution of each of the carbohydrates, as well as their 
putative breakdown products (where available) used as reference standards 
was prepared by dissolving the particular sugar in Milli-Q water.  
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Bioinformatic Analysis. Based on the analysis of the microarray results and 
functional characterisation of gene loci from B. breve UCC2003, as well as 
previously published data on HMO utilisation by B. longum subsp. infantis 
and B. bifidum and B. longum subsp. longum [18, 28-37], four genes were 
identified as crucial for the utilisation of Type I central moieties LNT and 
LNB, and Type II HMO moiety LNnT. On-line available genomic data sets 
of bifidobacteria were first retrieved from the NCBI website 
(http://www.ncbi.nlm.nih.gov) and aligned using an all-vs-all BLASTP 
approach[48], using 70 % of iterative similarity across all available 
Bifidobacterium species over 50 % of protein length and a 0.0001 e-value as 
a significance cut-off. The resulting alignment was subsequently clustered in 
MCL families of orthologous genes using the mclblastline algorithm[69]. The 
resulting output was used to first build a presence/absence binary matrix, and 
then the genes of interest were selected and represented in a heatmap 
employing a code colour grading that represents the degree of sequence 
similarity, with species ordered by origin of isolation. Bbr_1556 (nahA) and 
Bbr_1587 (lnbP) were selected from B. breve UCC2003, BLLJ_1505 (lnbX) 
from B. longum subsp. longum JCM1217 and BBPR_1438 (lnbB) was 
selected from B. bifidum PRL2010. 
 
Microarray data accession number. The microarray data obtained in this 
study have been deposited in NCBI’s Gene Expression Omnibus database and 
are accessible through GEO Series accession number GSE84710. 
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2.4 Results 
Growth of B. breve strains on LNT and LNnT. In order to determine if B. 
breve strains are capable of LNT and/or LNnT metabolism, growth in 
modified MRS medium (mMRS) supplemented with either 1 % (wt/vol) 
LNT, LNnT or lactose (as a positive control) was assessed for sixteen B. breve 
strains by measuring the OD600nm following 24 hours of anaerobic growth at 
37°C. All tested B. breve strains were generally observed to grow well (final 
OD600nm> 0.8) on both LNT and LNnT, with some variability between strains 
on one or both HMO substrates (Supplemental Fig. S2.1).  
 
Transcriptome analysis of B. breve UCC2003 grown on LNT and LNB. 
In order to identify genes that are involved in the metabolism of the Type I 
HMO central moiety LNT and its constituent component LNB, global gene 
expression was determined by microarray analysis during growth of B. breve 
UCC2003 in mMRS supplemented with LNT or LNB, and compared to the 
transcriptome of the strain when grown in mMRS supplemented with ribose. 
Ribose was selected as a suitable transcriptomic reference, as the metabolic 
pathway and gene expression profile for growth of UCC2003 on ribose is 
known and has been employed previously as a reference[39, 70]. Genes that 
were shown to be significantly upregulated in transcription above the 
designated cut-off (fold-change >2.5, P<0.001) are shown in Table 2.1. The 
genes upregulated in expression included those corresponding to the loci 
Bbr_0526-530, Bbr_1551-1553, Bbr_1554-1560 and Bbr_1585-1590. The 
possible involvement of these genes in LNT/LNB metabolism will be further 
discussed below.   
 
Genetic organisation of the genes involved in metabolism of LNT. Based 
on the microarray results and functional prediction of these LNT (and LNB)-
upregulated genes, we implicate the gene clusters Bbr_0526-0530, 
Bbr_1554-1560, Bbr_1585-1590 and possibly Bbr_1551-1553 (outlined in 
Fig. 2.2) in LNT and LNB metabolism in B. breve UCC2003.  
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Bbr_0527 and Bbr_0528 (designated here as lntP1 and lntP2, respectively) 
are both predicted to encode permease components of an ABC transporter 
system. Also located in this cluster (Fig. 2.2) is Bbr_0529 (designated lntA), 
which encodes a predicted β-galactosidase of the GH42 glycosyl hydrolase 
family. Bbr_0530 (designated here as lntS) encodes a putative solute-binding 
protein of an ABC transporter system. Located immediately upstream of this 
cluster, Bbr_0526 (designated lntR) encodes a putative LacI-type 
transcriptional regulator. We have previously implicated the Bbr_0526-530 
gene cluster, in the metabolism of galacto-oligosaccharides [62], where the 
genes were designated gosR (lntR), gosD (lntP1), gosE (lntP2), gosG (lntA) 
and gosC (lntS). Here, we chose to re-designate this cluster as the lnt cluster, 
as its primary function appears to be in LNT and LNnT metabolism (see 
below).  
Bbr_1551 (designated here as lacS) encodes a galactoside symporter, and is 
predicted to function in the transport of lactose and galacto-oligosaccharides 
into the cell. The lacS gene is located in a cluster that also contains genes 
Bbr_1552 (designated lacZ6), a β-galactosidase (GH2) previously shown to 
be involved in galacto-oligosaccharide metabolism [62], and Bbr_1553 
(designated lacI), a lacI-type regulator.  
Bbr_1555 (designated nahR) is predicted to encode a Nag-type transcriptional 
regulator. Bbr_1556 (designated nahA) encodes a putative β-N-
acetylhexosaminidase (GH20). Upstream of nahR is a gene encoding a 
putative solute binding protein (Bbr_1554 and designated here as nahS), 
while located downstream of nahA are Bbr_1558 (nahP1), Bbr_1559 (nahP2) 
and Bbr_1560 (nahT), which are predicted to specify two permeases and an 
ATP-binding protein; respectively (Fig. 2.2). 
Bbr_1587 (designated here as lnbP) encodes a clear homolog (89.84 % 
similarity to BBPR_1055 of B.bifidum PRL2010, and 97.62 % to Blon_2174 
of B. longum subsp. infantis ATCC 15697) of the previously characterised 
LNBP, which belongs to the 1,3-β-Galactosyl-N-acetylhexosamine 
phosphorylase family (GH112)[31, 71, 72]. The presumed function of this 
protein in UCC2003 is the cleavage and concomitant phosphorylation of 
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LNB, and its passage into the GNB/LNB pathway [71-75]. The lnbP gene is 
located in the cluster Bbr_1585-1590, which also includes genes encoding a 
UDP-glucose 4-epimerase (Bbr_1585; galE), a phosphotransferase family 
protein (Bbr_1586; nahK), two permease proteins (Bbr_1588 and Bbr_1589; 
galP1 and galP2, respectively), and a solute-binding protein (Bbr_1590; 
galS) (Fig. 2.2), which are all predicted to function in the metabolism of 
GNB/LNB.  
 
Heterologous expression, purification and biochemical characterisation 
of LntA and NahA, and enzymatic activity on LNT. In order to investigate 
the predicted enzymatic activities encoded by lntA (Bbr_0529) and nahA 
(Bbr_1556) on core Type I HMO structure LNT, the corresponding LntA and 
NahA proteins were purified as His-tagged versions (LntAHis and NahAHis; 
see Materials and Methods). Biochemical and substrate specificity 
characterisations were performed by incubating LntAHis and NahAHis on their 
own or in combination with LNT, and analysing the reaction products by 
HPAEC-PAD. Purified LntAHis was shown to remove the galactose moiety at 
the non-reducing end of the substrate LNT (Fig 2.3A), demonstrating 
hydrolytic activity towards Galβ-1,3GlcNAc in Type I HMO structures, and 
indicating a key role in the hydrolysis and utilisation of LNT.  
When NahAHis was incubated alone with LNT, no degradation of the 
tetrasaccharide structure was observed (Fig 2.3A). However, when LntAHis, 
and NahAHis were together incubated with LNT, complete breakdown of LNT 
to the monosaccharide constituents was observed. When LNT was incubated 
first with LntAHis, followed by an enzymatic heat denaturation step, and then 
incubated with NahAHis, different reaction product profiles were observed. 
Samples taken following the initial denaturation prior to the addition of 
NahAHis showed the presence of lacto-N-triose and galactose. Samples were 
then taken following subsequent incubation with NahAHis indicated the 
presence of galactose, GlcNAc and lactose.  
These results show that LntA hydrolyses LNT, releasing galactose and lacto-
N-triose. Lacto-N-triose is then hydrolysed by NahA, liberating Lactose and 
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GlcNAc. The lactose is then further broken down by LntA (and probably 
other β-Galactosidases in vivo), releasing galactose and glucose.  
 
Phenotypic analysis of B. breve strains harbouring mutations of genes 
implicated in LNT metabolism. In order to investigate if disruption of 
individual genes of the lnt cluster affect the ability of UCC2003 to utilise 
LNT, a number of insertion mutants, which either had been generated 
previously, or which were constructed here, were assessed. An insertion 
mutant was constructed in lntS, resulting in strain B. breve UCC2003-lntS. 
Insertion mutants in lntP1 and lntA, generating strains B. breve UCC2003-
lntP1 and B. breve UCC2003-lntA, respectively, had been generated in a 
previous study (then designated B. breve UCC2003-gosD and B. breve 
UCC2003-gosG, respectively)[62]. These strains were analysed for their 
ability to grow in mMRS supplemented with LNT or LNB, with lactose 
controls, as compared to B. breve UCC2003. A complete lack of growth was 
observed for B. breve UCC2003-lntA in media containing LNT, in contrast 
to normal growth by the wild type in the same media (Fig 2.4A). Growth of 
this mutant strain was not impaired in media containing LNB (not shown). 
As expected, reintroduction of the lntA gene on plasmid pBC1.2 under the 
control of the constitutive p44 promoter [76] (see Materials and Methods) in 
the UCC2003-lntA mutant restored the mutant’s inability to grow on LNT 
(Supplemental Fig. S2.3). Thus, transcriptome data, substrate hydrolysis 
profiles and mutant growth results demonstrate that this β-galactosidase is 
specifically required for the hydrolysis of the Type I HMO central moiety 
LNT at its Galβ1-3GlcNAc residue, liberating galactose and lacto-N-triose 
for further metabolic processing. Insertion mutants B. breve UCC2003-lntP1 
and B. breve UCC2003-lntS were shown to reach the same final optical 
density as wild type strain UCC2003 during growth in mMRS supplemented 
with LNT (Fig 2.4A), indicating that either these predicted transport 
components do not play a role in LNT metabolism, or that there are 
compensatory transport systems for this substrate.  
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In order to investigate if disruption of lnbP affects the ability of UCC2003 to 
utilise LNT and/or LNB, a Tn5 transposon insertion mutant of lnbP 
(designated B. breve UCC2003-lnbP) was adopted from a previous study[74] 
and compared to wild type B. breve UCC2003 for its ability to grow in mMRS 
broth supplemented with LNT or LNB, or lactose as control. As expected, 
and in contrast to the wild type control, B. breve UCC2003-lnbP displayed a 
near total inability to grow on LNB (Fig 2.4B). This mutant reached final 
OD600nm levels on LNT and lactose that are comparable to the wild type strain 
(Fig 2.4B), confirming the crucial role of lnbP in LNB metabolism, while it 
also shows that lntA plays no direct in vivo role in LNB metabolism. 
In order to investigate if disruption of lacS, nahS or nahA affects the ability 
of UCC2003 to utilise LNT, insertion mutants in these genes were assessed. 
The insertional mutant B. breve UCC2003-lacS[62] did not show any 
significant difference in the final OD reached following growth on LNT as 
compared with the wild type (Fig 2.4A). The insertional mutant in nahS 
(generated in this study), designated B. breve UCC2003-nahS, also did not 
exhibit a difference in final OD following growth in media containing LNT 
(as compared to the wild type, Fig 2.4A). This suggests that either nahS is not 
involved in LNT transport, or that while nahS and the other transport system 
components of the nah locus may be involved in the transport of LNT into 
the cell, their function is compensated by the activity of one or more other 
transport systems. The insertion mutant in nahA (generated in this study), 
designated B. breve UCC2003-nahA, was shown to exhibit a complete lack 
of growth in LNT-containing media (Fig 2.4A). Reintroduction of the nahA 
gene in trans on plasmid pBC1.2, under the transcriptional control of its own 
promoter [76] (see Materials and Methods), in the UCC2003-nahA mutant 
restored the ability to grow on LNT (Supplemental Fig. S2.3). These findings 
demonstrate that nahA is crucial for LNT metabolism, being responsible for 
the hydrolysis of lacto-N-triose, thereby liberating lactose and GlcNAc.  
 
Transcriptome analysis of B. breve UCC2003 grown on LNnT, 
lactosamine and lactose. In order to investigate which genes are involved in 
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the metabolism of Type II central moiety LNnT and its constituent component 
LacNAc, global gene expression was determined by microarray analysis 
during growth of B. breve UCC2003 in mMRS supplemented with each 
respective sugar, as well as lactose (which also possesses a Galβ-1,4 residue) 
as compared with gene expression during growth in mMRS supplemented 
with ribose (NB. We used a hydrochloride salt of lactosamine instead of 
LacNAc, as the latter was not commercially available in an affordable 
quantity). Genes that were shown to be significantly upregulated in 
transcription above the designated cut-off (fold-change >2.5, P<0.001) are 
shown in Table 2.1. The genes upregulated in expression included those 
located in the loci Bbr_0526-530, Bbr_1551-1553, Bbr_1554-1560 and 
Bbr_1585-1590. Possible involvement of these genes in LNnT/LacNAc 
metabolism are assessed below.   
 
Genetic organisation of the genes involved in metabolism of LNnT. Based 
on the results of the microarray analyses performed and functional annotation 
of LNnT/LacNAc-upregulated genes, we propose that the products of the 
gene clusters Bbr_0526-0530, Bbr_1551-1553 and Bbr_1554-1560 
(schematically outlined in Fig. 2.2) are involved in the metabolism of LNnT 
and LacNAc (present as central moieties in Type II HMO) in B. breve 
UCC2003. 
 
Heterologous expression, purification and biochemical characterisation 
of LntA, LacZ2, LacZ6, NahA, and enzymatic activity on Type II HMO 
structure LNnT. In order to investigate the predicted individual and 
combined enzymatic activities of the protein products lacZ2 (Bbr_0010), lntA 
(Bbr_0529), lacZ6 (Bbr_1552) and nahA (Bbr_1556) on core Type II HMO 
structure LNnT, the corresponding His-tagged protein products were 
overproduced and purified. Biochemical and substrate specificity 
characterisations were performed by incubating individual enzymes or 
combinations thereof with a particular substrate, and analysing the reaction 
products by HPAEC against a number of substrate standards and reaction 
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controls. Purified LntAHis was capable of removing the galactose moiety at 
the non-reducing end of LNnT (Fig 2.3B), as well as lactose (data not shown), 
demonstrating a triple specificity for Galβ-1,3GlcNAc, Galβ-1,4GlcNAc and 
Galβ-1,4Glc glycosidic linkages, and thus both Type I and Type II HMO 
central moieties and lactose. Purified LacZ2His and LacZ6His were, under the 
conditions applied, also capable of hydrolysing LNnT and lactose (data not 
shown). 
When both LntAHis and NahAHis were incubated with LNnT, complete 
hydrolysis of LNnT to its constituent monosaccharides was observed. When 
LNnT was incubated first with LntAHis, followed by an enzymatic heat 
denaturation step, and then incubated with NahAHis, different reaction product 
profiles were observed. Samples taken following the initial denaturation prior 
to the addition of NahAHis showed the presence of lacto-N-triose and 
galactose. Samples taken following the addition of NahAHis and subsequent 
incubation showed the presence of galactose, GlcNAc and lactose (Fig 2.3B). 
Similar results from separate and combined reactions were obtained using 
LacZ2His or LacZ6His, together with NahAHis on the substrate LNnT 
(Supplemental Fig. S2.2).  
These results agree with the model for Type II HMO metabolism proposed 
here; where LntA, LacZ2 and/or LacZ6 (and perhaps other β-galactosidases) 
hydrolyse LNnT, releasing galactose and lacto-N-triose, unlike LNT, which 
neither purified LacZ2 nor LacZ6 displayed the ability to hydrolyse (data not 
shown). Lacto-N-triose is then hydrolysed by NahA, liberating lactose and 
GlcNAc. Lactose is then further broken down by LntA (and other β-
Galactosidases, including LacZ2 and LacZ6, in vivo), releasing galactose and 
glucose. Therefore, these two β-Galactosidases may carry out hydrolysis of 
Type II HMO central moieties (in conjunction with LntA).  
 
Phenotypic analysis of B. breve strains harbouring mutations of genes 
implicated in LNnT metabolism. In order to investigate if disruption of 
individual genes of the lnt cluster affects the ability of UCC2003 to utilise 
LNnT, a number of insertion mutants were assessed. B. breve UCC2003-
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lntP1, B. breve UCC2003-lntS and B. breve UCC2003-lntA were analysed 
for their ability to grow in mMRS supplemented with LNnT with lactose 
controls, as compared to wild type B. breve UCC2003. B. breve UCC2003-
lntA reached the same final optical density following growth in media 
containing LNnT compared to wild type UCC2003 (Fig 2.4A). Transcriptome 
data and carbohydrate hydrolysis assays (see above) demonstrated that lntA 
is involved in LNnT metabolism, but its function can also be carried out by 
other glycosyl hydrolases, as mentioned. The insertion mutants B. breve 
UCC2003-lntP1 and B. breve UCC2003-lntS did not show any significant 
impairment in growth on either LNnT or lactose, as compared with the wild 
type (Fig 2.4A), indicating that either these predicted transport components 
do not play a role in LN(n)T metabolism or that there are additional transport 
systems that allow internalisation LNnT. It is most likely that lntP1, lntP2 
and lntS do indeed also function in the transport of extracellular LNnT into 
the cytoplasm, but that their function can be supplemented or indeed 
supplanted by other cellular transport systems. The lnbP insertion mutant, B. 
breve UCC2003-lnbP, was shown to reach final OD600nm levels on either 
lactose or LNnT that were comparable to those of the wild type strain (Fig 
2.4B), suggesting lnbP plays no direct role in LNnT utilisation.  
In order to investigate if disruption of each of the five individual genes lacZ2, 
lacZ6, lacS, nahS and nahA affects the ability of UCC2003 to utilise LNnT, 
mutants of these genes were assessed. The nahS and nahA insertion mutants 
mentioned above were used for this purpose, in addition to insertion mutants 
in the genes Bbr_1551 (lacS), Bbr_1552 (lacZ6), constructed in a previous 
study[62], as well as a Tn5 transposon mutant in Bbr_0010 (lacZ2), from a 
separate study[77]. These mutant strains were analysed for their ability to 
grow in mMRS supplemented with LNnT with a lactose (and ribose, in the 
case of B. breve UCC2003-lacZ2 and B. breve UCC2003-lacS) control, as 
compared to B. breve UCC2003. The insertion mutants B. breve UCC2003-
lacZ2 and B. breve UCC2003-lacZ6 did not show any significant impairment 
in growth on either LNnT, as compared to the wild type, as neither did the 
insertional mutant B. breve UCC2003-lacS (Fig 2.4A). While these growth 
analyses indicate that lacZ2 and lacZ6 are not essential for LNnT metabolism, 
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the hydrolysis assay results and LNnT-dependent transcriptional induction of 
lacZ6 (described above) suggest that these two glycosyl hydrolases play a 
role in LNnT hydrolysis, presumably in concert with lntA. The insertion 
mutant B. breve UCC2003-nahS was shown to exhibit a near total lack of 
growth in media supplemented with LNnT, as compared to the wild type 
grown in the same media (Fig 2.4A). As expected, reintroduction of the nahS 
gene on plasmid pBC1.2, under the regulation of its own promoter [76] (see 
Materials and Methods), in the UCC2003-nahS mutant reverted the mutant’s 
(near complete) inability to grow on LNnT (Supplemental Fig. S2.3). This 
indicates that nahS encodes the solute binding protein predominantly required 
for the uptake of LNnT, and that the nah locus-encoded transport system is 
of critical importance for the transport of the Type II central tetrasaccharide 
into the cell. In contrast to the wild type, B. breve UCC2003-nahA failed to 
grow in media containing LNnT (Fig 2.4A). As expected, reintroduction of 
the nahA gene on plasmid pBC1.2, under the regulation of its own promoter 
[76] (see Materials and Methods), in the UCC2003-nahA mutant reverted the 
mutant’s inability to grow on LNnT (Supplemental Fig. S2.3). This result 
demonstrates the essential role of the nahA product in LNnT metabolism, by 
hydrolysing lacto-N-triose at its GalNacβ1-3Gal linkage, liberating lactose 
and GlcNAc.  
Growth of the insertion mutants was not impaired on lactose, where all strains 
reached final OD600nm levels comparable to that reached by UCC2003, except 
for B. breve UCC2003-lacZ2 and B. breve UCC2003-lacS, as the interrupted 
genes in these mutants are known to be crucial for lactose metabolism[62, 77] 
(Fig 2.4A). B. breve UCC2003-lacZ2 and B. breve UCC2003-lacS did reach 
final OD600nm values similar to that of UCC2003 when grown on ribose (data 
not shown). 
 
Distribution of HMO central moiety utilisation-associated genes across 
the Bifidobacterium genus. Two signature genes, encoding glycosyl 
hydrolases essential to the catabolic pathways of HMO central moieties LNT, 
LNnT and LNB, in B. breve, were identified based on the above results for B. 
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breve UCC2003 (Supplemental Fig 2.3). The nahA gene was identified as 
being crucial for the degradation of both LNT and LNnT (through the 
hydrolysis of lacto-N-triose), and lnbP was identified as essential for the 
utilisation of LNB. Additionally, one signature gene, lnbB, was identified in 
B. bifidum as encoding the key glycosyl hydrolase required for the 
metabolism of LNT, based on previous literature[32] (Supplemental Fig 2.3). 
Another distinct glycosyl hydrolase required for the metabolism of LNT in 
this same way, lnbX, was identified in a strain of B. longum subsp. longum by 
Sakurama et al.[37], and thus was also selected (Supplemental Fig 2.3). No 
genes were selected from B. longum subsp. infantis, as this species and B. 
breve appear to share the same functional homologs and thus appear to utilize 
the same pathways for the metabolism of LN(n)T and LNB. The deduced 
amino acid sequences of these four genes were employed as the reference 
sequences in a multiple alignment of all available Bifidobacterium genomes 
retrieved from the NCBI database, as described, and represented in a heatmap, 
based on a cut-off of 70 % iterative similarity over 50 % protein length, and 
an e-value of <0.0001 (Fig 2.5). The representation obtained, ordered by 
origin of isolation, reveals the distribution of these key genes, and thus the 
metabolic pathways, required for LN(n)T/LNB utilisation across the 
Bifidobacterium genus. The B. bifidum gene lnbB and B. longum subsp. 
longum gene lnbX (whose products are responsible for the hydrolysis of LNT 
into LNB and lactose) appear to be individually unique to B. bifidum and B. 
longum subsp. infantis, respectively, with no clear homologs in any other 
species of Bifidobacterium including each other. The two B. breve signature 
genes used in the search yielded multiple significant hits for homologs, but to 
differing degrees. The analysis identified a relatively small number, i.e. four 
homologous nahA genes across the genus: one in the infant-associated species 
B. longum subsp. infantis, two in marmoset-associated and one tamarin-
associated species- B. callittrichos, B. ruteri, and B. saguini, respectively. On 
the other hand, lnbP yielded 16 significant matches to homologous genes in 
other Bifidobacterium species, isolated from both human and non-human-
related sources. The significant differences in the conservation of these genes 
across the genus are indicative of the importance of specific glycan moiety-
utilising pathways in bifidobacteria.   
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2.5 Discussion 
The role of HMOs as a selective substrate, for specific bacterial species in the 
neonatal gut, is now widely proposed as one of the key factors in the 
development of a healthy microbiota in early life. The high proportion of 
bifidobacteria, specifically the species B. breve, B. longum subsp. infantis and 
B. bifidum, in the microbiota of breastfed infants indicates their ability to 
utilise these carbohydrates as growth factors. Our findings allow us to propose 
a model for the utilisation of HMOs LN(n)T by B. breve (Fig 2.6). In this 
model, LN(n)T is internalised by the cell and subsequently degraded by 
intracellular pathways into monosaccharides for energy production. While B. 
breve is able to metabolize smaller HMO components, such as fucose, 
fucosyllactose and sialic acid, which are released through extracellular 
hydrolysis of larger molecules [16, 17, 22, 39, 40], our findings clearly show 
that B. breve can also utilise larger HMO structures. This expands our view 
of this gut commensal from being merely a scavenger, to an active and direct 
HMO utilizer. 
Our multi-pronged approaches reveal the activities of individual components 
and thus the overall pathways that facilitate LNT and LNnT utilisation by B. 
breve UCC2003. LntA exhibits a triple specificity for the Galβ-1,3GlcNAc 
and Galβ-1,4GlcNAc linkages of LNT and LNnT, as well as the Galβ-1,4Glc 
moiety of lactose, as previously suggested [62]. However, the ability of 
UCC2003-lntA to grow on LNnT, but not on LNT, indicates that while LNT 
can only be intracellularly hydrolysed by LntA, the hydrolysis of LNnT is not 
exclusively attributable to this β-galactosidase, and can be degraded by other 
cellular glycosyl hydrolases such as LacZ6 and LacZ2, releasing lacto-N-
triose for hydrolysis by NahA, and galactose. It should be noted that both 
lacZ2 and lacZ6 have previously been shown to be involved in the 
metabolism of lactose and galacto-oligosaccharides [62]. Interestingly, these 
results mirror those previously shown by Yoshida et al.[29], who, in B. 
longum subsp. infantis ATCC15697, demonstrated the preferential activities 
of one GH42 family glycosyl hydrolase (Bga42A) in hydrolysing Type I 
HMOs and one GH2 family glycosyl hydrolase (Bga2A) in hydrolysing Type 
II HMOs and lactose. 
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The transcriptomic results clearly implicate nahS, lntS, lntP1 and lntP2 in the 
utilisation on both LNT and LNnT, being involved in the internalisation of 
these sugars into the cell. The inability of the UCC2003-nahS mutant to grow 
on LNnT suggests the role of the nah locus-encoded transporter as the sole 
system responsible for LNnT internalisation by UCC2003. In contrast, since 
UCC2003-nahS displays growth on LNT comparable to that of the wild type 
strain, the nah transport system may not be involved in LNT transport, or may 
be, but with its function aided by one or more additional transport systems. 
The ability of the UCC2003-lntP1 and UCC2003-lntS to grow in mMRS 
supplemented with LNT demonstrates that the lnt transport system is also not 
exclusively, or potentially, at all, responsible for LNT internalisation. We 
therefore suggest that either these two transport systems may have at least 
partially overlapping substrate specificities, or that another yet undetermined 
transport system is partially, or wholly responsible for the internalisation of 
LNT. 
While LNT and LNnT enter the B. breve cell as distinct isomers, their 
degradation products are identical and are shuttled through the same 
metabolic routes for energy production, i.e. two galactose molecules and one 
glucose to the Leloir and F6P phosphoketolase pathways and one GlcNAc to 
the amino-sugar metabolising pathway (thus both directly and indirectly 
feeding into the Bifid Shunt) (Fig 2.6).  
Although found within the molecular structure of LNT, free LNB is not 
released during the degradation of the Type I HMO central moiety by B. breve 
UCC2003. However, despite the relative low abundance of free LNB in 
human breast milk and thus the breastfed infant gut, B. breve UCC2003 
possesses a distinct pathway for LNB utilisation. It has previously been 
suggested that LNB metabolism can be seen as a proxy for HMO utilisation 
by Bifidobacteria [17, 28], which explains the presence of this pathway in B. 
breve, which likely ‘sweeps up’ the free LNB released by the extracellular 
hydrolysis of larger HMO structures by other microbiota members, such as 
B. bifidum, and then utilise it via the GNB/LNB pathway.  
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The general model of LN(n)T and LNB utilisation in B. breve is mirrored by 
that found in B. longum subsp. infantis. The functional equivalent of lacZ2 
and lacZ6 in B. longum subsp. infantis ATCC15697 is bga2a [29]. The 
ortholog of lntA is bga42a[29], and the counterpart of nahA is nagZ [30]. A 
copy of lnbP is also found in B. longum subsp. infantis ATCC15697 [31]. In 
contrast, HMO central moiety utilisation in B. bifidum diverges somewhat 
from the B. breve/B. longum subsp. infantis model. While B. bifidum 
possesses functionally equivalent orthologs of lacZ2/lacZ6 (bbgIII)[78], and 
a nahA (bbhI and bbhII)[34], all of these appear to be extracellular proteins, 
as opposed to the (predicted) intracellular localisation of their B. breve 
counterparts. However, the biggest defining factor separating the B. breve/B. 
longum subsp. infantis model and the B. bifidum model appears to be the 
hydrolysis pathway of Type I central moiety LNT. In B. bifidum PRL2010 
LnbB hydrolyses LNT extracellularly at its GlcNAcβ1-3Gal linkage, 
releasing LNB, which is internalised, and phosphorolysed by lnbP1 and 
lnbP2; and lactose, which is hydrolysed by β-galactosidase activities.  
The absence of B. bifidum lnbB (and B. longum subsp. longum JCM1217 
lnbX) homologs in other Bifidobacterium species highlights its unique 
function in HMO metabolism. This agrees with previous knowledge, as 
already mentioned, of B. bifidum (and one strain of B. longum subsp. longum) 
utilizing a significantly different pathway for LNT utilisation, and of HMO 
metabolism as compared to B. breve and B. longum subsp. infantis. A 
similarity search for the two B. breve LN(n)T/LNB signature genes, nahA and 
lnbP, among bifidobacteria shows the presence of homologs in various 
species of Bifidobacterium, but the extent of their conservation differs 
considerably. The sixteen species of Bifidobacterium that were shown to 
possess an lnbP homolog, have been isolated from a range of environments, 
including faecal samples of (both infant and adult) humans, primates and 
other mammals. The conservation of this gene across various bifidobacterial 
species points toward the importance of this gene in the GNB/LNB pathway, 
which is common to many Bifidobacterium species, and has previously been 
shown to function in roles such as mucin metabolism [28, 74, 79, 80]. 
Interestingly, clear homologs of the nahA gene are only found in four other 
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bifidobacterial species, the human isolate B. longum subsp. infantis, and three 
other primate-associated species B. callitrichos and B. reuteri, originally 
isolated from marmoset faeces, and B. sanguini, originally isolated from 
tamarin faeces. As LNT and similar oligosaccharide structures can be found 
in the glycome of primate milk[81], the nahA homologs are expected to play 
a similar role in Bifidobacterium species associated with these hosts. This 
suggests a common adaptation of the LNT/LNnT-utilisation pathway among 
bifidobacteria associated with the primate gut, using their respective milk 
oligosaccharides as substrates, thereby explaining co-evolution with and 
colonisation of this host. 
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2.7 Tables and Figures
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Table 2.1. B. breve UCC2003 genes upregulated in transcription during growth in mMRS 
medium supplemented with 1 % LNT, LNnT, LNB, lactosamine-HCl, or lactose as the sole 
carbohydrate.  
The level of transcription is shown as a fold-value of increase in transcription on each carbohydrate, as compared to a ribose control, with a 
cut-off of a minimum 2.5-fold increase in transcription. Genes within the 4 loci focused on in this study are shown in bold script. 
a Based on comparative transcriptome analysis using B. breve UCC2003 grown on 1% LNT, LNnT, or LNB compared to growth on ribose. 
Microarray data were obtained using B. breve UCC2003 grown on 1% LNT, LNnT, or LNB and were compared with array data obtained 
when B. breve UCC2003 was grown on ribose as a control. 
b The cutoff point is 2.5-fold, with a P value of _0.001. —, value below the cutoff. 
   Fold upregulationb during growth on: 
Gene ID Gene name Function LNT LNnT LNB Lactosamine-
HCl 
Lactose 
Bbr_0417 galC Solute-binding protein of ABC transporter system for sugars ― ― ― 10.93 ― 
Bbr_0418 galD Permease protein of ABC transporter system for sugars  3.23 
 
5.18 
 
― 6.98 ― 
Bbr_0419 galE Permease protein of ABC transporter system for sugars 3.10 7.88 3.18 9.80 3.07 
Bbr_0420 galG GH42 lacZ4 Beta-galactosidase ― ― ― 3.85 ― 
Bbr_0421 galR Transcriptional regulator, LacI family ― ― ― ― ― 
Bbr_0422 galA GH53 galA Endogalactanase ― ― ― 4.07 ― 
Bbr_0490 Bbr_0490 Transcriptional regulator, DeoR family ― 3.27 ― 2.60 ― 
Bbr_0491 
 
galT Galactose-1-phosphate uridylyltransferase  ― ― 
 
5.08 
 
― ― 
Bbr_0492 galK Galactokinase ― ― 
 
3.57 ― ― 
Bbr_0526 lntR Transcriptional regulator, LacI family ― 3.95 ― 10.16 ― 
Bbr_0527 lntP1 Permease protein of ABC transporter system for sugars  6.81 
 
10.05 
 
― 8.57 3.48 
Bbr_0528 lntP2 Permease protein of ABC transporter system for sugars  3.23 10.64 
 
3.03 11.15 3.35 
Bbr_0529 lntA GH42 Beta-galactosidase 6.61 
 
12.58 
 
― 9.53 3.64 
Bbr_0530 lntS Solute-binding protein of ABC transporter system for sugars  4.15 
 
5.20 2.97 17.17 3.31 
Bbr_0845 glgP2 glgP2 Glycogen phosphorylase  ― ― ― 2.73 ― 
Bbr_0846 nagA1 nagA1 N-acetylglucosamine-6-phosphate deacetylase  ― ― ― 4.76 ― 
Bbr_0847 nagB2 nagB2 Glucosamine-6-phosphate isomerase  ― ― ― 5.82 ― 
Bbr_0848 Bbr_0848 Sugar kinase, ROK family 3.30 5.12 ― 10.69 ― 
Bbr_0849 Bbr_0849 NagC/XylR-type transciptional regulator  ― 2.90 ― 14.40 ― 
Bbr_0850 Bbr_0850 Aldose 1-epimerase family protein  ― ― ― 7.39 ― 
Bbr_0851 Bbr_0851 Glucose/fructose transport protein  2.91 3.75 ― 16.43 ― 
Bbr_0852 atsA2 Sulfatase family protein ― ― ― 4.18 ― 
Bbr_0853 atsB2 atsB Arylsulfatase regulator (Fe-S oxidoreductase) ― ― ― 2.70 ― 
Bbr_0854 Bbr_0854 Conserved hypothetical membrane spanning protein with DUF81 
domain 
― ― ― 4.03 ― 
Bbr_0855 Bbr_0855 Hypothetical protein ― ― ― 7.31 ― 
Bbr_0856 Bbr_0856 Conserved hypothetical membrane spanning protein ― ― ― 3.82 ― 
Bbr_1247 nagA2 
  
CE9 nagA2 N-acetylglucosamine-6-phosphate deacetylase 2.67 5.06 3.92 ― ― 
Bbr_1248 nagB3 nagB3 Glucosamine-6-phosphate isomerase  4.11 5.95 8.51 ― ― 
Bbr_1249 Bbr_1249 Transcriptional regulator, ROK family  ― ― ― 3.84 ― 
Bbr_1250 Bbr_1250 Sugar kinase, ROK family  2.44 7.70 ― 8.75 ― 
Bbr_1251 Bbr_1251 N-acetylglucosamine repressor  ― ― ― 7.71 ― 
Bbr_1252 pfkB Fructokinase ― ― ― ― ― 
Bbr_1550 Bbr_1550 Hypothetical protein ― 2.90 ― 28.72 2.81 
Bbr_1551 lacS Galactoside symporter  
 
13.10 
 
73.82 ― 
 
43.73 31.62 
Bbr_1552 LacZ6 GH2 Beta-galactosidase  
 
44.01 
 
105.71 
 
― 39.65 11.01 
Bbr_1553 lacI Transcriptional regulator, LacI family ― 4.56 ― 15.60 ― 
Bbr_1554 nahS Solute-binding protein of ABC transporter system (lactose)  
 
5.71 15.05 
 
9.91 
 
13.10 ― 
Bbr_1555 nahR NagC/XylR-type transciptional regulator 4.86 12.53 ― 21.74 ― 
Bbr_1556 nahA GH20 nagZ Beta-N-acetylhexosaminidase 2.65 3.74 ― 2.90 ― 
Bbr_1558 nahP Permease protein of ABC transporter system ― ― 4.97 ― ― 
Bbr_1559 nahT1 ATP-binding protein of ABC transporter system ― ― ― 2.66 ― 
Bbr_1560 nahT2 ATP-binding protein of ABC transporter system ― ― 3.42 2.51 ― 
Bbr_1585 galE UDP-glucose 4-epimerase  
 
― 
 
3.11 
 
3.33 4.12 ― 
Bbr_1586 nahK Phosphotransferase family protein 
 
4.55 10.69 
 
3.19 ― ― 
Bbr_1587 lnbP GH112 lacto-N-biose phorylase  
 
― 3.86 
 
6.52 
 
― ― 
Bbr_1588 galP1 Permease protein of ABC transporter system for sugars  
 
3.38 4.20 6.38 
 
― ― 
Bbr_1589 galP2 Permease protein of ABC transporter system for sugars  
 
2.78 5.47 4.05 
 
― ― 
Bbr_1590 galS Solute-binding protein of ABC transporter system for sugars  4.41 
 
4.45 16.49 
 
― ― 
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Figure 2.1. Schematic structures of Type I HMO moiety LNT, and Type II HMO moiety 
LNnT.  
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Figure 2.2. Schematic representation of the gene loci involved in the utilisation of LNT, LNnT 
and their substituents in B. breve UCC2003, as based on transcriptome analysis. The length of 
the arrows is proportional to the size of the open reading frame and the gene locus name, which 
is indicative of its putative function, is given at the top. Genes shown in red are predicted to 
encode proteins with an intracellular localisation, genes shown in green are predicted to encode 
proteins with a transmembrane localisation, and genes shown in blue are predicted to encode 
proteins with an extracellular localisation and a signal peptide sequence. The predicted function 
of each gene product is given in Table 2.1.  
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Figure 2.3. HPAEC chromatogram profiles of (a) LNT and (b) LNnT, when incubated in 
MOPS buffer (pH7) with: (I) LntA alone, (II) NahA alone, (III) LntA and NahA together, and 
(IV) LntA, followed by a denaturation step and the subsequent addition of NahA. 
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Figure 2.4. (a) Final OD600nm values after 24 hours of growth of wild type B. breve UCC2003 and mutants B. breve UCC2003-lntP1, B. breve 
UCC2003-lntA, B. breve UCC2003-lntS, B. breve UCC2003-nahA, B. breve UCC2003-nahS, B. breve UCC2003-lacZ2, B. breve UCC2003-lacS 
and B. breve UCC2003-lacZ6  in modified MRS containing 1 % (wt/vol) lactose, 1 % (wt/vol) LNT or 1 % (wt/vol) LNnT as the sole carbon 
source. (b) Final OD600nm values after 24 hours of growth of wild type B. breve UCC2003, and mutants B. breve UCC2003-lacZ2, B. breve 
UCC2003-lntA, B. breve UCC2003-lacZ6, and B. breve UCC2003-lnbP in modified MRS containing 1 % (wt/vol) lactose, 1% LNB, 1 % (wt/vol) 
LNT, 1 % (wt/vol) LNnT as the sole carbon source. 
The results are the mean values obtained manually from two separate experiments (due to the limited availability of certain carbohydrates). Error 
bars represent the standard deviation. 
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Figure 2.5. Heatmap representing the distribution of homologs of two genes from B. breve UCC2003, one gene from B. longum subsp. longum 
JCM1217 and one gene from B. bifidum PRL2010 across the Bifidobacterium genus. Gene products from the representative strain genomes of all 
online-available Bifidobacterium species with a significant homology of 70 % iterative similarity over 50 % of protein length are represented in 
the matrix, which employs a code colour grading that represents the degree of sequence similarity, with species ordered by origin of isolation. 
Bbr_1556 (nahA) and Bbr_1587 (lnbP) were selected from B. breve UCC2003, BLLJ_1505 (lnbX) was selected from B. longum subsp. longum 
JCM1217, and BBPR_1438 (lnbB) was selected from B. bifidum PRL2010. 
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Figure 2.6. Schematic representation of the proposed model for the metabolism of free LNT, LNnT and LNB by B. breve UCC2003.  
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2.8 Supplemental Material 
Supplemental Table S2.1. Oligonucleotide primers used in this work. 
Purpose Primer Sequence (5’-3’) 
Cloning of Bbr_1556 in pNZ8150 1556F 
1556R 
 
tgcatccagctgatgcatcaccatcaccatcaccatcaccatcacaacggtcaaacatctctgcaa 
tgcgcatctagaggattggaagcgcagatggtc 
Cloning of internal 465bp fragment of Bbr_0530 in pORI19 IM530F 
IM530R 
 
ctggtcaagcttgaaggagaccggcatcaagg 
ctggtctctagagtctggaacggcttggcgc 
Cloning of internal 488bp fragment of Bbr_1554 in pORI19 IM1554F 
IM1554R 
 
ctggtcaagcttgaaggagaccggcatcaagg 
ctggtctctagagtctggaacggcttggcgc 
Cloning of internal 443bp fragment of Bbr_1556 in pORI19 IM1556F 
IM1556R 
 
ctggtcaagcttcgaatacctcgccatccc  
ctggtctctagaccagtgacttcatccagtcgtc 
Amplification of tetW tetWFw 
tetWRv 
 
tcagctgtcgacatgctcatgtacggtaaggaagca 
gcgacggtcgaccataacttctgattgttgccg 
Confirmation of site specific homologous recombination 526confirm1 
526confirm2 
530confirm1 
530confirm2 
1554confrim1 
1554confrim2 
1556confrim1 
1556confrim2 
 
gcgctagctgttacaatggtc 
gccatttccaacccctctc 
gaggaaggagaacagaacgatg 
gcgaaaggaatggcttcatag 
ctgcgacgccaatgccgacaag 
ccgctactgcaggtcgccatcatcaagcac 
gcagctcatcgacgacatccgc 
gcgcgcgcagtcggtgac 
 
Cloning of 2086bp fragment containing Bbr_0529 into pNZ44 529pNZ44F 
529pNZ44R 
 
ctggtcctgcaggactcccatttgcccacacgtag 
cgagctctagagatttctcctcgacactg 
Cloning of p44-529 in pBC1.2 P44 Forward 
 
ctggtccggatccgagataatgccgactgtac 
Cloning of 1637bp fragment containing Bbr_1554 into PBC1.2  1554PBC1.2F 
1554PBC1.2R 
ctggtccggatccgccggaacaacagtctgc 
cgagctctagaattcaccgtttggattattgg 
Cloning of 2360bp fragment containing Bbr_1556 into PBC1.2 1556PBC1.2F 
1556PBC1.2R 
ctggtccggatccccacgcaggtggacaagt 
cgagctctagagaaatctcacaatcgcagcc 
Restriction sites incorporated into oligonucleotide primer sequences are indicated in bold, and His-tag sequences incorporated 
into nucleotide primer sequences are indicated in italics. 
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Supplemental Table S2.2. Bacterial plasmids and strains used in this work. 
Cmr, Emr,Kmr and Tetr, resistance to chloramphenicol, erythromycin, kanamycin and tetracycline, respectively. 
Collection of the University of Goteborg; CIP, Collection de l’Institut Pasteur; DSM, German Collection of Microorganisms and Cell Cultures; JCM, Japan 
Collection of Microorganisms; LMG, Belgian Co-ordinated Collection of Microorganisms; NCDO, National Collection of Dairy Organisms; NCFB, National 
Collection of Food Bacteria; NCIMB, National Collection of Industrial and Marine Bacteria; NCTC, National Collection of Type Cultures; UCC, University 
College Cork Culture Collection. 
  
 
 
Strain or plasmid Relevant Features 
(antibiotic resistances are given in brackets) 
Reference or 
Source 
Strains   
Escherichia coli strains   
 E. coli EC101 Cloning host, repA+ (kmr) [54] 
 E. coli EC101-pNZ-M.BbrII + M.BbrIII EC101 harbouring pNZ8048 derivative containing bbrIIM and bbrIIIM [52] 
 E. coli XL1-Blue supE44 hsdR17 recA1 gyrA96 thi relA1 lac F’ [proAB+ laclq lacZΔM15 Tn10(Tetr)] Stratagene 
 E.coli XL1-blue-pBC1.2-529 XL1-blue containing pBC1.2-529 (Cmr) This study 
Lactococcus lactis strains   
 L. lactis NZ9000 MG1363, pepN::nisRK, nisin-inducible overexpression host [67] 
 L. lactis NZ9700 Nisin-producing strain (Cmr) [67] 
 L. lactis NZ9000-pNZ-lacZ2 NZ9000 conatining pNZ-010 (Cmr) [62] 
 L. lactis NZ9000-pNZ-lntA NZ9000 conatining pNZ-529 (Cmr) [62] 
 L. lactis NZ9000-pNZ-lacZ6 NZ9000 conatining pNZ-1552 (Cmr) [62] 
 L. lactis NZ9000-pNZ-nahA NZ9000 conatining pNZ-1556 (Cmr) This study 
 L. lactis NZ9000-pNZ44-lntA NZ9000 containing pNZ44-529 (Cmr) This study 
Bifidobacterium sp. Strains   
 B. breve UCC2003 Isolate from nursling stool [53] 
 B. breve UCC2003-lacZ2 Tn5-transposon mutant in Bbr_0010 of UCC2003 (Tetr) [77] 
 B. breve UCC2003-lntP1 pORI19-tet-bbr_0527 insertion mutant of UCC2003 (Tetr) [62] 
 B. breve UCC2003-lntA pORI19-tet-bbr_0529 insertion mutant of UCC2003 (Tetr) [62] 
 B. breve UCC2003-lacS pORI19-tet-bbr_1551 insertion mutant of UCC2003 (Tetr) [62] 
 B. breve UCC2003-lacZ6 pORI19-tet-bbr_1552 insertion mutant of UCC2003 (Tetr) [62] 
 B. breve UCC2003-lnbP pORI19-tet-bbr_1587 insertion mutant of UCC2003 (Tetr) [74] 
 B. breve UCC2003-lntS pORI19-tet-bbr_0530 insertion mutant of UCC2003 (Tetr) This study 
 B. breve UCC2003-nahS pORI19-tet-bbr_1554 insertion mutant of UCC2003 (Tetr) This study 
 B. breve UCC2003-nahA pORI19-tet-bbr_1556 insertion mutant of UCC2003 (Tetr) This study 
 B. breve UCC2003-lntA-PBC1.2-lntA pORI19-tet-529 insertion mutant of UCC2003 harbouring complementation construct 
pBC1.2-529 (Tetr)(Cmr) 
This study 
 B. breve UCC2003-nahS-PBC1.2-nahS pORI19-tet-1554 insertion mutant of UCC2003 harbouring complementation 
construct pBC1.2-1554 (Tetr)(Cmr) 
This study 
 B. breve UCC2003-nahA-PBC1.2-nahA pORI19-tet-1556 insertion mutant of UCC2003 harbouring complementation 
construct pBC1.2-1556 (Tetr)(Cmr) 
This study 
 B. breve UCC2004 Isolate from infant faeces UCC 
 B. breve JCM7017 Isolate from human faeces JCM 
 B. breve JCM7019 Isolate from infant faeces JCM 
 B. breve NCFB2258 Isolate from infant intestine NCFB 
 B. breve UCC2005 Isolate from nursling stool UCC 
 B. breve 8815 Isolate from human faeces NCIMB 
 B. breve 11815 Isolate from infant intestine NCIMB 
 B. breve NIZO658 Isolate from human faeces NIZO 
 B. breve UCC2006 Mother’s milk UCC 
 B. breve UCC2007 Mother’s milk UCC 
 B. breve UCC2008 Isolate from infant/adult faeces UCC 
 B. breve LMG13208 Isolate from infant faeces LMG 
 B. breve UCC2009 Isolate from infant/adult faeces UCC 
 B. breve UCC2010 Mother’s milk UCC 
 B. breve UCC2011 Mother’s milk UCC 
 
Plasmids 
  
 pAM5 pBC1-puC19-(Tetr) [61] 
 pORI19 Emr, repA-, ori+, cloning vector (Emr) [54] 
 
 pORI19-tet-lntS Internal 465 bp fragment of bbr_0530 and tetW cloned in pORI19 (Emr) This study 
 pORI19-tet-nahS Internal 443 bp fragment of bbr_1554 and tetW cloned in pORI19 (Emr) This study 
 pORI19-tet-nahA Internal 443 bp fragment of bbr_1556 and tetW cloned in pORI19 (Emr) This study 
 pNZ8150 Cmr, nisin inducible translational fusion vector (Cmr) [63] 
 pNZ-nahA Cmr, pNZ8150 derivative containing translational fusion of Bbr_1556 encoding DNA 
fragment to nisin inducible promoter (Cmr) 
This study 
 pNZ44 pNZ8048 containing constitutive p44 promoter from Lactococcal chromosome (Cmr) [60] 
 pNZ44-lntA pNZ44 harbouring Bbr_0529 downstream of p44 promoter (Cmr) This study 
 pBC1.2 pBC1-pSC101-(Cmr) [61] 
 pBC1.2-lntA pBC1-pSC101-Cmr harbouring Bbr_0529 downstream of p44 promoter (Cmr) This study 
 pBC1.2-nahS pBC1-pSC101-Cmr harbouring Bbr_1554 (Cmr) This study 
 pBC1.2-nahA pBC1-pSC101-Cmr harbouring Bbr_1556 (Cmr) This study 
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Supplemental Table S2.3. Locus tags, names and product functions of B. breve UCC2003 and 
B. bifidum PRL2010 genes selected for bioinformatic analysis of LN(n)T/LNB utilisation-
associated homologs across the Bifidobacterium genus.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene ID Gene 
Name 
Location  of 
Activity 
Function in HMO Metabolism 
Bifidobacterium breve UCC2003 
Bbr_1556 nahA Intracellular nagZ Beta-N-acetylhexosaminidase; hydrolyses Lacto-N-Triose at GlcNAcβ1-
3Gal residue, releasing GlcNAc and galactose.  
 
Bbr_1587 lnbP Intracellular Lacto-N-biose phosphorylase; hydrolyses LNB, releasing GlcNAc and 
phosphorylated galactose. 
Bifidobacterium bifidum PRL2010 
BBPR_1438 
 
lnbB Extracellular Lacto-N-biosidase; hydrolyses LNT at its GlcNAcβ1-3Gal residue, releasing 
LNB and lactose.  
Bifidobacterium longum subsp. 
longum JCM1217 
  
 
 
BLLJ_1505 lnbX Extracellular Lacto-N-biosidase; hydrolyses LNT at its GlcNAcβ1-3Gal residue, releasing 
LNB and lactose. 
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Supplemental Figure S2.1. Final OD600nm values (measured using PowerWave microplate spectrophotometer) after 24 hours of growth of 16 B. 
breve strains in modified MRS containing 1 % (wt/vol) LNT, 1 % (wt/vol) LNnT or 1 % (wt/vol) lactose as the sole carbon source.  
The results are the mean values obtained manually from two separate experiments (due to the limited availability of certain carbohydrates). Error 
bars represent the standard deviation.
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Supplemental Figure S2.2. (A) HPAEC chromatogram profiles of LNnT, when incubated in 
MOPS buffer (pH7) with: (I) LacZ2 alone, (II) NahA alone, (III) LacZ2 and NahA together, 
and (IV) LacZ2, followed by a denaturation step and the subsequent addition of NahA. (B) 
HPAEC chromatogram profiles of LNnT, when incubated in MOPS buffer (pH7) with: (I) 
LacZ6 alone, (II) NahA alone, (III) LacZ6 and NahA together, and (IV) LacZ6, followed by a 
denaturation step and the subsequent addition of NahA. 
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Supplemental Figure S2.3. (A) Final OD600 values (measured manually) after 24 hours of growth of wild type B. breve UCC2003, the insertion 
mutant B. breve UCC2003-lntA, and the complementation strain B. breve UCC2003-lntA+PBC1.2-lntA in modified MRS containing 1 % (wt/vol) 
lactose or 1 % (wt/vol) LNT as the sole carbon source. The results are the mean values obtained from two separate experiments*. Error bars 
represent the standard deviation.  (B) Final OD600 values (measured manually) after 24 hours of growth of wild type B. breve UCC2003, the 
insertion mutant B. breve UCC2003-nahA, and the complementation strain B. breve UCC2003-nahA+PBC1.2-nahA in modified MRS containing 
1 % (wt/vol) lactose or 1 % (wt/vol) LNT as the sole carbon source. The results are the mean values obtained from two separate experiments*. 
Error bars represent the standard deviation. (C) Final OD600 values (measured manually) after 24 hours of growth of wild type B. breve UCC2003, 
the insertion mutant B. breve UCC2003-nahS, and the complementation strain B. breve UCC2003-nahS+PBC1.2-nahS in modified MRS 
containing 1 % (wt/vol) lactose or 1 % (wt/vol) LNT as the sole carbon source. The results are the mean values obtained from two separate 
experiments*. Error bars represent the standard deviation. 
*Experiments were carried out in duplicate due to a limited amount of carbohydrate material.  
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Chapter III 
Bifidobacterium breve UCC2003 employs multiple transcriptional 
regulators to control metabolism of particular human milk 
oligosaccharides. 
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transcriptional regulators to control metabolism of particular human milk 
oligosaccharides. AEM Vol. 84, No. 9. 
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3.1 Abstract 
Bifidobacterial carbohydrate metabolism has been studied in considerable 
detail for a variety of both plant and human-derived glycans, particularly 
involving the bifidobacterial prototype Bifidobacterium breve UCC2003. We 
recently elucidated the metabolic pathways by which the human milk 
oligosaccharide (HMO) constituents lacto-N-tetraose (LNT), lacto-N-
neotetraose (LNnT) and lacto-N-biose (LNB) are utilized by B. breve 
UCC2003. However, to date no work has been carried out on the regulatory 
mechanisms that control expression of the genetic loci involved in these 
HMO metabolic pathways. In the current study, we describe the 
characterization of three transcriptional regulators and corresponding 
operator and associated (inducible) promoter sequences, the latter governing 
transcription of the genetic elements involved in LN(n)T/LNB metabolism. 
The activity of these regulators is dependent on the release of specific 
monosaccharides, which are believed to act as allosteric effectors, and which 
are derived from the corresponding HMOs targeted by the particular locus.  
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3.2 Introduction 
Bifidobacteria represent high-G+C, Gram-positive, anaerobic members of the 
phylum Actinobacteria, and are common commensals of the mammalian, 
avian and insect gut. In humans, they are particularly abundant and prevalent 
among the gut microbiota of healthy, vaginally-delivered, breastfed infants 
[1], and are thought to confer a multitude of benefits to the neonatal host [2-
4]. For this reason, as well as because of their purported health-promoting 
activities in adults, bifidobacteria are used as functional ingredients in a 
variety of foods and therapeutic products. The use of prebiotics is also 
becoming commonplace for the improvement of both adult and infant (gut) 
health. A prebiotic has been defined as ‘a non-digestible food ingredient that 
beneficially affects the host by selectively stimulating the growth and/or 
activity of one or a limited number of bacteria in the colon, and thus improves 
host health’ [5].  
The archetypal prebiotic would appear to be human breastmilk, and in 
particular its bifidogenic constituents known as Human Milk 
Oligosaccharides (HMOs). HMOs represent specific glycans present in 
human breastmilk that are thought to shape, at least partly, the compositional 
structure of the neonatal gut microbiota [6, 7]. HMOs represent, after lactose, 
the second-largest carbohydrate component of breastmilk [6, 8], and 
constitute a heterogeneous mix of at least 200 distinct glycan structures [9]. 
The majority of complex HMO structures can be classified into one of two 
types, depending on their backbone composition. The more abundant Type I 
HMOs contain the core tetrasaccharide lacto-N-tetraose (LNT) within their 
structure (Galβ1-3GlcNAcβ1-3Galβ1-4Glc). Type II HMOs contain lacto-N-
neotetraose (LNnT), a stereoisomer of LNT, within their backbone (Galβ1-
4GlcNAcβ1-3Galβ1-4Glc). Lacto-N-biose (LNB; Galβ1-3GlcNAc) is a 
subunit of LNT and other Type I HMO structures, and can be released by the 
degradation of these sugars [10].   
The effects of the specific human breastmilk components on the prevalence, 
abundance and activity of members of the infant gut microbiota are currently 
enjoying an increasing amount of scientific and commercial attention, due to 
the beneficial roles they are believed to play in infant health and development 
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[11, 12]. Understanding the pathways by which specific HMOs are 
metabolized by particular microbial species that inhabit the infant gut is 
important, although our knowledge regarding these processes is still in its 
infancy, particularly with regards to the manner in which they affect 
microbiota development.  
It is not surprising that the dominant Bifidobacterium species found among 
the neonatal gut microbiota can utilise various HMO components as their sole 
carbohydrate source [9]. These species chiefly include strains of 
Bifidobacterium bifidum, Bifidobacterium longum subsp. infantis and 
Bifidobacterium breve. HMO utilization by B. bifidum and B. longum subsp. 
infantis is relatively well characterised. B. bifidum extracellularly hydrolyses 
complex HMO structures, including LNT and LNnT, employing secreted 
glycosyl hydrolases, followed by the internalisation and intracellular 
degradation/metabolism of (most of) the resulting mono- and di-saccharides, 
such as LNB [10, 13-19]. B. longum subsp. infantis internalises intact LNT, 
LNnT and LNB, and uses a series of sequential hydrolytic/phosphorolytic 
reactions acting from the non-reducing end of the carbohydrate structures to 
degrade them into their monosaccharide components for further metabolic 
processing [9, 10, 20-23]. However, B. infantis has also been demonstrated to 
take up and utilise fucosyl- and sialyl-lactose [24-26]. 
The metabolic pathways of LNT, LNnT and LNB have recently been 
elucidated in the prototype strain B. breve UCC2003 [27]. In the latter study, 
converging pathways of LNT and LNnT catabolism were identified, where 
monosaccharide moieties are sequentially released from the non-reducing end 
of either sugar by hydrolytic reactions. The genetic units responsible for the 
uptake and breakdown of these structures are the lnt locus (corresponding to 
locus tags Bbr_0526-0530) and the nah locus (locus tags Bbr_1554-1560) 
(Table 3.1 and Fig. 3.1). The lnt locus encodes proteins that are responsible 
for the internalisation of LNT and intracellular hydrolysis of both LNT and 
LNnT, releasing a galactose (Gal) moiety from their non-reducing end, and 
at the same time liberating the trisaccharide lacto-N-triose (GlcNAcβ1-
3Galβ1-4Glc). The nah locus specifies an LNT/LNnT uptake system, while 
it furthermore encodes a glycosyl hydrolase which liberates GlcNAc from the 
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non-reducing end of lacto-N-triose, leaving lactose, which itself is further 
degraded by lactose-specific glycosyl hydrolases. Additionally, the gene 
products of the lnp/glt locus (corresponding to locus tags Bbr_1585-1590; 
Table 3.1 and Fig. 3.1) are responsible for the internalisation and subsequent 
phosphorolysis of free LNB, releasing its constituent monosaccharides Gal-
1-phosphate and GlcNAc [27, 28]. We also identified the transcriptional 
upregulation of genes in the nag locus (locus tags Bbr_1247-1252; Table 3.1 
and Fig. 3.1) during growth on LNT, LNnT and LNB, indicating their role in 
the utilisation of these sugars, specifically in the multi-step metabolism of 
GlcNAc. The nag locus has previously been implicated in the metabolism of 
sialic acid and mucin-derived N-glycans, both of which contain GlcNAc as 
well [29, 30]. While the degradation routes of these key HMO structures have 
thus been identified, the regulatory mechanisms that control expression of 
these pathways have remained unexplored, both for B. breve and HMO-
utilising Bifidobacterium species as a whole. 
In the current study, we identified and characterized the genes encoding 
transcriptional regulators responsible for control of gene expression in four 
key HMO-associated loci in B. breve UCC2003 during growth on LNT, 
LNnT or LNB.  
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3.3 Materials and Methods 
Bacterial strains, plasmids, and culture conditions. Bacterial strains and 
plasmids used in this study are listed in Supplemental Table S3.2. B. breve 
UCC2003 was routinely cultured in either de Man Rogosa and Sharpe 
medium (MRS medium; Difco, BD, Le Pont de Claix, France) supplemented 
with 0.05 % cysteine-HCl or reinforced clostridial medium (RCM; Oxoid 
Ltd., Basingstoke, England). Growth of bifidobacterial strains for 
transcriptional and primer extension analyses was carried out in modified de 
Man Rogosa and Sharpe (mMRS) medium, which was prepared from first 
principles  (using individual components) [31], and which does not contain a 
fixed carbohydrate source. Prior to inoculation, the mMRS medium was 
supplemented with cysteine-HCl (0.05 %, wt/vol) and a particular 
carbohydrate source (1 %, wt/vol). It has previously been shown that mMRS 
does not support growth of B. breve UCC2003 in the absence of an added 
carbohydrate [32]. Carbohydrates used were ribose (Sigma Aldrich, 
Steinheim, Germany), LNB (Elicityl Oligotech, Crolles, France) and LNnT 
(Glycom, Lyngby, Denmark). A 1 % wt/vol concentration of carbohydrate 
was considered sufficient to encourage adequate growth for RNA harvesting. 
The addition of these carbohydrates did not significantly alter the pH of the 
medium, and therefore subsequent pH adjustment was not required. 
B. breve cultures were incubated under anaerobic conditions in a modular 
atmosphere-controlled system (Davidson and Hardy, Belfast, Ireland) at 
37°C. Lactococcus lactis strains were cultivated in M17 broth (Oxoid Ltd., 
Basingstoke, England) containing 0.5 % glucose [33] at 30°C. Escherichia 
coli strains were cultured in Luria-Bertani (LB) broth [34] at 37°C with 
agitation. Where appropriate, growth media contained tetracycline (Tet; 10 
μg ml-1), chloramphenicol (Cm; 5 μg ml-1 for L. lactis and E. coli, 2.5 μg ml-
1 for B. breve), erythromycin (Em; 100 μg ml-1) or kanamycin (Kan; 50 μg 
ml-1). Recombinant E. coli EC101 cells containing (derivatives of) pORI19 
were selected on LB agar containing Em and Kan, and supplemented with X-
gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) (40 μg ml-1) and 1 
mM IPTG (isopropyl-β-D-galactopyranoside).  
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Nucleotide sequence analysis. Sequence information was obtained from the 
Artemis-mediated [35] genome annotations of B. breve UCC2003 [36]. 
Database searches were performed using non-redundant sequences accessible 
at the National Center for Biotechnology Information (NCBI) 
(http://www.ncbi.nlm.nih.gov) using the basic local alignment search tool 
(BLAST) [37, 38]. Sequences were verified and analysed using the SeqMan 
and SeqBuilder programs of the DNAStar software package (version 10.1.2; 
DNAStar, Madison, WI, USA). 
 
DNA Manipulations. Chromosomal DNA was isolated from B. breve 
UCC2003 as previously described [39]. Plasmid DNA was isolated from 
Escherichia coli, Lactococcus lactis and B. breve using the Roche High Pure 
Plasmid Isolation kit (Roche Diagnostics, Basel, Switzerland). An initial lysis 
step was performed using 30 mg ml-1 of lysozyme for 30 minutes at 37°C 
prior to plasmid isolation from L. lactis or B. breve. Procedures for DNA 
manipulations were essentially performed as described previously [34]. All 
restriction enzymes and T4 DNA ligase were used according to the supplier’s 
instructions (Roche Diagnostics, Basel, Switzerland). Synthetic single 
stranded oligonucleotide primers used in this study (Supplemental Table 
S3.1) were synthesized by Eurofins (Ebersberg, Germany). Standard PCRs 
were performed using Taq PCRmaster mix (Qiagen) or Extensor Hi-Fidelity 
PCR Master Mix (Thermo Scientific, Waltham, United States) in a Biometra 
T3000 thermocycler Biometra, Göttingen, Germany) or a Life Technologies 
Proflex PCR System (Thermo Scientific, Waltham, United States). PCR 
products were visualized by ethidium bromide (EtBr) staining following 
agarose gel electrophoresis (1 % agarose). B. breve colony PCR reactions 
were performed as described previously [40]. PCR fragments were purified 
using the Roche high Pure PCR purification kit (Roche Diagnostics, Basel, 
Switzerland). Plasmid DNA was isolated using the Roche High Pure Plasmid 
Isolation kit (Roche Diagnostics, Basel, Switzerland). Plasmid DNA was 
introduced into E. coli by electroporation as described previously [34]. B. 
breve UCC2003 [41] and L. lactis [42] were transformed by electroporation 
according to published protocols. Correct orientation of DNA inserts and 
122 
 
integrity of all plasmid constructs (see also below) were verified by DNA 
sequencing, performed at Eurofins (Ebersberg, Germany). 
 
Construction of B. breve UCC2003 insertion mutants. Internal fragments 
of Bbr_0526 (designated here as lntR) (367 base pairs [bp] representing codon 
numbers 40 through to 162 of the 320 codons of this gene), Bbr_1249 
(designated here as nagR1) (502 bp representing codon numbers 64 through 
to 231 of the 375 codons of this gene), Bbr_1251 (designated here as nagR2) 
(507 bp representing codon numbers 62 through to 230 of the 405 codons of 
this gene), and Bbr_1555 (designated here as nahR) (448 bp representing 
codon numbers 74 through to 223 of the 380 codons of this gene) were 
amplified by PCR using B. breve UCC2003 chromosomal DNA as a template 
and primer pairs 526LacIInsFHindIII and 526LacIInsRXbaI, 
1249LacIInsFHindIII and 1249LacIInsRXbaI, 1251LacIInsFHindIII and 
1251LacIInsRXbaI, or 1555LacIInsFHindIII and 1555LacIInsRXbaI 
(Supplemental Table S3.1), respectively. The insertion mutants were 
constructed using a previously described approach [40], generating mutant 
strains B. breve UCC2003-lntR, B. breve UCC2003-nagR1, B. breve 
UCC2003-nagR2 and B. breve UCC2003-nahR, which carried disrupted lntR, 
nagR1, nagR2 and nahR genes, respectively (Supplemental Table S3.2). Site-
specific recombination of potential tet-resistant mutant isolates was 
confirmed by colony PCR using primer combinations TetWF and TetWR to 
verify tetW gene integration, and primers Bbr_526ConfirmP1 or 
Bbr_526ConfirmP2, Bbr_1249ConfirmP1 or Bbr_1249ConfirmP2, 
Bbr_1251ConfirmP1 or Bbr_1251ConfirmP2, and Bbr_1555ConfirmP1 or 
Bbr_1555ConfirmP2 (positioned upstream of the selected internal fragments 
of Bbr_0526, Bbr_1249, Bbr_1251 and Bbr_1555, respectively) in 
combination with primer TetWF to confirm integration at the correct 
chromosomal location (Supplemental Table S3.1).  
 
Analysis of global gene expression using B. breve DNA microarrays. 
Global gene expression was determined during log-phase growth of the 
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insertional mutant strains B. breve UCC2003-lntR, B. breve UCC2003-
nagR1, B. breve UCC2003-nagR2 and B. breve UCC2003-nahR in mMRS 
supplemented with ribose. The generated transcriptome data sets were 
compared to the transcriptome information obtained for log-phase wild-type 
B. breve UCC2003 cells when grown in mMRS supplemented with ribose. 
Ribose was selected as a suitable transcriptomic reference, as the metabolic 
pathway and gene expression profile for growth of UCC2003 on ribose is 
known and has been employed previously as a reference [43, 44]. DNA 
microarrays containing oligonucleotide primers representing each of the 1864 
identified open reading frames on the genome of B. breve UCC2003 were 
designed and obtained from Agilent Technologies (Palo Alto, Ca., USA). 
Methods for cell disruption, RNA isolation, RNA quality control, 
complementary DNA synthesis and labelling were performed as, described 
previously [45]. Two independent biological replicates were used for each 
array using a Cy3/Cy5 dye-swap, as described previously [45]. Labelled 
cDNA was hybridized using the Agilent Gene Expression hybridization kit 
(part number 5188-5242) as described in the Agilent Two-Colour 
Microarray-Based Gene Expression Analysis v4.0 manual (publication 
number G4140-90050). Following hybridization, microarrays were washed 
in accordance with Agilent’s standard procedures and scanned using an 
Agilent DNA microarray scanner (model G2565A). Generated scans were 
converted to data files with Agilent's Feature Extraction software (Version 
9.5). DNA-microarray data were processed as previously described [46-48]. 
Differential expression tests were performed with the Cyber-T 
implementation of a variant of the t-test [49].  
 
Construction of overexpression vectors, protein overproduction and 
purification. For the construction of plasmids pNZ-lntR, pNZ-nagR1 and 
pNZ-nahR, DNA fragments encompassing lntR, nagR1 and nahR were 
generated by PCR amplification from chromosomal DNA of B. breve 
UCC2003 using Q5 High-Fidelity DNA polymerase and primer combinations 
526PurFSmaI and 526PurRXbaI, 1249PurFPvuII and 1249PurRXbaI, or 
1555PurFEcoRV and 1555PurXbaI, respectively (Supplemental Table S3.1). 
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An in-frame N-terminal His10-encoding sequence was incorporated into the 
forward primers 526PurFSmaI, 1249PurFPvuII and 1555PurFEcoRV to 
facilitate downstream protein purification. The generated amplicons were 
digested with SmaI and XbaI, PvuII and XbaI, or EcoRV and XbaI, 
respectively, and ligated into the ScaI and XbaI digested, nisin-inducible 
translational fusion plasmid pNZ8150 [50]. The ligation mixtures were 
introduced into L. lactis NZ9000 by electrotransformation and transformants 
were then selected based on chloramphenicol (Cm) resistance. The plasmid 
content of a number of Cm-resistant transformants was screened by restriction 
analysis and the integrity of positively identified clones was verified by 
sequencing. 
Nisin-inducible gene expression and protein overproduction was performed 
as described previously [51-53]. In brief, 50 ml of M17 broth supplemented 
with 0.5 % (wt/vol) glucose was inoculated with a 2 % inoculum of a 
particular L. lactis strain, followed by incubation at 30°C until an OD600 of 
0.5 was reached, at which point protein expression was induced by addition 
of cell-free supernatant of a nisin-producing strain [54], followed by 
continued incubation for a further 2 hours. Cells were harvested by 
centrifugation, and crude cell extract was obtained as described previously 
[55]. Although protein purification of LntR-His, NahR-His and NagR1-His 
was achieved using His tag affinity chromatography, the purification 
procedure appeared to render the proteins inactive in subsequent 
electrophoretic mobility shift assays (EMSAs). For this reason, crude cell 
extracts, prepared in a 10 mM Tris-HCl lysis buffer (pH 7.0), were adopted 
for the EMSAs (see below). 
 
Electrophoretic mobility shift assay (EMSA). DNA fragments representing 
different portions of the promoter regions upstream of lntP1 (locus tag 
Bbr_0527) and lntS (locus tag Bbr_0530), nagB3 (locus tag Bbr_1248) and 
nagK (locus tag Bbr_1250), lnpB (locus tag Bbr_1586) and gltA (locus tag 
Bbr_1590) and nahS (Bbr_1554) and nahA (Bbr_1556) were prepared by 
PCR using IRD700-labelled primers pairs (Integrated DNA Technologies, 
Coralville, Indiana, United States) (Supplemental Table S3.1). EMSAs were 
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performed essentially as described previously [51, 56]. In all cases, binding 
reactions were carried out in a final volume of 20 µl in the presence of 
poly[d(I-C)] in binding buffer (20 mM Tris-HCl, 5 mM MgCl2, 0.5 mM DTT, 
1 mM EDTA, 100 mM KCl, 10 % glycerol). Varying amounts of crude 
protein extract, ranging from 140 ng to 180 ng, of the LntR-, NahR-, or 
NagR1-(over)producing L. lactis NZ9000 strain constructed, and a fixed 
amount of DNA probe (0.1 pmol) was mixed on ice and subsequently 
incubated for 15 min at 37°C. In order to assess if the binding activity of LntR, 
NahR, or NagR1 is modulated by a carbohydrate ligand, various 
carbohydrates including galactose, galactose-1-phosphate, galactose-6-
phosphate (all Sigma Aldrich, Steinheim, Germany), LNT (Glycom, Lyngby, 
Denmark), LNnT (Glycom, Lyngby, Denmark), LNB (Elicityl Oligotech, 
Crolles, France), glucose, N-acetylglucosamine, N-acetylglucosamine-6-
phosphate or lactose (all Sigma Aldrich, Steinheim, Germany) ranging in 
concentration from 50 to 0.0625 mM, were included to the binding reaction 
buffer. Samples were loaded onto a 6 % non-denaturing PAA gel prepared in 
TAE buffer (40 mM Tris acetate [pH 8.0], 2 mM EDTA) and run in a 0.5-to-
2.0 x gradient of TAE at 100 V for 90 min in an Atto Mini PAGE system 
(Atto Bioscience and Biotechnology, Tokyo, Japan). Signals were detected 
using Odyssey Infrared Imaging System (Li-Cor Biosciences UK Ltd, 
Cambridge, UK) and captured using the supplied software Odyssey V3.0. 
Primer extension analysis. Total RNA was isolated from B. breve 
UCC2003, grown in mMRS supplemented with 1 % LNnT or 1 % LNB, to 
early exponential phase, using a previously described Macaloid method [57]. 
RNA samples were treated with RNase-free DNase (Ambion). Primer 
extension was performed by annealing 1 pmol of IRD700 synthetic 18-mer 
oligonucleotides to 15 μg of RNA as described previously [58]. Sequence 
ladders of the presumed promoter regions immediately upstream of lntP1, 
lntS, nagB3, nagK, lnpB, gltA, nahS or nahA, amplified from both UCC2003 
genomic DNA which were run alongside the primer extension products, were 
produced using the same primer as the primer extension reaction and 
employing the Thermo Sequenase Primer Cycle Sequencing Kit; Amersham. 
Separation was achieved on a 6.5 % Li-Cor Matrix KB Plus acrylamide gel. 
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Signal detection and image capture was performed by means of a Li-Cor 
sequencing instrument (Li-Cor Biosciences). 
 
Operator Consensus Sequence Prediction, using MEME and 
WEBLOGO online software tools. Co-regulated promoter regions were 
assessed for the presence of operator sequences by the use of the MEME 
(Multiple Em for Motif Elicitation) online tool (http://meme-
suite.org/tools/meme) [59], which were the visualized by the WebLogo 
online tool (http://weblogo.berkeley.edu/logo.cgi) [60, 61]. Sequences used 
for consensus sequence prediction are given in Supplemental Table S3.4. 
 
Microarray data accession number. The microarray data obtained in this 
study have been deposited in NCBI’s Gene Expression Omnibus database and 
are accessible through GEO Series accession number GSE105108. 
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3.4 Results 
Identification of putative transcriptional regulator-encoding genes in the 
vicinity of HMO-utilisation loci. In a previous study, we had observed that 
genes within four chromosomal loci exhibit transcriptional induction during 
growth of B. breve UCC2003 on LNT, LNnT or LNB as the sole carbohydrate 
source [27]. This indicates that these genes are subject to transcriptional 
regulation, which was presumed to be either directly or indirectly controlled 
by the presence of these HMO substrates. The four loci concerned are: the lnt 
locus (Bbr_0526-530), the nah locus (Bbr_1554-1560), the nag locus 
(Bbr_1247-1250) and the lnp/glt locus (Bbr_1585-1590) (Fig. 3.1; see Table 
3.1 for a description of [predicted] functions). Detailed scrutiny of these four 
loci and neighbouring regions showed that the lnt and nah loci are flanked by 
or contain a predicted regulator-encoding gene, respectively: lntR 
(Bbr_0526), encoding a LacI-type repressor, and nahR (Bbr_1555), encoding 
a NagC/XylR-type repressor (Fig. 3.1A and 3.1B). The nag locus is 
associated with two genes, nagR1 (Bbr_1249) and nagR2 (Bbr_1251), both 
predicted to encode ROK/NagC family-type repressors, while no regulator-
encoding gene was observed in close vicinity of the lnp/glt locus (Fig. 3.1C 
and 3.1D). NagC/XylR-type and ROK/NagC-type repressors are both 
members of the large family of ROK-type transcriptional regulators [62]. The 
four identified putative regulator-encoding genes were thus selected as 
candidates for mutagenesis in order to ascertain their role, if any, in the 
transcriptional regulation of the lnt, nah, nag and lnp/glt loci.  
 
Generation and transcriptomic analysis of insertional mutants in 
putative HMO-associated regulator-encoding genes. Individual insertional 
mutants were constructed in lntR, nahR, nagR1 and nagR2, resulting in B. 
breve strains UCC2003-lntR, UCC2003-nahR, UCC2003-nagR1 and 
UCC2003-nagR2, respectively (see Materials and Methods). In order to 
identify promoters/genes that are subject to transcriptional control of these 
predicted regulators, global gene transcription data was obtained from 
microarray-based analyses performed on the B. breve UCC2003-lntR, 
UCC2003-nahR, UCC2003-nagR1 and UCC2003-nagR2 insertion mutants, 
128 
 
grown in mMRS supplemented with ribose, as compared to the transcriptome 
of the UCC2003 wild type strain grown under the same conditions. 
Transcriptome analysis of the lntR mutant revealed the upregulation of the 
adjacent lntP1, lntP2, lntA and lntS genes of the lnt locus (Table 3.1 and Fig. 
3.1), when this mutant was grown on ribose (as compared to wild type 
UCC2003), all of which were also previously found to be upregulated in 
expression during growth of wild type UCC2003 on LNT or LNnT [27]. This 
corroborates the notion that LntR is a LacI-type repressor and that this protein 
negatively regulates the LNT/LNnT-dependent transcription of genes within 
the lnt cluster. Conversely, the array data obtained for the nahR mutant only 
revealed transcriptional upregulation (compared to the UCC2003 control) of 
the nahS gene (Table 3.1), when grown on ribose. This is consistent with 
previously observed expression patterns in UCC2003, with the exception of 
nahA, which may have been expected to exhibit transcriptional upregulation 
in the nahR mutant, as its expression was increased during growth on LNT 
and LNnT in B. breve UCC2003 [27]. These results suggest that NahR, a 
NagC/XylR-type repressor, is responsible for the transcriptional regulation of 
at least one gene of the nah cluster. For the nagR1 mutant, upregulation of 
nagA2, nagB3 and nagK (but not nagR2 or nagK2), as well as all of the genes 
of the lnp/glt locus (Table 3.1) was observed when grown on ribose (as 
compared to the UCC2003 control). These results suggest that NagR1, a 
ROK/NagC family-type repressor, is responsible for the transcriptional 
regulation of (part of) the nag and lnp-glt clusters. This is consistent with 
transcriptomic data previously obtained for wild type UCC2003 during 
growth on LN(n)T and LNB, which demonstrated the transcriptional 
upregulation of genes in both of these loci [27]. When the transcriptome of 
UCC2003-nagR2 was compared to that of UCC2003 when grown on ribose, 
the nagR2 mutant exhibited increased transcription of genes in the mal locus 
(locus tags Bbr_0118-0123), which is known to be involved in 
maltooligosaccharide metabolism [63, 64], and Bbr_1719-1721 (predicted to 
function in fatty acid metabolism) [65] (data not shown), none of which are 
predicted to function in HMO metabolism, nor were shown to be upregulated 
in our previous wild type arrays on LNT, LNnT or LNB [27]. These results 
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thus show that NagR2 is not involved in the transcriptional control of the loci 
responsible for LNT, LNnT or LNB metabolism, and no further investigation 
of this regulator was carried out. The lntR, nahR and nagR1 genes, however, 
were selected for further study, as described below, in order to further 
elucidate their regulatory activity and specificity.  
 
Promoter mapping through identification of the transcription start sites. 
Based on the transcriptome findings, we presumed that LntR, NahR and 
NagR1 act as transcriptional regulators of (certain genes of the) lnt, nah and 
nag/lnp/glt loci, respectively. Gene expression patterns observed for the 
regulator gene mutants, and examination of the genetic layout and 
transcriptome profiles of these loci allowed us to assign putative promoter-
containing regions within each locus. In order to verify these predicted 
promoter regions, the associated transcription start sites (TSS) were 
experimentally determined by primer extension analyses.  
The lnt locus was deduced to contain at least two promoters: one just upstream 
of lntP1 (Fig. 3.2A) and one in front of lntS (Fig. 3.2B). The lntP1 and lntS 
genes on the B. breve UCC2003 genome encode a permease and a solute-
binding protein of an ABC-transporter system, respectively, and exhibit an 
increase in transcription upon growth on LNT, LNnT, LNB, lactosamine or 
lactose [27]. The transcription start sites (TSS) of the presumed lntP1 and lntS 
promoters were determined by primer extension analysis using RNA 
extracted from B. breve UCC2003 grown in mMRS supplemented with 1 % 
LNnT. An extension product was identified 41 nucleotides 5’ of the predicted 
translational start site of the lntP1 gene (Supplemental Fig. S3.1A), while the 
TSS for the lntS gene was identified 154 nucleotides 5’ of the predicted 
translational start site (Supplemental Fig. S3.1B). In both cases, the TSS was 
preceded by -10 and -35 hexamers that resemble (bifidobacterial) consensus 
vegetative promoter recognition sequences [66, 67].   
The nah locus was deduced to contain at least two promoters: one just 
upstream of nahS (Fig. 3.2C) and one in front of nahA (Fig. 3.2D). The nahS 
and nahA genes on the B. breve UCC2003 genome encode a solute-binding 
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protein of an ABC-transporter system, and a GH20 N-acetylhexosaminidase, 
respectively. While an increase in transcription was only observed for nahS 
in the nahR mutant-based array, both this gene and nahA were found to be 
subject to transcriptional induction when wild-type UCC2003 is grown on 
LNT, LNnT or lactosamine [27]. The TSSs of the presumed nahS and nahA 
promoters were determined by primer extension analysis using RNA 
extracted from B. breve UCC2003 grown in mMRS supplemented with 1 % 
LNnT. An extension product was identified 59 nucleotides 5’ of the predicted 
translational start site for the nahS gene (Supplemental Fig. S3.1C), while the 
TSS upstream of nahA was identified 74 nucleotides 5’ of the predicted nahA 
translational start site (Supplemental Fig. S3.1D). The nahS upstream region 
contained a -10 and a -35 hexamer just upstream of the TSS resembling 
bifidobacterial promoter sequences [66, 67], while in the case of the nahA 
promoter region the TSS is preceded by a sequence that resembles a canonical 
-10 promoter sequence, although no associated -35 hexamer could be 
identified. 
The nag and lnp/glt loci were each deduced to contain at least two promoters, 
just upstream of the genes: nagB3 (Fig. 3.2E) and nagK (Fig. 3.2F), and lnpB 
(Fig. 3.2G) and gltA (Fig. 3.2H), respectively, based on the associated genetic 
lay-out coupled to transcription patterns of the nagR1 mutant or when 
UCC2003 was grown on LNB [27]. The transcription start sites (TSS) of the 
presumed nagB3, nagK, lnpB and gltA promoters were determined by primer 
extension analysis using RNA extracted from B. breve UCC2003 grown in 
mMRS supplemented with 1 % LNB. An extension product was identified 
155 nucleotides 5’ of the predicted translational start site for the nagB3 gene 
(Supplemental Fig. S3.1E), while the transcriptional start site of nagK was 
identified 35 nucleotides 5’ of the predicted translational start site 
(Supplemental Fig. S3.1F). An extension product was identified 43 
nucleotides 5’ of the predicted translational start site for the lnpB gene 
(Supplemental Fig. S3.1G), while the transcription start site for the gltA gene 
was identified 44 nucleotides 5’ of the predicted translational start site 
(Supplemental Fig. S3.1H). All four regions contained -10 and -35 hexamers 
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just upstream of the TSS that resembled bifidobacterial vegetative promoter 
recognition sequences. 
 
Identification of regulator-operator interactions using electromobility 
shift assays and in silico analysis. In order to establish if the LntR, NahR 
and NagR1 proteins directly and specifically interact with operator sequences 
within the identified promoter regions of the lnt, nah, and nag/lnp/glt gene 
clusters, respectively, electrophoretic mobility shift assays (EMSAs) were 
performed. For the purpose of performing EMSAs, the lntR, nahR and nagR1 
genes were first individually cloned into the nisin-inducible vector pNZ8150 
with an N-terminal His tag-encoding sequence to facilitate protein expression 
and purification in L. lactis NZ9000 (see Materials and Methods). As had 
been noted previously for other regulators from bifidobacteria [52, 55, 68], 
LntR, NahR and NagR1 could be obtained as purified proteins, but had lost 
their DNA binding activity during some stage of the purification process. 
Thus, instead of purified protein, crude cell extracts of (nisin-induced) L. 
lactis NZ9000 pNZ-lntRHis, L. lactis NZ9000 pNZ-nahRHis and L. lactis 
NZ9000 pNZ-nagR1His were used to carry out the EMSAs. Crude cell extract 
obtained from nisin-induced L. lactis NZ9000 pNZ8150 (empty vector) 
incubated with the respective DNA fragments was used as a negative control. 
The DNA fragments used were various short amplicons representing different 
segments of the putative promoter regions (Fig. 3.2, Supplemental Table 
S3.3). 
LntR-containing crude extract was shown to specifically bind to the IRD700-
labelled DNA fragments lntP1a and lntP1b, but not with lntP1c (Fig. 3.2A, 
Supplemental Table S3.3). A double mobility-shift was observed for 
fragment lntP1a, indicative of two distinct LntR binding sites being present 
on this fragment, while a single mobility shift was visible for fragment lntP1b. 
Similarly, LntR was able to bind to IRD700-labelled DNA fragments lntSb 
and lntSa, in the latter case being visible as a double mobility-shift 
(suggesting the presence of two distinct LntR-binding sites), while no binding 
was observed with lntSc (Fig. 3.2B, Supplemental Table S3.3). Inspection 
and comparison of the four fragments in which binding was observed 
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revealed the presence of at least one complete conserved sequence, 
representing an inverted repeat, in all four fragments, while two such 
conserved sequences were observed in fragments lntP1a and lntSa (being 
consistent with the observed double mobility-shift). Comparative analysis of 
these inverted repeats identified a 14-nucleotide consensus sequence (Fig. 
3.3A), containing a conserved ‘CG’ at its centre, which is a well-documented 
conserved feature of operator sequences bound by LacI-type regulators [69, 
70]. This consensus sequence furthermore contains a conserved 5’ ‘TG’ and 
3’ ‘CA’ at its flanking ends, a feature previously documented in operator 
sequences identified for other LacI-type regulators encoded by B. breve 
UCC2003 [43, 51, 55]. In both promoter regions, one such presumed operator 
sequence was found closely downstream of or partially overlapping the 
predicted -10 element of the promoter region, while the second was found 
closely upstream of the predicted -35 element of the promoter region 
(Supplemental Fig. S3.1A, S3.1B). The positions of these identified operators 
are consistent with LntR acting as a repressor for the identified lnt promoters 
[71, 72]. 
The results obtained with the L. lactis NZ9000 pNZ-nahRHis crude extract 
demonstrated specific binding to the IRD700-labelled DNA fragments nahSa 
and nahSb, but not with nahSc (Fig. 3.2C, Supplemental Table S3.3). 
Furthermore, binding was observed for IRD700-labelled DNA fragment 
nahAa, but not to fragment nahAb or nahAc (Fig. 3.2D, Supplemental Table 
S3.3). Sequence inspection and comparison of the NahR-bound DNA 
fragments revealed the presence of an inverted repeat sequence, which was 
common to these fragments, yet not present in fragments to which NahR did 
not bind. These inverted repeat elements therefore represent putative operator 
sequences required for the NahR protein. Further analysis of these inverted 
repeats identified a 10-nucleotide consensus sequence (Fig. 3.3B). Conserved 
5’ C and 3’ G nucleotides at the extreme flanks of this consensus sequence 
have previously been observed for operator sequences of certain NagC/XylR-
type regulators [73]. The presumed operator upstream of nahS overlaps with 
the downstream end of the predicted -10 promoter element (Supplemental 
Fig. S3.1C), while the nahA-associated operator was found to be roughly 110 
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bp upstream of the predicted -10 element (Supplemental Fig. S3.1D). The 
position of the identified nahS operator, and the consensus obtained between 
this and the putative operator identified for nahA, confirm the function of 
NahR as a repressor for nahS. While binding of NahR may occur at the nahA 
operator, its binding does not appear to directly interfere with the nahA 
promoter. This agrees with the lack of upregulation in nahA expression 
observed for the nahR mutant, though the transcriptional role of NahR in this 
case, if any, is not clear. The mapped locations of the operator, -10 and -35 
sequences are shown in Supplemental Figure S1.  
The results obtained with the crude extract obtained from nisin-induced L. 
lactis NZ900 pNZ-nagR1His revealed specific binding to the IRD700-labelled 
DNA fragments nagB3a, nagB3b and nagB3c (with a weak apparent double-
shift observed for nagB3a), but not to fragment nagB3d (Fig. 3.2E, 
Supplemental Table S3.3). Specific binding was identified for IRD700-
labelled DNA fragment nagKa, while no binding was detected when fragment 
nagKb was used (Fig. 3.2F, Supplemental Table S3.3). Binding of the NagR 
protein was also demonstrated for the IRD700-labelled DNA fragments 
lnpBa and lnpBc, but not with lnpBb (Fig. 3.2G, Supplemental Table S3.3). 
Finally, NagR1 was shown to bind IRD700-labelled DNA fragments gltAa, 
gltAb and gltAc (Fig. 3.2H, Supplemental Table S3.3). Inspection and 
comparison of the nagB3, nagK, lnpB, and gltA-associated fragments in 
which binding was observed revealed the presence of a common sequence, 
representing an inverted repeat (with two repeats present in the fragment 
nagB3a, consistent with the observed double-shift), while being absent within 
fragments for which no binding was observed. These sequence motifs are 
presumed to act as operator sequences for the NagR1 protein. In silico 
analysis of these inverted repeat sequences revealed a 23-nucleotide 
consensus (Fig. 3.3C). Interestingly, while this obtained consensus motif 
bears little resemblance to many previously proposed binding motifs for 
ROK/NagC family-type repressors from other bacteria [74], a substantial 
degree of similarity can be observed to motifs identified previously for other 
ROK/NagC-type regulators encoded by B. breve UCC2003 [30, 55]. The 
putative nagB3, nagK, lnpB and gltA operators were all found to be 
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overlapping with or encompassing the predicted -10 or -35 elements 
(Supplemental Fig. S3.1E, S3.1F, S3.1G, S3.1H). The positions of these 
identified operators corroborate the notion that NagR1 acts as a 
transcriptional repressor of its target genes (i.e. nagB3, nagK, lnpB and gltA).  
 
Identification of transcriptional effectors. In order to identify effectors that 
control the binding activity of LntR, NahR and NagR1, we performed EMSAs 
with fragments containing the binding motifs for each regulator, in the 
presence of a range of carbohydrates, including: lactose, LNB, LNT, LNnT, 
galactose, galactose-6-phosphate (Gal-6-P), galactose-1-phosphate (Gal-1-
P), GlcNAc, N-acetylglucosamine-6-phosphate (GlcNAc-6P), GalNAc or 
glucose (at a standard concentration of 20 mM) (Supplemental Fig. S3.2). 
These carbohydrates were chosen as they include both the complete structures 
and various components (or breakdown products) of LNT, LNnT or LNB. 
Carbohydrates which did not elicit any effect on fragment binding by the 
regulator (at a concentration of 20 mM) were assumed not to represent 
transcriptional effectors for that particular regulator. If an inhibition in 
binding was observed at 20 mM, the EMSA was repeated at a range of 
descending concentrations (or in some cases higher concentrations were used 
for a related molecule [e.g. Gal, Gal-1-P and Gal-6-P]). For LntR, galactose 
was found to reduce binding of this regulator to its DNA targets at a 
concentration of 10 mM or less (Fig. 3.4A). Gal-6-P and Gal-1-P were also 
found to reduce target DNA binding of LntR, but at considerably higher, and 
perhaps biologically irrelevant concentrations of ≥20 mM (Supplemental 
Figure S3.3). For NahR, only GlcNAc was found to reduce interaction 
between NahR and its DNA target at a minimum concentration of 0.0625 mM 
(Fig. 3.4B), while in the case of NagR1, GlcNAc-6-P was found to prevent 
NagR1-binding activity at a minimum concentration of 1 mM (Fig. 3.4C, 
3.4D). 
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3.5 Discussion 
The dominance of (certain) bifidobacteria within the breastfed neonatal gut 
microbiota [1] is substantially aided by the ability of these infant-associated 
species to utilise indigestible HMO residues as a carbon source [9]. Our 
previous work demonstrated that consumption and utilisation of LNT, LNnT 
or LNB by B. breve UCC2003 is facilitated by interrelated catabolic pathways 
[27]. While pathways for HMO utilisation in other Bifidobacterium species 
have been identified and elucidated [13, 21, 22], very little work has been 
carried out with regard to their regulation. Our results reveal molecular details 
of the transcriptional regulation of B. breve UCC2003 loci responsible for 
LN(n)T/LNB metabolism, and provide insights into how metabolism of these 
HMOs is controlled in B. breve UCC2003.  
In the current study, we identified four transcriptional regulators, three of 
which were shown to be involved in regulating LN(n)T/LNB metabolism in 
UCC2003 (Fig 3.5). Microarray analysis of insertional mutants in lntR, nahR, 
nagR1 and nagR2 identified genes under the regulation of each encoded 
regulator. LntR and NahR were shown to represent ‘local’ regulators, i.e. 
controlling transcription of genes adjacent to lntR and nahR, respectively. In 
contrast, NagR1 regulates transcription of not only the ‘local’ nag locus, but 
also of the genetically unlinked lnp/glt locus. We also investigated the 
transcriptome effect of a mutation in Bbr_1251 (nagR2), however, the 
affected genes are not believed to be involved in HMO metabolism, but 
apparently in malto-oligosaccharide and fatty acid metabolism. While LacI-
type, NagC/XylR-type and ROK/NagC-type regulators have all previously 
been identified and characterised in B. breve UCC2003 [30, 51, 52, 55], 
functional analysis of regulators in other bifidobacteria is comparatively 
undocumented. However, a recent study identified homologous transcription 
factors for those of LntR, NagR1and NagR2 in a range of different 
Bifidobacterium species [75]. 
Details of promoter and operator sequences specific to the LntR, NahR and 
NagR1 regulators were elucidated using a combination of electromobility 
shift and primer extension analyses. These operator results, for the most part, 
agree with those predicted by Khoroshkin et al. [75]. The operator sequences 
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predicted in their study concur with our experimentally determined data, both 
in approximate location and number, for both LntR and NagR1, with the 
exception of one additional predicted operator for LntR, and two for NagR1. 
An additional NagR1 operator sequence was predicted upstream of gltA, 
however, this did not appear to be functional, based on the lack of a double 
mobility-shift in the EMSA’s for that region. This operator may indeed be a 
non-functional relic resulting from a duplication event. Khoroshkin et al. [75] 
also predicted an operator sequence upstream of the gene Bbr_1884 for 
NagR1 binding, though we did not examine this. However, based on the 
predicted functions of this gene in the Bifid Shunt, it may also be tied into the 
overall regulation of LNB and LacNAc metabolism carried out by NagR1. 
An additional LntR operator was predicted upstream of lntR itself, which may 
function in lntR transcriptional auto-regulation. The observed lack of 
upregulation in nahA transcription for the nahR mutant appears discordant 
with the transcriptional increase of this gene that was previously observed in 
wild type UCC2003 during growth on LN(n)T [27], as well as the presence 
of the functional nahA operator sequence for NahR binding identified in this 
study. However, this may be explained if transcriptional induction of nahA is 
mediated by both LntR and NahR. This possibility is corroborated by the 
presence of an inverted repeat sequence resembling an LntR operator and this 
intriguing possibility merits further experimental investigation.  
Perhaps most interestingly of all was the identification of the effectors for 
each transcriptional regulator. Binding of LntR to its targets is impeded by 
Gal, NahR-mediated operator binding is prevented by the presence of 
GlcNAc, while NagR1-operator interaction is prevented by the presence of 
GlcNAc-6-P. In each case, the genes under transcriptional control by their 
respective regulator encode the metabolic machinery responsible for the 
release (and/or generation) of the effector monosaccharide from the substrate 
at that metabolic step. For example, Gal is released from the non-reducing 
end of LN(n)T through the hydrolytic activity of LntA, which is encoded by 
the lnt locus [27]. Transcriptional repression of this locus is thus believed to 
be relieved by the presence of the released monosaccharide, which is 
presumed to interact with the allosteric effector site typical of LacI-type 
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repressors [55, 71, 76, 77]. A similar scenario applies to GlcNAc release 
which acts as the effector for the NahR regulator that controls transcription 
of nahS, and to GlcNAc-6-P which governs the activity of the NagR1, the 
presumed transcriptional regulator of the lnp/glt and nag loci. The possible 
dual regulation of nahA transcription, as mentioned above, would mean that 
both the presence of the lnt locus activity product (and LntR effector) 
galactose, and the nah locus activity product (and NahR effector) GlcNAc, 
are required for the induction of nahA expression. This provides an extra level 
of transcriptional and thus metabolic control, ensuring the expression of nahA 
strictly during LN(n)T metabolism, despite GlcNAc release during 
metabolism of other sugars, such as LNB, sialic acid and sulphated GlcNAc 
[27, 29, 30]. Interestingly, in the case of GlcNAc-6-P and NagR1, the lnp/glt 
locus is required for the degradation of LNB, while the activity of the nag 
locus results in the generation of GlcNAc-6-P from liberated GlcNAc, during 
both HMO and sialic acid metabolism [29]. This may not be surprising, as 
sialic acid residues are commonly found in HMO [6], and more importantly, 
GlcNAc is a breakdown product of LNB (as well as LNT and LNnT).  
Interestingly, previous work has shown that transcriptional induction takes 
place of the lnt locus during growth of UCC2003 on galacto-oligosaccharides 
(GOS) [78]. This would appear to disagree with the high degree of specificity 
of transcriptional induction by effectors of these HMO-associated loci. 
However, it is worth noting that GOS consist mainly of galactose [79, 80], 
and that the intracellular release of galactose during GOS metabolism by 
UCC2003 would be sufficient to cause transcriptional induction of the lnt 
locus. 
Thus, the presence and initial degradation of such a structure (i.e. LNT, LNnT 
or LNB) indirectly induces further expression of the locus required for its 
degradation, until the sugar is no longer available, at which point the absence 
of inducers will cause a return to transcriptional repression. Initial 
internalisation and degradation is likely facilitated by a low level of ‘leaky’ 
gene expression of the locus. In the case of LNT and LNnT degradation, this 
regulation is a two-step process, at the level of LN(n)T degradation first (by 
the lnt locus), and then at the level of (LN(n)T breakdown product) lacto-N-
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triose degradation (by the nah locus). Regulation of LNB metabolism is 
managed in a single step, at the level of LNB phosphorolysis and GlcNAc 
phosphorylation (by the lnp/glt and nag loci). We see that all three regulators 
in this transcriptional control network belong to distinct families of regulator 
proteins, despite functioning in similar roles as saccharide-controlled 
repressors. In conclusion, our results reveal a tightly controlled system for 
transcriptional regulation of genes encoding the metabolic machinery 
required for (certain) HMO metabolism in B. breve UCC2003. Such tight 
regulation is necessary for infant-associated bifidobacteria such as B. breve, 
where switching metabolic processing to and from milk-derived sugars such 
as HMO and lactose, and plant-derived carbohydrate sources [81] is a regular 
occurrence during the weaning period. Moreover, this suggests the evolution 
of specific catabolic responses to the presence of and for the utilisation of 
specific HMO moieties by B. breve, and poses the question as to whether such 
regulatory systems have similarly evolved in other infant-associated 
Bifidobacterium species. 
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3.7 Tables and Figures 
Table 3.1. B. breve UCC2003 regulator mutant genes upregulated in transcription during 
growth in mMRS medium supplemented with 1 % ribose as the sole carbohydrate, as compared 
to the wild type (control).  
The level of transcription is shown as a fold-value of increase in transcription on each carbohydrate, as compared to a ribose control, with a 
cut-off of a minimum 2.0-fold increase in transcription.  
a Based on comparative transcriptome analysis using B. breve UCC2003-lntR, B. breve UCC2003-nahR and B. breve UCC2003-nagR1 grown 
on 1% ribose, as compared to wild-type B. breve UCC2003 grown under the same conditions as a control. 
b The cutoff point is 2.0-fold, with a P value of _0.001. —, value below the cutoff. 
N/A indicates that the fold-value for increase in transcription for this gene is not included, as this is the gene in which the mutation was made, 
and thus does not accurately represent its natural transcription under these conditions.  
The level of transcription is not given for the regulator-encoding genes containing the mutations in their respective arrays, as their transcription 
has been interrupted, and thus cannot be considered as reliable.  
 
 
 
    Fold upregulationa,b during growth on:  
Gene ID Gene name Function UCC2003-
lntR 
UCC2003-
nahR 
UCC2003-
nagR1 
Bbr_0526 lntR Transcriptional regulator, LacI family N/A - - 
Bbr_0527 lntP1 Permease protein of ABC transporter system for sugars  3.84 - - 
Bbr_0528 lntP2 Permease protein of ABC transporter system for sugars  3.77 - - 
Bbr_0529 lntA GH42 Beta-galactosidase 2.78 - - 
Bbr_0530 
 
lntS Solute-binding protein of ABC transporter system for sugars  5.66 - - 
Bbr_1247 nagA2 CE9 nagA2 N-acetylglucosamine-6-phosphate deacetylase - - 6.70 
Bbr_1248 nagB3 nagB3 Glucosamine-6-phosphate isomerase  - - 9.11 
Bbr_1249 nagR1 Transcriptional regulator, ROK family  - - N/A 
Bbr_1250 
 
nagK Sugar kinase, ROK family  - - 2.29 
Bbr_1251 nagR2 Transcriptional regulator, ROK family  - - - 
Bbr_1252 
 
nagK2 Sugar kinase, pfkB family  - - - 
Bbr_1554 nahS Solute-binding protein of ABC transporter system (lactose)  - 17.44 - 
Bbr_1555 nahR NagC/XylR-type transciptional regulator - N/A - 
Bbr_1556 nahA GH20 nagZ Beta-N-acetylhexosaminidase - - - 
Bbr_1558 nahP Permease protein of ABC transporter system - - - 
Bbr_1559 nahT1 ATP-binding protein of ABC transporter system - - - 
Bbr_1560 
 
nahT2 ATP-binding protein of ABC transporter system - - - 
Bbr_1585 lnpD UDP-glucose 4-epimerase  - - 3.06 
Bbr_1586 lnpB Phosphotransferase family protein - - 3.36 
Bbr_1587 lnpA GH112 lacto-N-biose phorylase  - - 2.90 
Bbr_1588 gltC Permease protein of ABC transporter system for sugars  - - 2.91 
Bbr_1589 gltB Permease protein of ABC transporter system for sugars  - - 3.02 
Bbr_1590 gltA Solute-binding protein of ABC transporter system for sugars  - - 5.07 
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Figure 3.1. Schematic representation of HMO metabolism-associated loci in B. breve UCC2003, as identified previously [22]. (a) The genes of 
the lnt locus. (b) The genes of the nah locus. (c) The genes of the nag locus, and adjacent genes nagR2 and nagK2. (d) The genes of the lnp/glt 
locus. The length of the arrows is proportional to the size of the open reading. Genes shown in red possess a predicted promoter in their upstream 
intergenic region. Genes shown in green are predicted to encode a regulator protein. Genes shown in blue were identified as not possessing a 
predicted promoter in their upstream intergenic region. 
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Figure 3.2. EMSA images showing LntR (a and b), NahR (c and d), and NagR1 (e to h) interactions with a range of DNA fragments from the 
regions in the proximity of their predicted target promoters, in order to identify their approximate locations. The locations and sizes of fragments 
used, in relation to the promoter regions’ respective transcription start sites, are given in Table S1 in the supplemental material. The panels at the 
right schematically represent the locations of the DNA fragments used in relation to the locations of the putative operator sequences (red boxes), 
transcription start sites (green arrows), and genes (arrows in blue boxes). In each panel, “-” indicates a negative control, where an equivalent 
amount of the crude cell extract from NZ9000 harboring empty plasmid pNZ8150 was added instead of the crude extract from the regulator-
expressing NZ9000 strain. 
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Figure 3.3. WebLogo representation of the operator motif consensus sequences for (a) the 
LacI-type regulator LntR, (b) the NahC/XylR-typr regulator NahR and (c) the ROK/NagC-type 
regulator NagR1, predicted using in silico analysis. Predicted operator sequences identified in 
the intergenic regions containing the co-regulated promoters for each regulator using the 
MEME online tool. Motif consensuses were generated by inputting these predicted operator 
sequences to the WebLogo online tool. The locations and sequences of each operator are shown 
alongside their respective consensus sequence.  
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Figure 3.4. EMSA images showing (a) LntR, (b) NahR, and (c) and (d) NagR1 interactions with promoter-containing DNA fragments, with the 
addition of a gradient of their respective inducers, ranging from 0mM-20mM. In each panel, ‘C’ indicates a negative control, where an equivalent 
amount crude cell extract from NZ9000 harbouring empty pNZ8150 was added instead of crude extract from the regulator-expressing NZ9000 
strain.  
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Figure 3.5. Schematic representation of the proposed model for transcriptomic regulation of LNT, LNnT and LNB metabolism by B. breve 
UCC2003. LNT and LNnT are internalised and intracellularly degraded through sequential hydrolysis and release of monosaccharides from their 
non-reducing ends. These released monosaccharides (or their metabolites) act as effectors relieving transcriptional repression of the loci encoding 
the cellular components responsible for liberation of these glycans. As such, liberated galactose relieves transcriptional repression of the lnt locus, 
and N-acetylglucosamine relieves transcriptional repression of the nah locus. Similarly, intracellular degradation of LNB (derived from the 
extracellular hydrolysis of complex HMO structures by other infant GIT microbes) releases N-acetylglucosamine and galactose-1-phosphate. 
GlcNAc is further converted into GlcNAc-6-P, which relieves transcriptional repression of the lnp/glt and nag loci. 
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3.8 Supplemental Material 
Supplemental Table S3.1. Oligonucleotide primers used in this work. 
Restriction sites incorporated into oligonucleotide primer sequences are indicated in bold, and His-tag sequences 
incorporated into nucleotide primer sequences are indicated in italics. 
 
Purpose Primer Sequence (5’-3’) 
Cloning of Bbr_0526 in pNZ8150 526F 
526R 
 
tgcatccccgggatgcatcaccatcaccatcaccatcaccatcacgcgagaccaacacaggtttcc 
tgcgcatctagacgtttcccgtataccattaatcag 
 
Cloning of Bbr_1555 in pNZ8150 1555F 
1555R 
 
tgcatcgatatcatgcatcaccatcaccatcaccatcaccatcactacgctaaatccaatccc 
tgcgcatctagacggcggcacggtgatctg 
Cloning of Bbr_1249 in pNZ8150 1249F 
1249R 
 
tgcatccagctgatgcatcaccatcaccatcaccatcaccatcactcgtatcccggtcttgcc 
tgcatccagctgatgtcgtatcccggtcttgcc 
 
Cloning of internal 465bp fragment of 
Bbr_0526 in pORI19 
IM526F 
IM526R 
 
ctggtcaagcttcgttgaagccgcgatgga 
ctggtctctagagtcaacggtggggcagtg 
 
Cloning of internal 488bp fragment of 
Bbr_1555 in pORI19 
IM1555F 
IM1555R 
 
ctggtcaagcttgctggccatcgatacggac 
ctggtctctagactcgtcgttcagcagcac 
Cloning of internal 443bp fragment of 
Bbr_1249 in pORI19 
IM1249F 
IM1249R 
 
ctggtcaagcttcgaagaaggcctattgcg 
ctggtctctagacagcagaatcgccgaacc 
 
Cloning of internal 488bp fragment of 
Bbr_1251 in pORI19 
IM1251F 
IM1251R 
 
ctggtcaagcttgaagagaccggcgacctgg 
ctggtctctagagccattgtcgatgacgcc 
 
Amplification of tetW tetWFw 
tetWRv 
 
tcagctgtcgacatgctcatgtacggtaaggaagca 
gcgacggtcgaccataacttctgattgttgccg 
 
Confirmation of site specific homologous 
recombination 
526confirm1 
526confirm2 
1555confirm1 
1555confirm2 
1249confrim1 
1249confrim2 
1251confrim1 
1251confrim2 
 
gcgctagctgttacaatggtc 
gccatttccaacccctctc 
tacgctaaatccaatccc 
gacgcaagggccaacaaccgc 
catacagccgccacggcac 
tcgtatcccggtcttgcc 
gcagacgatactgcacgcg 
gtcaagcatctctaccac 
Amplification of Bbr_0527 promoter fragments 
with IRD700-labelled oligonucleotides 
527IRDfa 
527IRDra 
527IRDfb 
527IRDrb 
527IRDfc 
527IRDrc 
 
ctcgcccctcgcttgtctctc 
gcataggcacggcagcgac 
attgttttcgtgaccattg 
gaataatgaacacgaacacg 
caattttggtcaaccttcg 
cgcgcgtagttctcgac 
Amplification of Bbr_0530 promoter fragments 
with IRD700-labelled oligonucleotides 
530IRDfa 
530IRDra 
530IRDfb 
530IRDrb 
530IRDfc 
530IRDrc 
 
gccgaacggtgtgctggtgg 
cttcatcgttctgttctccttc 
cgataacacgcccgccatc 
gctggacttgccgctatc 
cttcatagagccacttc 
ctcgaagtccttggcaac 
Amplification of Bbr_1554 promoter fragments 
with IRD700-labelled oligonucleotides 
1554IRDfa 
1554IRDra 
1554IRDfb 
1554IRDrb 
1554IRDfc 
1554IRDrc 
 
gtcgctgggattggatttagcg 
gtggctatgactgcgcgc 
cggctttcaggataacaccca 
ggatttggcggcgcgatc 
ccaaacaaaatagttgctacggc 
gttgagtgcggtgtaggtctcc 
Amplification of Bbr_1556 promoter fragments 
with IRD700-labelled oligonucleotides 
 
 
 
 
1556IRDfa 
1556IRDra 
1556IRDfb 
1556IRDrb 
1556IRDfc 
1556IRDrc 
 
ctggacggctgctcaaagc 
gcagagatgtttgaccgttcat 
ggtgacgacgccactctgc 
gtggtttgcggttgccct 
gccatctcaggaccgaacg 
ggtcgtcaaggtgatgaatcc 
Amplification of Bbr_1248 promoter fragments 
with IRD700-labelled oligonucleotides 
 
 
 
 
1248IRDfa 
1248IRDra 
1248IRDfb 
1248IRDrb 
1248IRDfc 
1248IRDrc 
1248IRDfd 
1248IRDrd 
 
cctcctgcctgaacgatg 
gacaatgatgatttccggc 
gttagggaacttcactaatacattcc 
cctgggagatgtcgatcgactc 
gtccgtacgtccataattgtaagtag 
cctgggagatgtcgatcgactc 
gatgggcggctttgggcag 
cctgggagatgtcgatcgactc 
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Supplemental Table S3.1. Oligonucleotide primers used in this work. 
Restriction sites incorporated into oligonucleotide primer sequences are indicated in bold, and His-tag sequences 
incorporated into nucleotide primer sequences are indicated in italics. 
 
 
 
 
 
 
Purpose Primer Sequence (5’-3’) 
Amplification of Bbr_1250 promoter fragments with IRD700-
labelled oligonucleotides 
1250IRDfa 
1250IRDra 
1250IRDfb 
1250IRDrb 
 
gatgccgttgtggtagagatg 
ggtgttatcagtcattgcctatcc 
gcgtgtcgcgtatgaggc 
ggtgttatcagtcattgcctatcc 
Amplification of Bbr_1586 promoter fragments with IRD700-
labelled oligonucleotides 
1586IRDfa 
1586IRDra 
1586IRDfb 
1586IRDrb 
1586IRDfc 
1586IRDrc 
 
cggttcgtcgaaaatccaag 
cagtgcgaagtgtgaggcg 
gccgcttattgcggctttatag 
ctttgagggcagaagtaactagttc 
gtatgcgcgttcgtccac 
ctttgagggcagaagtaactagttc 
Amplification of Bbr_1590 promoter fragments with IRD700-
labelled oligonucleotides 
 
1590IRDfa 
1590IRDra 
1590IRDfb 
1590IRDrb 
1590IRDfc 
1590IRDrc 
 
ggcccgctggcagattag 
ggcaagagcagccacgatg 
gacagatgtctgagcggtc 
gaatcgggcagacggtgc 
cgcgcagaaattgttagttagg 
gaatcgggcagacggtgc 
Amplification of region containing Bbr_0527 promoter region 
for sequencing ladders 
527promF 
527promR 
 
gcattgctgtcattcgccacac 
gaataatgaacacgaacacg 
Amplification of region containing Bbr_0530 promoter region 
for sequencing ladders 
530promF 
530promR 
 
gcgtgcggatgaaactgg 
gtctggaacggcttggcgc  
Amplification of region containing Bbr_1554 promoter region 
for sequencing ladders 
1554promF 
1554promR 
 
cgtttcctcgaccccagttc 
gaatgtgtccttgagcttggc 
Amplification of region containing Bbr_1556 promoter region 
for sequencing ladders 
1556promF 
1556promR 
 
ctggacggctgctcaaagc 
ggtcgtcaaggtgatgaatcc 
Amplification of region containing Bbr_1248 promoter region 
for sequencing ladders 
1248promF 
1248promR 
 
ggaggctttggcggtacgg 
cctgggagatgtcgatcgactc 
Amplification of region containing Bbr_1250 promoter region 
for sequencing ladders 
1250promF 
1250promR 
 
gatgccgttgtggtagagatg 
ggtgccacccacatcaacac 
Amplification of region containing Bbr_1586 promoter region 
for sequencing ladders 
1586promF 
1586promR 
 
gcgagaccttcgaccttcagcc 
cggcacgagattgtaagacac 
Amplification of region containing Bbr_1590 promoter region 
for sequencing ladders 
1590promF 
1590promR 
 
ggcccgctggcagattag 
gaatcgggcagacggtgc 
527 promoter for primer extension analysis 527PE 
 
gcataggcacggcagcgac 
530 promoter for primer extension analysis 530PE 
 
cttcatcgttctgttctccttc 
1554 promoter for primer extension analysis 1554PE 
 
gttcatgttggtcttctttcc 
1556 promoter for primer extension analysis 1556PE 
 
gcagagatgtttgaccgttcat 
1248 promoter for primer extension analysis 1248PE 
 
ctgcccaaagccgcccatc 
1250 promoter for primer extension analysis 1250PE 
 
ggtgttatcagtcattgcctatcc 
1586 promoter for primer extension analysis 1586PE 
 
gcgatgtcaaatagtgtttcc 
1590 promoter for primer extension analysis 1590PE ggcaagagcagccacgatg 
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Supplemental Table S3.2. Bacterial plasmids and strains used in this work. 
Cmr, Emr,Kmr and Tetr, resistance to chloramphenicol, erythromycin, kanamycin and tetracycline, respectively. 
UCC, University College Cork Culture Collection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Strain or plasmid Relevant Features 
(antibiotic resistances are given in brackets) 
Reference or 
Source 
Strains   
Escherichia coli strains   
 E. coli EC101 Cloning host, repA+ (kmr) [42] 
 E. coli EC101-pNZ-M.BbrII + M.BbrIII EC101 harbouring pNZ8048 derivative containing bbrIIM and bbrIIIM [40] 
Lactococcus lactis strains   
 L. lactis NZ9000 MG1363, pepN::nisRK, nisin-inducible overexpression host [54] 
 L. lactis NZ9700 Nisin-producing strain [54] 
 L. lactis NZ9000-pNZ-lntR (Cmr), NZ9000 conatining pNZ-lntR This study 
 L. lactis NZ9000-pNZ-nahR (Cmr), NZ9000 conatining pNZ-nahR This study 
 L. lactis NZ9000-pNZ-nagR1 (Cmr), NZ9000 conatining pNZ-nagR1 This study 
Bifidobacterium sp. Strains   
 B. breve UCC2003 Isolate from nursling stool [41] 
 B. breve UCC2003-lntR (Tetr), pORI19-tet-bbr_0526 insertion mutant of UCC2003 This study 
 B. breve UCC2003-nahR (Tetr), pORI19-tet-bbr_1555 insertion mutant of UCC2003 This study 
 B. breve UCC2003-nagR1 (Tetr), pORI19-tet-bbr_1249 insertion mutant of UCC2003 This study 
 B. breve UCC2003-nagR2 (Tetr), pORI19-tet-bbr_1251 insertion mutant of UCC2003 This study 
 
Plasmids 
  
 pAM5 pBC1-puC19-(Tetr) [82] 
 pORI19 (Tetr), (Emr), repA-, ori+, cloning vector [42] 
 pORI19-tet-lntR (Tetr), (Emr), Internal 367 bp fragment of bbr_0526 and tetW cloned in pORI19 This study 
 pORI19-tet-nahR (Tetr), (Emr), Internal 448 bp fragment of bbr_1554 and tetW cloned in pORI19 This study 
 pORI19-tet-nagR1 (Tetr), (Emr), Internal 502 bp fragment of bbr_1249 and tetW cloned in pORI19 This study 
 pORI19-tet-nagR2 (Tetr), (Emr), Internal 507 bp fragment of bbr_1251 and tetW cloned in pORI19 This study 
 pNZ8150 (Cmr, nisin inducible translational fusion vector [50] 
 pNZ-lntR (Cmr), pNZ8150 derivative containing translational fusion of Bbr_0526 encoding 
DNA fragment to nisin inducible promoter 
This study 
 pNZ-nahR (Cmr), pNZ8150 derivative containing translational fusion of Bbr_1555 encoding 
DNA fragment to nisin inducible promoter 
This study 
 pNZ-nagR1 (Cmr), pNZ8150 derivative containing translational fusion of Bbr_1249 encoding 
DNA fragment to nisin inducible promoter 
This study 
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Supplemental Table S3.3. Locations and sizes of fragments used in electromobility shift 
assays, in relation to the promoter regions’ respective transcription start sites. 
Binding of the amplified DNA fragment by the regulator protein, and thus formation of a DNA-protein complex is observed as a shift in band 
position in the EMSA gel.  
A positive result for a band shift is represented by a ‘+’. A double-shift is represented by a ‘++’. No observed shift is represented by a ‘-‘. 
Fragment positions are given in relation to the deduced transcription start site (0). 
‘*’ indicates that one of the identified inverted repeat sequences is partially interrupted by or in close proximity to the terminus of the fragment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fragment Name Fragment Start (Position) Fragment End 
(Position) 
Fragment Size (bp) Number of identified 
inverted repeats 
Shift Observed (+/-) 
lntP1a -174 +74 249 2 ++ 
lntP1b -89 +173 263 2* + 
lntP1c +5 +258 254 0 - 
lntSa -132 +159 292 2 ++ 
LntSb -56 +252 309 2* + 
lntSc +30 +337 308 0 - 
nahSa -197 +90 288 1 + 
nahSb -91 +211 303 1 + 
nahSFc +4 +289 286 0 - 
nahAa -206 +95 302 1 + 
nahAb -70 +226 297 0 - 
nahAc +11 +310 300 0 - 
nagB3a -176 +175 352 2 ++ 
nagB3b -84 +338 423 2* + 
nagB3c -22 +338 361 1 + 
nagB3d +94 +338 245 0 - 
nagKa -283 +49 333 1 + 
nagKb -283 -59 225 0 - 
lnpBa -227 +93 321 1 + 
lnpBb +4 +262 259 0 - 
lnpBc -91 +262 354 1 + 
gltAa -419 +83 503 1 + 
gltAb -304 +205 510 1 + 
gltAc -59 +205 265 1 + 
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Supplemental Table S3.4. Predicted operator sequence used for the in silico generation of 
operator sequence motif consensuses.  
A Not identified by EMSA analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Regulator Operator Name Sequence 
LntR lntP1ir1 tgttttcgtgacca 
 lntP1ir2 tgataacgtaaaca 
 lntS1ir1 tgttagcgataaca 
 lntS1ir2 tgttatcgcaacca 
NahR nahSir1 cataatcatg 
 nahAir1 catcacgatg 
NagR1 nagB3ir1 aattgtaagtagtattaacaaat 
 nagB3ir2 atctgttagggaacttcactaat 
 nagKir1 atttgttaagatagttgtcaata 
 lnpBir1 ttatgtatatatacttaacaaat 
 gltAir1 aattgttagttaggttgacaata 
 gltAir2A ctttgtaaggagtattaataaaa 
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Supplemental Figure S3.1. Schematic representations (I) of the lntP1 (a) and lntS (b) promoter 
regions for the binding of LntR. Underlining indicates the 10 and 35 hexamers, and ribosome 
binding sites deduced from the primer extension results; experimentally determined 
transcriptional start sites (TSS) are indicated by asterisks. The dashed lines under sequences 
with names in boldface indicate the inverted-repeat lntP1ir1, lntP1ir2, lntSir1 and lntSir2 
binding sequences displayed above the lollipops. The arrows in the right panels (II) indicate 
the primer extension products. 
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Supplemental Figure S3.1. Schematic representations (I) of the nahS (c) and nahA (d) 
promoter regions for the binding of NahR. Underlining indicates the 10 and 35 hexamers, and 
ribosome binding sites deduced from the primer extension results; experimentally determined 
transcriptional start sites (TSS) are indicated by asterisks. The dashed lines under sequences 
with names in boldface indicate the inverted-repeat nahSir1 and nahAir1 binding sequences 
displayed above the lollipops. The arrows in the right panels (II) indicate the primer extension 
products. 
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Supplemental Figure S3.1. Schematic representations (I) of the nagB3 (e) and nagK (f) 
promoter regions for the binding of NagR1. Underlining indicates the 10 and 35 hexamers, and 
ribosome binding sites deduced from the primer extension results; experimentally determined 
transcriptional start sites (TSS) are indicated by asterisks. The dashed lines under sequences 
with names in boldface indicate the inverted-repeat nagB3ir1 and nagKir1 binding sequences 
displayed above the lollipops. The arrows in the right panels (II) indicate the primer extension 
products. 
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Supplemental Figure S3.1. Schematic representation (I) of the lnpB (g) and gltA (h) promoter 
regions for the binding of NagR1. Underlining indicates the 10 and 35 hexamers, and ribosome 
binding sites deduced from the primer extension results; experimentally determined 
transcriptional start sites (TSS) are indicated by asterisks. The dashed lines under sequences 
with names in boldface indicate the inverted-repeat lnpBir1 and gltAir1 binding sequences 
displayed above the lollipops. The arrows in the right panels (II) indicate the primer extension 
products. 
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Supplemental Figure S3.2. EMSA images showing (a) LntR, (b) NahR, and (c) NagR1 interactions with promoter-containing DNA fragments, 
with the addition of a range of potential carbohydrate inducers, at a concentration of 20mM. In each panel, ‘C’ indicates a negative control, where 
an equivalent amount crude cell extract from NZ9000 harbouring empty pNZ8150 was added instead of crude extract from the regulator-expressing 
NZ9000 strain. 
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Supplemental Figure S3.3. EMSA images showing LntR interactions with promoter-containing DNA fragments, with the addition of a gradient 
(a) Gal-1-P and (b) Gal-6-P, ranging from 0mM-50mM. In each panel, ‘C’ indicates a negative control, where an equivalent amount crude cell 
extract from NZ9000 harbouring empty pNZ8150 was added instead of crude extract from the regulator-expressing NZ9000 strai
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Chapter IV 
Screening of infant faecal samples for human milk oligosaccharide-
utilising Bifidobacterium isolates. 
 
 
 
 
Faecal Samples were provided by the InfantMet Project.  
Valentina Ambrogi and Mariane Vigoureux assisted with the faecal sample 
screening, in material preparation, isolate subculuturing and ITS PCR 
analysis. 
Dr. Francesca Bottacini carried out the GH profile analysis.  
 
B. breve isolates obtained in the work of this chapter were used in the 
publication: 
Bottacini, F., Morrissey, R., Roberts, R.J., James, K., van Breen, J., 
Egan, M., Lambert, J., van Limpt, K., Knol, J., O’Connell Motherway, 
M., & van Sinderen, D. (2018). Comparative genome and methylome 
analysis reveals restriction/modification system diversity in the gut 
commensal Bifidobacterium breve. NAR Volume 46, Issue 8.  
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4.1 Abstract 
Utilisation of Human Milk Oligosaccharides (HMOs) represents an important 
adaptation that facilitates the establishment and dominance of bifidobacteria 
in the intestinal microbiota of the breastfed neonate. This adaptation comes 
in the form of a range of distinct metabolic strategies employed by different 
infant-associated Bifidobacterium species. The particular arsenal of glycosyl 
hydrolases (GHs) encoded by the genomes of these species is believed to be 
a reflection of their HMO metabolizing abilities. In the current study, faecal 
samples of exclusively breastfed infants were screened for bifidobacteria 
based on their ability to grow on various glycans, including lactose, GOS and 
the HMO sugars 3’-sialyllactose, 2’-fucosyllactose and 3-fucosyllactose, as 
selective carbohydrate sources. A range of bifidobacterial species were 
obtained, varying between the selective carbohydrate used, and supporting 
the notion of selective HMO consumption. We analysed GH profiles of 
representative strains of each of the identified species, correlating these 
profiles with their preferential carbohydrate-based selection, and thereby 
highlighting the importance of carbohydrate utilisation strategies for 
bifidobacterial colonisation in the infant gut.   
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4.2 Introduction 
Bifidobacteria are among the first colonisers of the infant gut, and have been 
shown to dominate the intestinal microbiota of, in particular, breastfed 
neonates [1, 2]. Being Gram-positive, anaerobic members of the 
Actinobacteria phylum, Bifidobacterium species are commensals of the 
mammalian, avian and insect gut, and currently garner a great deal of 
scientific and commercial interest because of their purported benefits to infant 
host health and development [3-8].  
Breastfeeding is known to impact on the microbiota composition of the infant 
gut [9-12]. Perhaps the most influential component of human breastmilk in 
terms of its impact on infant microbiota composition is a group of related 
glycans, commonly referred to as Human Milk Oligosaccharides (HMOs). 
They represent a heterogeneous mix of at least 200 distinct glycan structures 
[13], constituting, after lactose, the second-largest carbohydrate component 
of breastmilk [10, 14]. All HMO structures contain (at the reducing end) 
lactose as the base, which is elongated through the addition of a lacto-N-biose 
(LNB) moiety or its stereoisomer N-acetyllactosamine (LacNAc), creating 
the tetrasaccharides lacto-N-tetraose (LNT) or lacto-N-neotetraose (LNnT), 
respectively. These, in turn, may be elongated by the addition of further LNB 
or LacNAc residues at the reducing end. Any of these structures, including 
lactose itself (though lactose is not considered an HMO), may be fucosylated 
or sialylated [10, 13, 15]. 
Selective consumption of HMOs provides a major advantage to the 
establishment of specific microbes in the breastfed neonatal gut microbiota, 
and few do this as successfully as bifidobacteria [5, 13, 16, 17]. This is 
reflected in the enrichment of specific infant-associated species in the 
breastfed neonatal gut microbiota [1], in particular Bifidobacterium bifidum, 
Bifidobacterium longum subsp. infantis, Bifidobacterium longum subsp. 
longum, Bifidobacterium breve, Bifidobacterium pseudocatenulatum and 
(though less frequently) Bifidobacterium kashiwanohense [1, 18-22]. B. 
bifidum and certain strains of B. longum subsp. longum have been shown to 
carry out the extracellular hydrolysis of complex HMOs, including LN(n)T 
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and fucosylated and sialylated structures, prior to the import and metabolism 
of (some of) the resultant mono- and di-saccharides, [23-30], while B. 
kashiwanohense is thought to internalise and intracellularly hydrolyse small 
fucosylated HMO structures, such as fucosyllactose [2]. B. breve and B. 
longum subsp. infantis are known to internalise intact neutral HMO moieties 
such as LNT, LNnT and LNB, and sequentially hydrolyse these 
oligosaccharides for the subsequent metabolism of their monosaccharide 
constituents [13, 23, 31-35]. However, B. infantis has also been demonstrated 
to take up and utilise small-mass fucosylated and sialylated HMO structures. 
These HMO moieties, such as fucosyl-/sialyl-lactose and fucosylated or 
sialylated LN(n)T, are internalised [36], and then degraded into their 
constituent monosaccharides by an array of glycosyl hydrolases, including 
fucosidases and sialidases [23, 31, 37-39]. At present, little to nothing is 
known about HMO metabolism in B. pseudocatenulatum, except for its 
ability to consume LNT [40]. Recent work has correlated differences in 
neonatal microbiota composition with variations in the specific HMO 
components consumed by the infant and thus microbiota itself [41]. Thus, it 
should follow that such differences extend to the Bifidobacterium component 
of the neonatal microbiota. Previous work has highlighted considerable 
differences in metabolic capabilities and strategies for carbohydrate 
utilisation by different bifidobacterial species [42], and as such, the 
propagation or isolation of specific species of Bifidobacterium should be 
dependent on the available carbohydrate source.  
In this chapter, we describe the generation of a strain bank of 502 
Bifidobacterium isolates, belonging to the species B. breve, B. bifidum, B. 
longum (subsp. infantis and longum), B. pseudocatenulatum and B. 
kashiwanohense from the faeces of exclusively breastfed infants in the first 
4-8 weeks of life, using various sugars as the selective carbohydrate. The 
employed selective carbohydrates include the HMO components 3’-
sialyllactose (3’-SL), 2’-fucosyllactose (2’-FL) and 3-fucosyllactose (3-FL), 
as well as the sugars lactose and galacto-oligosaccharides (GOS). Lactose 
[42] and GOS [23, 43, 44] are substrates efficiently used by a wide range of 
Bifidobacterium species, both of infant and adult origin, and thus provide an 
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excellent comparison for the species isolated using these substrates to those 
obtained using HMO, especially as lactose comprises the dominant 
carbohydrate component of breastmilk [10], while GOS is a prebiotic 
frequently included in infant formula milk [45, 46]. The species identity of 
the isolates obtained was determined, revealing interesting differences 
between bifidobacterial species isolated using HMO and those obtained using 
less selective substrates. Furthermore, we compare the distribution of 
glycoside hydrolases (GHs) involved in carbohydrate metabolism in 
representative strains (previously sequenced other publications) of all species 
obtained in the screening, with particular focus on HMO utilisation, revealing 
insights into key metabolic adaptations common to infant-associated 
Bifidobacterium species. 
  
173 
 
4.3 Materials and Methods 
Faecal sample handling and strain isolation. Faecal samples were obtained 
from the APC Microbiome Institute human clinical sample collection (stored 
at -80°C), originally collected for the InfantMet Cohort [47]. Mothers were 
approached for consent between February 2012 and May 2014 at the Cork 
University Maternity Hospital, with ethical approval provided by the Cork 
University Hospital Research Ethics Committee (ethical approval reference: 
ECM (w) 07/02/2012). Faecal samples were selected based on infant age at 
the time of collection (age range: 4-8 weeks) and the requirement of exclusive 
breastfeeding up the point of sample collection. This information was 
obtained from the InfantMet subject metadata [47]. Bifidobacterium culture 
isolates were obtained using a method based on that employed in the 
InfantMet study [47], though with the following significant modifications. All 
sample preparation and platings were carried out under anaerobic conditions 
in a modular atmosphere-controlled system (Davidson and Hardy, Belfast, 
Ireland) at 37 °C. One gram of frozen faecal sample was thawed anaerobically 
at 37°C, and resuspended in 10 ml PBS (Sigma Aldrich, Ireland) 
supplemented with 0.05 % L-cysteine hydrochloride (Sigma Aldrich, 
Ireland). Selection of bifidobacteria was performed by spread-plating 10 
aliquots of 1 ml of the faecal resuspension on: modified de Man Rogosa and 
Sharpe (mMRS) agar prepared from first principles [48], supplemented with 
1 % (wt/vol) 2’-fucosyllactose, 3-fucosyllactose, 3’-sialyllactose (all Glycom 
A/S, Lyngby, Denmark) or lactose (Sigma Aldrich, Ireland), as well as 0.05 
% L-cytseine HCl, 100 μg/ml mupirocin (Oxoid, Fannin, Ireland) and 50 units 
nystatin suspension (Sigma Aldrich, Ireland). As a control, faecal 
resuspensions were also plated on TOS Propionate Agar (Merck KGaA, 
Darmstadt, Germany), supplemented with 0.05 % L-cysteine HCl, 100 μg/ml 
mupirocin and 50 units nystatin suspension. Agar plates were incubated 
anaerobically at 37 °C for 72 h. Emerging colonies from selected plates were 
resuspended in 1 ml of PBS supplemented with 0.05 % L-cysteine HCl, after 
which the resuspensions from around 10 plates of a single sample were pooled 
and homogenised, and serial-diluted in the aforementioned PBS, and dilutions 
between 1x10-4 and 1x10-8 were spread-plated on the same type of 
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HMO/lactose-supplemented modified de Man Rogosa and Sharpe (mMRS) 
agar or TOS propionate agar from which the colonies were obtained, as 
described above, and incubated anaerobically at 37 °C for 72 h. A 
representative number of single, isolated colonies were selected from the 
serial dilution plates, and again re-streaked onto the same type of agar plates 
as isolated from, and incubated anaerobically at 37 °C for 48 h. This sub-
cultivation process was repeated twice, after which single isolated colonies 
were inoculated into modified de Man Rogosa and Sharpe (mMRS) medium 
prepared from first principles, supplemented with 1 % lactose and 0.05 % L-
cysteine HCl. Pure cultures of were stocked and stored at -80°C.  
 
Confirmation of Bifidobacterium isolates, and species identification. Pure 
cultures were confirmed as bifidobacteria using the fructose-6-phosphate 
phosphoketolase assay [49], as well as employing PCR reactions based on the 
ITS (Intergenic Spacer region between the 16S and 23S rRNA-encoding 
genes) and ruvAB sequences, using primer pairs Bifspp and 23Sbif [50], and 
ruvABf and ruvABr, respectively (Supplemental Table S4.1). The amplicons 
from the ITS- and ruvAB-based PCR reactions were sequenced (MWG 
Eurofins, Ireland) using the same primers as those used for the PCR, and the 
resulting sequences were assembled (Seqman, Seqbuilder, DNAStar Suite) 
and subject to a nucleotide BLAST (NCBI) in order to determine their species 
identity.  
 
Bacterial strains and culture conditions. Bifidobacterium cultures were 
routinely cultured in modified de Man Rogosa and Sharpe (mMRS) medium 
prepared from first principles [48], supplemented with cysteine-HCl (0.05 %, 
wt/vol) and 1 % lactose. Bifidobacterium cultures were incubated under 
anaerobic conditions in a modular atmosphere-controlled system (Davidson 
and Hardy, Belfast, Ireland) at 37°C.  
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Comparison of glycoside hydrolase content in infant-associated 
bifidobacteria. Publicly available genome sequences from bifidobacterial 
strains were selected to represent each species isolated during the faecal 
screening. The glycosyl hydrolase (GH) content of these representative 
strains were obtained from the information stored within the publicly 
available CAZy database (http://www.cazy.org/), and compared. The strains 
used for this purpose were: B. breve UCC2003 [51], B. longum subsp. longum 
NCC2705 [52], B. longum subsp. infantis ATCC 15697 [31], B. bifidum 
PRL2010 [53], B. kashiwanohense JCM 15439 [54] and B. 
pseudocatenulatum DSM 20438 [55]. 
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4.4 Results 
Generation of a strain bank of infant-derived bifidobacteria. Using 
selective growth media we isolated bifidobacteria from seventeen faecal 
samples, which had been derived from seventeen exclusively breastfed (at the 
time of sampling, according to proforma data provided by the mothers), 
healthy and full-term 4 to 8 week-old infants. This subject selection ensured 
the presence of a microbial gut population that was highly dependent on 
breast milk for growth, whilst also allowing for the development of a ‘typical’ 
infant gut microbiota.  
Samples were treated as described in the InfantMet study [47], with a number 
of modifications, as described in the Materials and Methods section. The 
inclusion of mupirocin in all media used ensured the selection of 
bifidobacteria [56, 57], while the inclusion of nystatin ensured fungal 
inhibition [58]. The use of anaerobic conditions during sample preparation, 
plating, resuspension and secondary plating ensured minimal oxidative stress 
to the bifidobacteria present, thus minimizing loss of potential isolates. 
Resuspension and re-plating of obtained bacteria following the initial plating 
and incubation was conducted to eliminate false positives due to growth on 
residual lactose (or other carbohydrates) present in the faeces prior to 
selection on a particular carbohydrate source. The mMRS used was 
supplemented with lactose, or various HMO components as the sole 
carbohydrate source, in order to select for Bifidobacterium isolates capable of 
such a particular HMO. The HMO components included: 3’-sialyllactose (3’-
SL), 2’-fucosyllactose (2’-FL) and 3-fucosyllactose (3-FL). TOS propionate 
agar, containing galactooligosaccaharides (GOS) as the carbohydrate source, 
was also used as a control medium to generally select for bifidobacteria.  
A bank of 502 Bifidobacterium isolates was generated, of which 252 were 
isolated using lactose, 157 isolated using GOS and 93 isolated using HMO 
(Fig. 4.1). This bank of isolates, following species identification, was shown 
to consist of 177 B. breve, 108 B. bifidum, 7 B. kashiwanohense, 177 B. 
longum (subsp. longum/infantis) and 33 B. pseudocatenulatum isolates (Fig. 
4.1, Fig. 4.2). Of these, 252 were isolated from mMRS agar with 1 % lactose, 
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93 were isolated from mMRS agar with 1 % HMO (3’-SL, 2’-FL or 3-FL) 
and 157 were isolated from TOS (GOS) propionate agar. While comparing 
the numbers of each species within the total bank of isolates obtained does 
not provide us with a great deal of information (as equal number of isolates 
were not obtained using each substrate), examining the relative proportions 
of each species obtained for a given substrate separately reveals a very 
interesting correlation between the carbohydrate(s) present and the species 
isolated. When using HMO (3’-SL, 2’-FL or 3-FL) as the selective 
carbohydrate, over 75 % of the 93 isolates obtained were identified as B. 
bifidum (Fig. 4.1). The remaining isolates were made up of equal proportions 
(~7.5 %) of B. breve, B. kashiwanohense and B. pseudocatenulatum strains, 
and a mere 1 % were shown to belong to B. longum spp. (Fig. 4.1). This 
starkly contrasts with the profile of the isolates obtained using lactose as a 
selective carbohydrate, where no B. kashiwanohense isolates were obtained, 
while just 2 % of the isolates were identified as B. bifidum (Fig. 4.1). 
Conversely, B. breve and B. longum spp. dominated these isolates, making up 
44 % and 51 %, respectively, of the 252 isolates characterized (Fig. 4.1). The 
isolates obtained using TOS (GOS) propionate agar provided something of a 
more balanced species profile. While no B. kashiwanohense strains were 
isolated using this medium either, B. breve, B. longum spp., B. bifidum and B. 
pseudocatenulatum composed 38 %, 31 %, 20 % and 11 % of the 157 isolates 
obtained, respectively (Fig. 4.1).  
These results show that, as expected, the utilized carbohydrate source and 
medium base influenced the frequency at which certain bifidobacterial 
species were isolated from these faecal samples. There appears to be a strong 
bias for the selection of B. bifidum and B. kashiwanohense when faecal 
samples were screened using the HMO’s 3’-SL, 2’-FL or 3-FL as the selective 
substrate. This is echoed in the much lower occurrence of B. bifidum and the 
absence of B. kashiwanohense among isolates obtained using lactose or GOS 
as the selective carbohydrate. In contrast, B. breve and B. longum spp. appear 
to dominate among the isolates obtained using lactose as a carbohydrate. B. 
pseudocatenulaum was obtained using all 3 substrates, composing 3-11 % of 
the isolates. Of the 3 substrates used, GOS appears to have generated the most 
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balanced proportion of Bifidobacterium species isolates. However, in the case 
of the GOS-derived isolates, it must be noted that the composition of the TOS 
propionate medium base differs from that of the mMRS medium base. As 
such, other components than just the carbohydrate source may have affected 
the species obtained using this medium in comparison to mMRS 
supplemented with lactose or HMO. 
 
Distribution of glycoside hydrolases in infant-associated bifidobacteria. 
In order to find a correlation between infant-associated Bifidobacterium 
species obtained by carbohydrate-based selection and the array of glycosyl 
hydrolases (GHs) expressed by these species, an analysis of the distribution 
of GH families across the species we isolated in the infant faecal screening 
was carried out. One representative strain of each species was selected for this 
purpose and compared for their GH-encoding content; namely B. breve 
UCC2003 [51], B. longum subsp. longum NCC2705 [52], B. longum subsp. 
infantis ATCC 15697 [31], B. bifidum PRL2010 [53], B. kashiwanohense 
JCM 15439 [54] and B. pseudocatenulatum DSM 20438 [55].  
Analysis of the GH distribution across the genomes of these 6 species reveals 
a significant variation in the array of GH families (Fig. 4.2). A core set of 
highly-conserved GH families was observed across all 6 species, including: 
GH2 and GH42 β-galactosidases, GH3 β-glucosidases, GH13 α-amylases and 
GH 23 lysozymes. The conservation of GH2 and GH42 β-galactosidases 
across these 6 infant-derived species is unsurprising, as both these classes of 
GH have been shown to be involved in lactose hydrolysis [23, 25, 26, 31, 32, 
35], which comprises the largest carbohydrate component of breastmilk. GH2 
β-galactosidases have also been previously implicated in the utilisation of 
GOS [59], which may explain the relatively balanced proportion of species 
obtained using this substrate. Furthermore, both GH42 and GH2 β-
galactosidases have also been demonstrated to degrade the neutral HMO 
tetrasaccharide LNnT in Bifidobacterium species, while GH42 β-
galactosidases have also been demonstrated to degrade LNT [26, 32, 35]. 
Here, B. breve was found to be particularly rich in GH2 β-galactosidases. 
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GH3 β-glucosidases typically act on plant-derived oligosaccharides and 
polysaccharides, as has previously been observed in both B. longum subsp. 
infantis [60] and B. longum subsp. longum [61]. GH13 α-amylases represent 
the most dominant GH family of the Bifidobacterium glycobiome [62], and 
also act on a wide range of plant-derived carbohydrates [42]. This is 
interesting, as such plant-derived glycans represent the dominant 
carbohydrates in the adult mammalian diet [63]. GH23 lysozymes are 
typically associated with the degradation of exopolysaccharides such as chitin 
[64].  
Examining the differences between the GH content of these species, however, 
provides some interesting insights into their specific carbohydrate utilisation 
capabilities. The presence of GH33 sialidases appears strictly conserved in B. 
breve, B. longum subsp. infantis and B. bifidum. This is remarkable, as B. 
bifidum comprised the vast majority of isolates obtained using 3’-SL as the 
selective carbohydrate. B. bifidum is known to encode sialidases capable of 
sialyllactose degradation [28]. A small number of B. breve isolates were also 
obtained using 3’-SL as the selective substrate, and while, however, B. breve 
UCC2003 is not capable of degrading sialyllactose, it has been previously 
shown to utilise sialic acid released in the extracellular hydrolysis of 
sialyllactose by B. bifidum [65, 66]. The sialidase expressed by B. breve may 
in fact function in the hydrolysis of other sialylated HMO structures, such as 
sialyl-LN(n)T. While GH95 α-L-fucosidases appear to be distributed across 
most of the 6 species, GH29 α-L-fucosidase-encoding genes are only present 
in the genomes of B. longum subsp. infantis, B. bifidum and B. 
kashiwanohense. Of the 6 species examined here, these three are the only ones 
that have been demonstrated to typically degrade fucosyllactose [2, 23, 27, 
29, 37, 39]. This agrees with the make-up of species isolated here using 2’-
FL or 3-FL as the selective carbohydrate. B. bifidum was by a substantial 
margin the dominant species isolated using fucosyllactose, and this substrate 
was also the only substrate from which B. kashiwanohense was isolated. This 
suggests the conservation of a GH29 rather than a GH95 α-L-fucosidase as 
key to the utilisation of fucosyllactose, the latter perhaps primarily 
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functioning in the degradation of larger fucosylated HMO structures, such as 
fucosyl-LN(n)T.  
Shifting the focus to differences in the distribution of GH families not 
associated with carbohydrates used in the screening also reveals some 
interesting patterns among the 6 species. The species B. longum subsp. 
longum and B. pseudocatenulatum, which are frequently found in the 
microbiota of both adults and infants, appear rich in GH family proteins 
associated with the metabolism of plant-derived carbohydrates, often absent 
from the strictly infant-associated species B. longum subsp. infantis and B. 
bifidum, including GH31 α-glucosidases, GH120 β-xylosidases and GH127 
β-L-arabinofuranosidases. B. breve and B. kashiwanohense appear to possess 
a mix of both HMO-specific and plant-derived glycan-specific GH family 
proteins.  
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4.5 Discussion 
Bifidobacteria employ a range of strategies to allow them to utilise an array 
of carbohydrates. This wide variation in carbohydrate metabolic capabilities 
has been observed in both adult and infant-associated Bifidobacterium species 
[13, 16, 42, 67], with particular specialisations in the latter group enabling the 
selective development of these species in the environment of the breastfed 
infant gut. While lactose comprises the predominant carbohydrate component 
of breastmilk, and is metabolised by a wide range of bifidobacteria [42], the 
adaptation to consume HMO sugars is believed to play a major role in the 
establishment of B. breve, B. bifidum, B. longum subsp. infantis, B. 
kashiwanohense, B. longum subsp. longum and B. pseudocatenulatum as part 
of the (breastfed) neonatal gut microbiota [1, 18-22]. In particular, the 
consumption of sialylated and fucosylated HMO glycans is a strategy 
efficiently employed by infant-associated Bifidobacterium species [5, 13, 16, 
17]. Here, we observe significant variation in Bifidobacterium species 
isolated using the HMOs fucosyllactose or sialyllactose, as compared lactose 
or GOS. 
Analysis of the strains isolated using each selective carbohydrate source 
clearly shows the influence of carbohydrate source on the species of 
Bifidobacterium obtained from infant faecal samples. The strong bias for 
selection of B. bifidum in the case of the selective sugars 2’-FL, 3-FL or 3’-
SL supports the notion of B. bifidum being an efficient utiliser of fucosylated 
and sialylated HMOs through the activity of its extracellular fucosidases and 
sialidases [13, 23, 67]. While by no means the dominant species obtained 
using this substrate, B. kashiwanohense was only obtained using 2’-FL as the 
selective carbohydrate. This is not surprising, however, as not only has 
previous work demonstrated the ability of B. kashiwanohense to consume 
fucosyllactose [2], but it has also highlighted that this species is rarely isolated 
(only previously isolated twice, in both cases from infant faeces) [22, 54]. 
The inclusion of lactose or GOS in the media appears to encourage growth, 
and thus isolation of B. longum spp. and B. breve. This makes sense in the 
context of their metabolic capabilities, as while all strains obtained in this 
screening process are capable of utilising lactose [42], B. breve and B. longum 
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subsp. infantis can also target and efficiently utilise other galactose-rich 
small-molecular weight glycans such as LNT and LNnT [13, 23, 31-35]. 
While the primer sets used did not enable the subspeciation of B. longum spp. 
isolates into the longum or infantis subspecies, it would be plausible that 
many of these isolates belong to subsp. longum. B. longum subsp. infantis is 
more commonly associated with the microbiota of breastfed infants, whereas 
subsp. longum is more common in the microbiota of adults and formula-fed 
infants [1, 19, 50, 68]. However, the former are capable of utilising free 
fucosyl- and sialyl-lactose [2, 69], and a greater proportion of B. longum 
isolates would be expected using these HMO substrates if they indeed were 
of the subspecies infantis. The prevalence of B. pseudocatenulatum across the 
isolates obtained from all used substrates suggests its ability to grow equally 
well on HMO or alternative carbohydrate sources. This would agree with 
previous work which has identified it as a commensal member of both the 
infant and adult gut microbiota [1, 50, 68].  
Of course, the main caveats to the results obtained from this screening are that 
not all samples were screened using the exact same set of carbohydrates, and 
some samples may intrinsically be richer in certain Bifidobacterium species, 
which would create a natural bias for the selection of particular species on a 
sample-by-sample basis. Nonetheless, the compiled results show a trend 
toward the selection of specific species based on the carbohydrate source 
used, namely HMO or non-HMO. 
Examining the results of the screening in the context of the GH content of a 
representative strain for each species further strengthens the argument for the 
partitioning of specific carbohydrate metabolism into different infant-
associated species, particularly with regard to HMO components. While they 
do not represent the GH content of all strains of each species, these strains 
represent the general features of each as an indication of their carbohydrate 
utilisation capabilities. The observed conservation of fucosidase- and 
sialidase-encoding genes, particularly in B. bifidum, agrees with its ability to 
utilise fucosylated and sialylated HMOs [16, 27, 28]. Likewise, the observed 
presence of fucosidases in B. kashiwanohense may correlate with the ability 
of the species to utilise fucosyllactose [2]. However, as only two genomes of 
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this species are currently publicly available, this is yet to be considered as a 
common feature of B. kashiwanohense [54, 70]. B. longum subsp. infantis 
also expresses sialidases and fucosidases, and has been demonstrated to 
utilise both fucosyllactose and sialyllactose [2, 37, 38]. However, it may be 
the case that B. bifidum and to a lesser extent, B. kashiwanohense, may simply 
be more efficient utilisers of these particular HMO moieties, accounting for 
the former’s dominance and latter’s presence in the isolates obtained using 
fucosyl- or sialyl-lactose as the selective carbohydrate. While B. longum 
subsp. infantis is capable of metabolising free fucosyllactose and sialyllactose 
[2, 69], this species is known to internalise and intracellularly degrade larger, 
complex fucosylated and/or sialylated HMO (such as fucosyl-/sialyl-LN(n)T) 
[14, 16, 17], and may preferentially consume these over fucosyl-/sialyl-
lactose. This may account for the lower abundance of B. longum isolates 
obtained, if they are belonging to subsp. infantis, compared to B. bifidum or 
B. kashiwanohense, in the isolates obtained using fucosyllactose or 
sialyllactose. However, as mentioned, it is highly likely that these B. longum 
isolates belong to the subsp. longum, which does typically not consume HMO 
substrates [14, 16, 17]. 
Analysing the overall GH content of the six analysed genomes reveals an 
interesting pattern in terms of the origin of the carbohydrates targeted. While 
all six species possess GH family proteins which target lactose (which is 
expected as it represents the dominant carbohydrate in breastmilk ahead of 
HMO), an enrichment of GH family proteins targeting HMO-derived sugars 
is observed in B. bifidum and B. longum subsp. infantis, and an enrichment of 
GH family proteins targeting plant-derived sugars is observed in B. longum 
subsp. longum and B. pseudocatenulatum, with B. breve and B. 
kashiwanohense encoding members of both GH families. This may provide 
an advantage during exclusive breastfeeding in early infancy for specialist 
HMO-consuming species such as B. bifidum and B. longum subsp. infantis. 
Subsequent weaning would be expected to present an opportunity for species 
capable of both HMO and plant-derived sugar metabolism such as B. breve 
and B. kashiwanohense, while subsequent to the transition to exclusively solid 
foods may favour more adult-associated species, such as B. longum subsp. 
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longum and B. pseudocatenulatum, which specialise in the metabolism of a 
range of plant-derived sugars. Such differences in the species of 
Bifidobacterium present in the gut microbiota over the course of infancy have 
previously been observed [1, 50, 71, 72].  
However, this analysis of GH distribution in these strains of course has its 
limitations. We only included a small number of species from the 
Bifidobacterium genus in this analysis; just the six species we obtained in our 
isolations, all of which are associated with the infant gut microbiota (as well 
as the adult for B. longum subsp. longum and B. pseudocatenulatum). 
Furthermore, we examined the GH content of just a single representative 
strain for each species. In order to obtain a more comprehensive picture of the 
distribution of GH’s across the genus, such an analysis would need to be 
repeated using a much wider range of Bifidobacterium species, from a range 
of different environments, and as many strains of each as possible. 
On the whole, our work has allowed the development of a methodology for 
the isolation of HMO-utilising bifidobacteria from infant faeces, and this 
method can easily be adjusted for the selection of bifidobacteria under 
different selective conditions and/or from different sources. Our findings 
furthermore support the notion that HMO-utilisation abilities of 
bifidobacteria, particularly with regards to fucosyllactose and sialyllactose, 
impact on their establishment in the breastfed infant gut microbiota. Recent 
work has indeed demonstrated that variations in HMO composition influence 
the overall gut microbiota structure of infants [41]. Individual HMO 
components, or combinations thereof, may be used in the future as 
supplements or therapeutics to formula-fed infants, to aid in the development 
of a normal gut microbiota by encouraging the establishment of key infant-
associated Bifidobacterium species.  
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4.7 Tables and Figures 
Table 4.1. Total number of isolates of Bifidobacterium belonging to each species obtained 
during the screening of infant faeces. The number of isolates belonging to each species, and 
total number of isolates obtained are given for each carbohydrate substrate used, as well as the 
overall number of isolates of each species. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Carbohydrate B. breve B. bifidum B. kashiwanohense B.  longum spp. B. pseudocatenulatum Total Isolates 
Lactose 110 5 0 128 9 252 
TOS 60 32 0 48 17 157 
HMO* 7 71 7 1 7 93 
Total 177 108 7 177 33 502 
*HMO substrates used were 3-SL, 2-FL or 3-FL 
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Table 4.2. Number of isolates of Bifidobacterium belonging to each species obtained from 
each individual faecal sample. The number of isolates belonging to each species, and total 
number of isolates obtained are given for each carbohydrate substrate used, as well as the 
overall number of isolates of each species. 
 
 
 
 
 
 
Sample Carbohydrate B. breve B. bifidum B. kashiwanohense B. longum spp. B. pseudocatenulatum Total Bifidobacteria 
091W4 Lactose 2 0 0 6 8 16 
TOS 0 0 0 11 12 23 
Total 2 0 0 17 20 39 
095W4 Lactose 0 0 0 23 0 23 
TOS 0 0 0 4 0 4 
Total 0 0 0 27 0 27 
180W8 Lactose 1 0 0 23 0 24 
TOS 0 0 0 4 0 4 
Total 1 0 0 27 0 28 
082W4 Lactose 29 0 0 0 0 29 
TOS 3 0 0 0 0 3 
Total 32 0 0 0 0 32 
200W4 Lactose 22 0 0 0 0 22 
TOS 8 0 0 0 0 8 
Total 30 0 0 0 0 30 
144W4 Lactose 27 3 0 0 1 31 
TOS 6 0 0 0 0 6 
Total 33 3 0 0 1 37 
215W4 Lactose 5 0 0 0 0 5 
TOS 8 0 0 0 1 9 
Total 13 0 0 0 1 14 
060W4 Lactose 0 0 0 67 0 67 
Total 0 0 0 67 0 67 
017W4 3-SL 5 32 0 0 1 38 
TOS 27 9 0 0 0 36 
Total 32 41 0 0 1 74 
131W4 2-FL 0 0 7 0 0 7 
Total 0 0 7 0 0 7 
139W4 Lactose 19 2 0 4 0 25 
Total 19 2 0 4 0 25 
165W4 Lactose 5 0 0 5 0 10 
Total 5 0 0 5 0 10 
003W4 2-FL 2 0 0 0 3 5 
TOS 8 0 0 0 0 8 
Total 10 0 0 0 3 13 
005W4 3-FL 0 7 0 0 1 8 
3-SL 0 2 0 0 0 2 
TOS 0 12 0 2 0 14 
Total 0 21 0 2 1 24 
007W4 2-FL 0 19 0 1 0 20 
TOS 0 7 0 9 4 20 
Total 0 26 0 10 4 40 
061W4 2-FL 0 0 0 0 2 2 
TOS 0 0 0 18 0 18 
Total 0 0 0 18 2 20 
070W4 2-FL 0 11 0 0 0 11 
TOS 0 4 0 0 0 4 
Total 0 15 0 0 0 15 
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Figure 4.1. Propotions of each isolated Bifidobacterium species obtained in total during the screening of infant faecal samples, as well as for each 
selective carbohydrate source used.  
*HMO includes samples screened using 2-FL, 3-FL or 3-SL as the selective carbohydrate source.  
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Figure 4.2. Heatmap representing the distribution of encoded glycosyl hydrolases, belonging 
to each GH family, across the genomes of B. breve UCC2003, B. 
longum subsp. longum NCC2705, B. longum subsp. infantis ATCC 15697, B. 
bifidum PRL2010, B. kashiwanohense JCM 15439 and B. pseudocatenulatum DSM 20438. A 
code colour grading is employed, which represents the number of glycosyl hydrolases of the 
same family encoded in each genome. Glycosyl hydrolase families which are known to 
function in the degradation of the HMO’s 2-FL, 3-FL or 3-SL, lactose and/or GOS are indicated 
by shading.  
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4.8 Supplemental Material  
Supplemental Table S4.1. Oligonucleotide primers used in this work. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Purpose Primer Sequence (5’-3’) 
Amplification of the ITS region for 
Bifidobacterium isolate species identification 
Bifspp 
23Sbif 
 
ggtgtgaaagtccatcgct 
gtctgccaaggcatccacca 
Amplification of the ruvAB region for 
Bifidobacterium isolate species identification 
ruvabf 
ruvabr 
 
ygcncagaaratcatyct 
agrtcrtgsacdatvgccc 
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The bifidogenic effect of HMOs is now well accepted to be of significant 
importance to the establishment and persistence of bifidobacteria as part of 
the (breastfed) infant gut microbiota. Several microbiota studies have 
demonstrated the ability of (the consumption of) breastmilk to significantly 
increase relative abundance levels of bifidobacteria in the infant gut [1-4]. 
These observations are in line with the fact that various infant-associated 
species of Bifidobacterium are known to metabolise individual HMO 
components [5-8]. A significant understanding, including the precise 
metabolic pathways and associated enzymatic activities, of the mechanisms 
of HMO utilisation in B. bifidum, B. longum subsp. infantis has been acquired 
[6, 9-11]. In addition, as part of the work described in this thesis, knowledge 
on the mechanisms of HMO utilisation by B. breve [12] and B. 
kashiwanohense has vastly improved.  
As our understanding of these HMO utilisation preferences and pathways in 
infant-associated bifidobacteria increases, it has provided a much more in 
depth appreciation of the bifidogenic effect of HMOs. It furthermore, as has 
been suggested previously, highlights the existence of remarkable co-
evolution events between humans and certain bifidobacterial species as part 
of a breastfeed-driven symbiosis [13, 14]. Since lactation is a general feature 
of mammalian biology, it is likely that this co-evolution also exists in other 
mammals. The presence of various indigestible milk oligosaccharides has 
been observed in milk and colostrum samples of a range of other mammals 
[15], and bifidobacteria have similarly been isolated from the faeces of a wide 
array of mammals [16]. Analysis of the distribution of particular 
LN(n)T/LNB utilisation genes across the Bifidobacterium genus, as discussed 
in Chapter II [12], provides corroborating evidence for the existence of this 
co-evolutionary phenomenon in other mammals, particularly among 
primates. The observation that homologs of the nahA gene, encoding N-
acetylhexosaminidase responsible for the hydrolysis of the LN(n)T 
component lacto-N-triose into lactose and GlcNAc, are present in 
Bifidobacterium species isolated from marmosets and tamarins, indeed 
suggests similar co-evolutionary symbioses in other lactating mammals. This 
demonstrates the importance of maternal milk as a tool for the development 
258 
 
of a specific gut microbiota in the mammalian neonate, with bifidobacteria as 
a dominant component, and in turn, underscores the importance of 
bifidobacteria for a healthy development of these neonates.  
The health benefits that bifidobacteria have been claimed to endow their 
human (and, by extension, mammalian) infant host are wide-ranging and 
extensive. As discussed in the introduction, such benefits range from the 
generation of essential nutrients from dietary sources, protection from 
pathogens, to immunomodulatory effects, and these so-called probiotic 
properties are the basis of wide-spread commercial exploitation of 
Bifidobacteria for infant health [17]. Likewise, the numerous benefits of 
HMOs to the infant have also been well-documented [18, 19], in particular 
their role as a bifidogenic prebiotic. It is expected that the use of HMOs as 
beneficial supplements and in formaula for infants will become more 
commercially viable, thereby creating opportunities for the generation of new 
prebiotics to modulate the infant gut microbiota, and thus to improve infant 
health. The use of prebiotics such as GOS and inulin in infant formula milk 
as bifidogenic agents is well-documented [20]. However, the use of HMOs is 
believed to provide an opportunity for the selection of a more specific, 
breastfed-type microbiota that is not observed in infants that are formula-fed 
[21, 22]. Furthermore, it may also create opportunities for the use of 
synbiotics, where (particular) HMOs are combined with infant-associated 
bifidobacterial cultures, to help modulate the infant microbiota. Several 
studies have documented how the infant gut microbiota composition is 
influenced by factors such as C-section delivery, pre-term birth or antibiotic 
usage [23-25]. The use of synbiotic formulations may be a powerful approach 
to restore or create a Bifidobacterium-rich (specifically of infant-associated 
species) gut microbiota characteristic of healthy, breastfed neonates [1, 25].  
The two major caveats to these potential applications are the possible risks of 
using individual HMOs (as opposed to the highly complex mix of HMOs in 
breast milk, the composition of which changes during lactation), and the 
current inability to commercially produce sufficient quantities of HMOs. 
With regards to the former point, HMO research is a relatively new field, 
particularly studying its effects when used as a therapeutic agent in humans. 
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As such, the full range of short-term and long-term effects in individuals are 
unknown at this time. HMOs are naturally present in breastmilk as a complex, 
heterogeneous mixture [26], and therefore the inclusion of high quantities of 
one or a few HMOs in the infant diet may unnaturally skew the microbiota, 
and select for an atypical, or potentially even harmful composition, through 
the portential disproportionate proliferation of opportunistic pathogens or 
accumulation of deleterious metabolites. Indeed, it has been observed that 
differing HMO compositions in milk have a direct effect on the gut 
microbiota composition in infants [2], demonstrating the power of the 
prebiotic effect of (particular) HMOs. Regarding the scarce availability of 
synthetically/enzymatically-produced HMOs, the major limiting factor is the 
inability, at present, to generate large-scale batch quantities of high-purity 
HMOs. However, advances in techniques for such commercially viable HMO 
syntheses, particularly by biotechnological methods [27, 28], show promise 
for addressing this limitation in the future. 
Before such advances are realised into commercial and/or therapeutic 
applications, it is important to understand the mechanisms by which these 
bifidogenic effects occur. As stated, the pathways of HMO utilisation in the 
dominant infant-associated Bifidobacterium species; B. bifidum, B. longum 
subsp. infantis and B. breve, as well as the less-prevalent species B. 
kashiwanohense, have now been well-characterised. This research has 
demonstrated the striking specificity of each species for a very particular set 
of HMO components, whether that is the rather broad range HMO structures 
metabolized by B. bifidum through its extracellular enzyme approach [6, 9]; 
the specific small-mass HMOs internalised and intracellularly digested by B. 
longum subsp. infantis [11], the neutral, simple HMO glycans metabolised by 
B. breve (Chapter II, [12]), or strictly small-mass fucosylated HMOs 
consumed by B. kashiwanohense (Chapter V, [8]). What this reveals is a form 
of resource partitioning among infant-associated Bifidobacterium species for 
specific HMO components, which may, in fact, allow the co-existence of 
multiple species within the intestinal niche of a single infant host. Such 
resource partitioning in microbial communities is by no means a new concept, 
and has been observed in other environments [29, 30]. The case observed here 
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with the selective consumption of HMOs by bifidobacteria in the breastfed 
infant gut, however, is an interesting case of this concept applied to species 
within a single genus. This phenomenon, with respect to the community of 
HMO-utilising bifidobacteria within the breastfed infant gut, is even further 
increased in the depth of its complexity, with the occurrence of HMO cross-
feeding, as has observed between B. bifidum and B. breve [31].  
Further study of HMO metabolism in less common, infant-derived 
Bifidobacterium species, such as B. longum subsp. longum and B. 
pseudocatenulatum, as well as in other infant gut-associated bacteria outside 
of the Bifidobacterium genus, is necessary in order to gain an even more 
complete picture of the relationship between HMOs and bifidobacteria. 
Additionally, while the work in Chapter III of this thesis goes some way to 
describe the mechanisms of transcriptional regulation of HMO metabolism in 
B. breve UCC2003, there is still little knowledge of this vital process in other 
infant-associated bifidobacteria, and such research is necessary to fully 
understand the control mechanisms that regulate these metabolic processes at 
a more in depth level.  
Altogether, the presented work of this thesis is important for our 
understanding of HMO utilisation in infant-associated bifidobacteria, in 
particular in the species B. breve and B. kashiwanohense. However, it only 
represents a tiny segment of the overall picture in the context of the 
relationship between HMOs and Bifidobacterium species, and moreover the 
overall microbiota, in the infant gut. As our knowledge of the patterns and 
mechanisms of utilisation by these species expands, we not only reveal more 
of the fascinating natural bifidogenic, prebiotic nature of HMOs, but we also 
step closer to the use of HMOs alone, or in combination with bifidobacteria, 
to create food products and therapeutics which can effect significant 
beneficial changes in the infant gut microbiota. 
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